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Abstract  
 
The impact of sex and menopause in Alzheimer’s disease remains understudied despite 
increasing evidence of greater female risk, particularly in middle aged APOE4 carriers. 
Exploratory analysis of data generated from the Cognitive Ageing Nutrition and 
Neurogenesis (CANN) study in humans revealed that APOE carrier-status and its 
interaction with hormone-therapy alter both circulating n-3 PUFA status and cognitive 
performance. Cognitive performance was greater in individuals receiving hormone-
therapy, with specific APOE4 benefits apparent. To further study the influence of sex 
hormones on APOE4 status, we utilised a female APOE-TR mouse model, and induced 
ovarian failure (VCD injections). Recognition memory and spatial memory were assessed 
using object recognition, Y-maze, and Barnes maze. VCD abolished recognition memory 
in APOE4-TR mice (p<0.05), whilst APOE4 genotype alone led to ~45% and ~15% 
reductions in Barnes and Y-maze performance. Molecular analysis indicated both VCD 
and genotype related deficits in synaptic plasticity, which were more evident in APOE4-
VCD treated animals, with Bdnf gene-expression and protein levels reduced 30% and 2-
fold respectively. Brain DHA levels were 13% lower in VCD treated animals, 
independent of genotype. Model animals were provided with DHA-rich n-3 PUFA 
supplementation at two physiologically relevant doses to explore treatment efficacy. 
Deficits in recognition memory observed in APOE4 VCD treated mice were restored by 
high fish-oil supplementation (p < 0.05). Conversely, despite nominally increasing 
Barnes maze performance, high fish-oil supplementation did not significantly improve 
spatial memory impairment. Protein and gene-expression analysis again supported the 
behavioural findings with BDNF/Akt pathway significantly increased in response to high 
fish-oil in APOE4 mice (p < 0.05). High fish-oil also increased Igf-1, Mapk1 and Ntrk2 
expression, potentially explaining BDNF/Akt modulation. Both doses were effective in 
restoring Brain DHA levels, however the higher dose increased DHA:AA further. 
Together, these results indicate cognitive and neurological impacts of menopause, which 
are exacerbated by APOE4, and ameliorated through high fish-oil supplementation.
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 Literature review: The Effect of APOE genotype on 
Alzheimer’s disease risk is influenced by sex and 
docosahexaenoic acid status    
 
A large proportion of my literature review presented below has been published in 
Neurobiology of aging as a narrative review article in 2018 (Pontifex, Vauzour et al. 
2018) and updated and expanded with literature published in the last two years. 
 
Alzheimer’s disease a global health burden  
 
Dementia is an umbrella term encompassing a number of complex neurological and 
neurodegenerative disorders that manifest progressively over time, with deleterious 
behaviours and genetic predisposition contributing to compromised cognitive functions. 
Of these diseases, Alzheimer’s disease (AD) is the most common, accounting for ~70% 
of dementia cases. AD incidence doubled from 1990 to 2016 (Nichols, Szoeke et al. 
2019), making the disease a serious global health concern. Current projections estimate a 
further tripling of cases (152 million) by 2050 (Patterson 2018), and with no disease 
modifying treatments currently available, the societal, health care and economic pressures 
relating to this debilitating disease will undoubtedly escalate. Many promising drug 
candidates, most of which have been focused towards preventing amyloid beta (Aβ) 
pathology (production, aggregation or clearance) have unfortunately failed to convey any 
clinical benefit (Panza, Lozupone et al. 2019), either as a result of poor efficacy or safety 
concerns. Therefore, it may be time to rethink our approach, whether that be discovering 
more suitable targets and drug candidates or utilising validated lifestyle strategies to 
prevent or delay the onset.  
It is well established that lifestyle factors such as diet and exercise have a modulatory 
impact on AD risk (Nichols, Szoeke et al. 2019). Therefore, successful implementation 
of an intervention in “at-risk” individuals, based upon these low-risk lifestyle factors, may 
offer a plausible approach to at-least reduce AD onset. Strategies capable of delaying 
disease onset by as little as two years, would have profound implications on current 
disease burden (Brookmeyer, Gray et al. 1998), with recent predictive UK models 
suggesting that a two or five year delay would result in a respective 19% or 33% reduction 
in the predicted AD prevalence by 2050 (Lewis F 2014).  
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APOE4 mediated AD risk 
 
APOE4 risk, a consequence of altered protein structure 
 
The apolipoprotein E ε4 allele (APOE4) is the strongest prevalent genetic risk factor for 
sporadic late-onset Alzheimer’s disease (LOAD). Possession of one or two APOE4 
alleles, confers respectively 3-4, and 8-12-fold increased risk, and substantially reduces 
age of disease onset (Davidson, Gibbons et al. 2007, Heffernan, Chidgey et al. 2016).  
Structurally, the mature 299 amino acid APOE protein consists of three distinct regions: 
1) The N-terminal domain (1-167), an anti-parallel four-helix bundle containing the 
receptor-binding region (136-150); 2) The C terminal domain (192-299), a α-helical 
structure encompassing the lipid-binding region (260-299), and 3) a flexible hinge region 
(192–222) which connects the two (Hatters, Peters-Libeu et al. 2006, Phillips 2014). 
Three common APOE variants exist in the population. Despite each differing by only one 
or two amino acid changes at positions 112 and 158 (APOE2: Cys, Arg; APOE3: Cys 
Cys; APOE4: Arg Arg) (Hatters, Peters-Libeu et al. 2006, Phillips 2014), each are 
structurally distinct, with contrasting biophysical properties, such as stability, protein 
folding and affinity for specific molecules (e.g. lipoprotein and receptor preference) 
(Hatters, Peters-Libeu et al. 2006, Phillips 2014). Arginine at position 112, is unique to 
APOE4 and enables re-orientation of Arg-61 away from the N-terminal 4 helix bundle 
assisting in the formation of a salt bridge between Arg-61 (N terminal domain) and Glu-
255 (C- Terminal domain) (Dong, Wilson et al. 1994). This so called domain interaction 
has subsequently been suggested as the molecular basis for the deleterious effects of 
APOE4 (Dong and Weisgraber 1996, Hatters, Peters-Libeu et al. 2006, Zhong and 
Weisgraber 2009, Phillips 2014). Interestingly, studies exploring the use of small 
molecule correctors, which aim to transform or nullify the aberrant APOE4 domain 
interaction have produced promising results, providing evidence for this theory (Wang, 
Najm et al. 2018). 
 
Contribution of APOE genotype to AD risk  
 
The human APOE gene, located on chromosome 19, has three common alleles, ε2, ε3 and 
ε4. Relative to the most common isoform APOE3 (allele frequency 78%), the rarer 
APOE2 (allele frequency 7%) is considered protective (Liu, Kanekiyo et al. 2013), whilst 
the APOE4 isoform (allele frequency 14%) predisposes to AD. Systematic reviews and 
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meta-analyses consistently describe strong APOE4-AD associations. For example the 
AlzGene database reports increased odds ratios (ORs) for both heterozygous (OR: 2.8, 
95% CI: 2.3–3.5) and homozygotes (OR: 11.8, 95% CI: 7.0–19.8) APOE4 relative to 
‘neutral’ APOE3 homozygotes (Bertram, McQueen et al. 2007). The APOE4 allele is 
concentrated within the AD population, with prevalence reaching in excess of 50% 
relative to the global frequency estimated at 14% (in people <65 years of age) (Hallman, 
Boerwinkle et al. 1991, Eisenberg, Kuzawa et al. 2010, Ward, Crean et al. 2012). Such 
associations are also apparent in mild cognitive impairment (MCI). APOE- ε4 carriers are 
3.0-3.7 times more likely to develop MCI compared to all other groups (Viticchi, Falsetti 
et al. 2017) and APOE4 MCI are more likely to convert to a more severe state of MCI 
(mMCI) or AD (Scarabino, Broggio et al. 2016). APOE4 has been associated with 
hippocampal, amygdala and medial-temporal lobe atrophy (Manning, Barnes et al. 2014, 
Lupton, Strike et al. 2016), which underlies the greater development and conversion rates 
in this genotype subgroup.  
A consensus is developing that the impact of the APOE4 allele on AD risk diminishes 
upon reaching extreme ages (>90 years) (Corrada, Paganini-Hill et al. 2013, Valerio, 
Raventos et al. 2014). Such a trend is unexpected given that the APOE4 variant is 
attributed to an increased risk and reduced age of onset. The phenomenon has been 
attributed to the survivor effect and the fact that these individuals have other phenotypic 
attributes, which offer protection with many APOE4 carriers reaching extreme ages with 
normal cognition (Corder, Saunders et al. 1994, Rebeck, Perls et al. 1994). The study of 
such individuals is likely to provide valuable insights into strategies to mitigate the effect 
of genotype at younger ages. 
 
APOE4 persistence is a product of its environment? 
 
Although controversial, protective, and evolutionary advantages for APOE4 in pre-
industrial societies have been reported (Oriá, Patrick et al. 2007). In such populations 
where malnutrition and infection is rife, carriers of APOE4 appear to receive a survival 
advantage (Oriá, Patrick et al. 2007, Fujioka, Phelix et al. 2013, Huebbe and Rimbach 
2017, Trumble, Stieglitz et al. 2017), and carrier prevalence is markedly increased 
(Abondio, Sazzini et al. 2019). This advantage is associated with APOE4’s ability to 
respond to environmental stresses such as inhibiting parasite growth. In complete contrast 
to developed populations, Trumble and colleagues showed this can lead to protection 
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from cognitive impairment (Trumble, Stieglitz et al. 2017), and is a prime example of 
how APOE4 mediated pathophysiology is a product of its environment. 
In addition, whilst a significant risk factor in developed societies, possession of APOE4 
does not categorically determine AD outcome (Corder, Saunders et al. 1993, Liu, 
Kanekiyo et al. 2013). Indeed, although APOE4 prevalence within global AD populations 
varies considerably ranging from 41% - 61% (Farrer, Cupples et al. 1997, Corbo and 
Scacchi 1999, Crean, Ward et al. 2011), only half of APOE4 homozygotes develop AD 
by age 90 years (Henderson, Easteal et al. 1995). This indicates that the penetrance of the 
APOE4 allele, its influence on the rate of cognitive decline and the likelihood of 
transitioning to MCI and AD, is variable and therefore potentially modifiable (Singh, 
Singh et al. 2006, Ward, Crean et al. 2012, Fenesi, Fang et al. 2017, Moser and Pike 
2017). 
 
APOE4 is pleiotropic in AD pathogenesis  
 
 Although APOE4 is a well-established determinant of AD, a fundamental understanding 
of its role in AD pathophysiology, and clarity as to which processes are causative rather 
than associative, remain unclear. Instead, research has identified a range of plausible 
disease mechanisms, ranging from amyloid beta (Aβ) pathology to lipid and cholesterol 
metabolism, which highlights the pleiotropic nature of APOE4. 
Aβ dependant mechanisms: The influence of APOE on Aβ metabolism and pathology 
has been widely described (Table 1.1). Containing an Aβ-binding motif (244-272) (Liu, 
Wu et al. 2011), APOE is able to interact directly with Aβ (Bales, Verina et al. 1999), and 
can be found co-localised with senile plaques and neurofibrillary tangles, indicating a 
likely involvement in the process (Strittmatter, Saunders et al. 1993). Indeed, carriers of 
APOE4 are routinely found to have higher cortical Aβ concentrations (Fouquet, Besson 
et al. 2014), more extensive senile plaque formation (Rodriguez, Tai et al. 2014), and 
earlier pathological onset (Kok, Haikonen et al. 2009), which correlates with greater 
synapse loss and neurodegeneration (Koffie, Hashimoto et al. 2012). This has been 
elegantly demonstrated, in vivo by Wu and colleagues (Wu, He et al. 2017), who observed 
greater cognitive decline after administering intra-cerebrovenrticular co-injection of both 
Aβ and ApoE4 simultaneously, compared to Aβ, ApoE4 or saline alone. Overall APOE 
mediated effects lead to changes in Aβ processing affecting: aggregation, degradation and 
clearance, in a genotype dependant manner (APOE- ε4 > APOE- ε3 > APOE- ε2) (Liu, 
Kanekiyo et al. 2013).  
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Table 1.1 Complexity of the amyloid beta (Aβ)*APOE interaction 
Affected 
process  
Mechanism 
Accumulation  APOE receptor binding increases amyloid precursor protein 
transcription and Aβ secretion, in a genotype dependant manner 
with ApoE4 having the greatest effect (Huang, Zhou et al. 2017) 
Accumulation  APOE binds Aβ oligomers and fibrils (at high concentrations) 
stabilising the molecule and reducing aggregation/fibril growth. 
APOE4 is the least effective and therefore promotes aggregation 
(Garai, Verghese et al. 2014) 
Accumulation  APOE4 acts as a scaffold aiding and increasing oligomerization of 
Aβ (Hashimoto, Serrano-Pozo et al. 2012) 
Clearance  APOE4 reduces apoE/Aβ complex stability, increasing soluble 
oligomeric Aβ levels (Tai, Bilousova et al. 2013) 
Clearance  APOE4 has reduced affinity for toxic Aβ and is therefore a poor 
vehicle for clearance in comparison to ApoE3 (Petrlova, Hong et 
al. 2011)  
Clearance  APOE4 disrupts Aβ clearance across the BBB (Deane, Sagare et 
al. 2008, Verghese, Castellano et al. 2013) 
Degradation  APOE4 reduces levels of Aβ degradation enzymes (e.g. insulin-
degrading enzymes) (Jiang, Lee et al. 2008, Du, Chang et al. 2009) 
Aβ, Amyloid beta, BBB, Blood brain barrier  
 
TAU phosphorylation: Defective TAU with abnormal phosphorylation, characterised 
by its hyper-phosphorylated state and capacity to form neurofibrillary tangles is a 
hallmark of many dementias, including AD. Transgenic mouse models and in vitro 
investigation have revealed that this deleterious tau phosphorylation increases as a result 
of APOE4 expression (Tesseur, Van Dorpe et al. 2000, Meng, Tianwen et al. 2016). 
Interestingly diet may exacerbate this aberrant phosphorylation induced by APOE4, with 
high cholesterol intake linked to upregulation of tau kinases, and increased tau 
phosphorylation in APOE Knockout mice (Rahman, Akterin et al. 2005). However, this 
tau-APOE interaction may be reliant upon Aβ deposition (Farfel, Yu et al. 2016). Indeed 
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blocking the APOE-Aβ interaction appears to ameliorate both tau and Aβ pathology (Liu, 
Breitbart et al. 2014). 
Mitochondrial dysfunction and Endoplasmic reticulum (ER) stress: The APOE4 
domain interaction is fundamental to the deleterious effects the protein imposes on 
mitochondria and ER. Consistent with this, removal of the interaction (e.g. via mutation) 
restores typical non-pathological function (Zhong, Ramaswamy et al. 2009, Chen, Ji et 
al. 2011). In the ER, APOE4 prompts quality control processes to activate unfolded 
protein stress responses, whilst simultaneously targeting APOE for degradation (Zhong, 
Ramaswamy et al. 2009), resulting in diminished functional APOE, increased APOE 
fragmentation, increased ER stress and ultimately neurotoxicity. In addition both 
mitochondria (Chang, ran Ma et al. 2005, Nakamura, Watanabe et al. 2009), and the ER 
(Liang, Xue et al. 2019), are susceptible to fragmented APOE4. Although not fully 
understood, APOE4-induced mitochondrial dysfunction, has been proposed to occur via 
disrupting expression of mitochondrial energy metabolism genes (Chen, Ji et al. 2011), 
with both fragmented and whole APOE4 reducing mitochondrial respiratory complex 
expression. This may explain why cerebral glucose hypo-metabolism is observed in 
APOE4 carriers before clinical AD develops (Chen, Ji et al. 2011).  
Blood brain barrier (BBB) and cerebrovascular dysfunction: APOE4 is increasingly 
recognised for its implications on cerebrovascular (CV) and blood brain barrier (BBB) 
integrity (Tai, Thomas et al. 2016). These structures are crucial in maintaining efficient 
nutrient supply to the energy demanding brain, and selectively restricting access to the 
brain parenchyma. APOE4 results in altered cerebral blood flow rates in humans, and 
mouse models (Michels, Warnock et al. 2016, Wiesmann, Zerbi et al. 2016) which 
correlate to brain dysfunction in AD (Bangen, Restom et al. 2012). APOE4 targeted 
replacement (TR) mice display visible vascular atrophy, evident from reduced blood 
vessel density and thickness, as revealed by immuno-histofluorescence and perfusion 
transport coefficients (glucose, diazepam) (Bell, Winkler et al. 2012, Alata, Ye et al. 
2015). Similarly, cerebral amyloid angiopathy is increased by APOE4 inducing 
inflammatory and necrotic processes (Tai, Thomas et al. 2016). The integrity of the BBB 
relies heavily upon APOE, with knockout mice developing significant BBB membrane 
permeability, which is highly sensitive to injury (N. Methia 2001). Interestingly, 
regulation of the BBB may be APOE dependent (Nishitsuji, Hosono et al. 2011), with 
APOE4 TR mice exhibiting BBB transport deficiencies (29% reduction in 3H-glucose 
transport across the BBB) (Alata, Ye et al. 2015), and an increased membrane leakiness 
(dextran and diazepam) (Bell, Winkler et al. 2012), as well as reduced cerebral 
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vascularisation and thinner basement membranes (Alata, Ye et al. 2015). In vitro, BBB 
models indicate dysregulated phosphorylation of the tight junction protein occludin, with 
APOE4 altering kinase activation in a lipoprotein receptor-related protein (LRP) 
dependant manner, ultimately impacting tight junction integrity (Nishitsuji, Hosono et al. 
2011). Research conducted by Halliday and colleagues utilising human frontal cortex 
samples, further supports APOE4’s involvement in BBB breakdown with biomarkers of 
BBB degeneration significantly increased with the APOE4 genotype (Halliday, Rege et 
al. 2016).  
Neuroinflammation: Neuroinflammation plays a fundamental role in neurodegeneration 
and AD pathology (Heneka, Carson et al. 2015). It is apparent that APOE is a key 
regulator of inflammatory responses, with removal of APOE leading to greater 
inflammatory responses and macrophage activation (Dorey, Chang et al. 2014). 
Neuroinflammation is altered in an isoform dependant manner with ApoE4 behaving 
similarly to APOE knockout. The APOE4 genotype is associated with greater pro-
inflammatory responses, both generally and after neurotoxic insult, stimulating the 
production of cytokines (IL-1β, IL-6, IL12p40, TNF-α) and nitric oxide species (Guo, 
LaDu et al. 2004, Jofre-Monseny, Loboda et al. 2007, Vitek, Brown et al. 2009). These 
findings are reflected in mouse models in which APOE4 mice display greater 
neuroinflammation and immune cell activation in comparison to APOE3 counterparts 
(Belinson and Michaelson 2009, Rodriguez, Tai et al. 2014, Rodriguez, Tai et al. 2014). 
The increased inflammatory response exhibited by apoE4 offers an explanation as to why 
only APOE4 carriers appear to more responsive to the dementia risk reduction associated 
with anti-inflammatory drug use (Szekely, Breitner et al. 2008). 
Cholesterol and fatty acid metabolism: As a key component of lipoproteins, APOE is 
associated with the metabolism and transport of lipids, cholesterol and PUFA in the 
periphery (Chouinard-Watkins and Plourde 2014). Produced mainly by astrocytes, APOE 
also has a significant presence in the brain as the major and almost exclusive 
apolipoprotein in the central nervous system (CNS), where it has an essential role in 
maintaining cholesterol supply and recycling/distributing lipids. Thus, abnormalities 
associated with APOE4 have profound effects in the brain. Indeed APOE4 is associated 
with decreased lipid and cholesterol CNS transport, which has detrimental implications 
on neuronal repair, remodelling and synaptic plasticity (Mahley 2016). This may in part 
be driven by APOE4’s inability to form lipid-rich APOE particles in the brain; it instead 
produces lipid-poor APOE particles, which are deplete of cholesterol (Hu, Liu et al. 
2015).  
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Interestingly, APOE4 is similarly associated with n-3 PUFA dysregulation, which in 
turn may modulate cholesterol homeostasis (Pincon, Coulombe et al. 2016). The 
interaction involving APOE4 and n-3 PUFA will be explored extensively in the 
following sections. 
Synaptic Plasticity: Considered as a prerequisite to developing AD (Selkoe 2002), 
synaptic plasticity loss of function is reportedly influenced by APOE genotype. APOE4 
is associated with reduced dendritic spine density and length in both human, and mouse 
models (Ji, Gong et al. 2003, Dumanis, Tesoriero et al. 2009). In mice such effects have 
been reported to occur as early as 4 months of age (Sun, He et al. 2017). Similarly APOE4 
has been shown to attenuate long term potentiation in the hippocampus reducing 
activation of CAMK2A and p-CREB (Qiao, Gao et al. 2014). These effects may be 
exacerbated by Aβ and tau (Koch, Di Lorenzo et al. 2017, Wu, He et al. 2017). 
 
Impact of Sex on AD risk 
 
Sex disparity in MCI and AD incidence 
 
Sex influences dementia risk and prevalence (Podcasy and Epperson 2016). Above the 
age of 65 years there are approximately twice as many female AD cases (Seshadri, Wolf 
et al. 1997). Although the higher prevalence has been attributed to longevity, the global 
five year longer lifespan in females (2017) can only partially explain this phenomenon 
(Snyder, Asthana et al. 2016), with age-adjusted prevalence and death rates consistently 
higher in females. The reasons for this are still unclear, although it has been suggested 
that increased incidence in women may be related to the loss, after menopause, of the 
neuroprotective effect of oestrogens, important in maintaining synaptic plasticity, 
neurotransmission and BBB integrity (Maggioli, McArthur et al. 2016, Karp, Mason et 
al. 2017, McEwen and Milner 2017). However, current clinical trials using hormone 
replacement therapy (HRT) have failed to yield any promising results (Marjoribanks, 
Farquhar et al. 2017). Interestingly, analysis of murine hippocampal expression profiles 
reveals that key AD associated genes affecting energy (e.g. Foxo1, Igf-1, Ldhb of the 37 
genes found) and amyloid deposition (e.g. Bace1 and App of the 10 genes found) are 
considerably altered prematurely in females, predisposing them to the development of the 
disease (Zhao, Mao et al. 2016).  
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A greater penetrance of an APOE4  genotype in females, first reported in the early 90s 
(Payami, Montee et al. 1994), could also explain these higher AD rates. A subsequent 
meta-analysis, found that carrying one APOE4 allele had a substantial effect on AD risk 
in females relative to non-carriers (OR: ≈4 at 65 years), whilst their male counterparts 
remained at similar risk (OR: ≈1 at 65 years) (Farrer, Cupples et al. 1997) (Table 1.2 and 
Figure 1.1). This somewhat ‘understudied’ association, has been reiterated over the years 
(Gao, Hendrie et al. 1998, Bretsky, Buckwalter et al. 1999, Holland, Desikan et al. 2013, 
Xing, Tang et al. 2015), including work conducted by Altmann and colleagues who 
observed that the conversion of healthy controls to MCI/AD in APOE4 carriers was 
stronger in women (HR: Female = 1.81 Male = 1.27), with female APOE- ε3/ ε4 more 
likely converting from MCI to AD (HR: Female = 2.17 and Male = 1.51 versus APOE- 
ε3/ ε3) (Figure 1.1) (Altmann, Tian et al. 2014). A contemporary meta-analysis from the 
Global Alzheimer’s Association Interactive Network (n=27 studies, 58,000 participants) 
has offered novel insight into this interaction. Despite no overall significant difference 
between men and women on APOE4 -AD in 55-85 year olds, the influence of sex emerged 
as being age-dependent. APOE4  females were at higher risk of MCI at ages 55-70 years 
and of AD at 65-75 years relative to APOE4  males, with the sexual dimorphism 
disappearing after 75 years (Neu, Pa et al. 2017) (also Figure 1.1). This indicates that a 
higher susceptibility to the APOE4 allele in females is most evident in the decade(s) 
following menopause. As with the overall reduction of penetrance of genotype on AD 
risk at older ages described above, a loss of effect of sex may be due to selective survival 
of those females less sensitive to genotype or the effect of genotype being lessened by an 
overall higher AD risk profile (Corrada, Paganini-Hill et al. 2013).  
Figure 1.1 The impact of sex on Mild cognitive impairment (MCI) and Alzheimer’s 
disease (AD) risk in APOE-Ε4 carriers relative to non-carriers  
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From left to right in chronological order: 
Farrer LA et al. 1997: Odds ratios (OR) for AD risk compared to APOE-Ε3/E3.  
Altmann A. et al., 2014: Report the hazard ratios (HR) for the conversion from (a) 
healthy controls (HC) to MCI/AD in APOE-Ε4 carriers vs. non-carrier, or (b) MCI to 
AD conversion in APOE-Ε3/E4 vs. APOE-Ε3/E3 
Neu SC et al. 2017: OD for MCI or AD compared to APOE-Ε3/E3. Sex did not 
influence the sensitivity of APOE-Ε3/E4-AD association in the overall group (aged 55-
85 years) (P=0.53). Females versus males APOE-Ε3/E4 had a higher OR of MCI 
(P=0.05) at ages 55-70 years (P=0.05) and of AD at 65-75 years (P=0.002). 
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Table 1.2 Key studies supporting the notion of an APOE-Ε4 *sex interaction 
Study Study type Basic participant criteria  Follow up length  Outcome (OR/RR/HR) 
Farrer 
 (Farrer, Cupples 
et al. 1997) 
Meta-analysis  
N=14,537 
40 research groups contributed 
patient data: 
 APOE genotype  
 Sex  
 Age at disease onset  
 Ethnic background  
  
NA  In comparison with APOE- ε3/ ε3, the sexual 
dimorphism in AD risk was 1.5 times greater in APOE- 
ε3/ ε4 individuals (P=.01) 
 See Figure 1.1 
Altmann 
 (Altmann, Tian 
et al. 2014) 
Prospective 
cohort 
N=8,084 
Biomarkers 
N=980 
 Subjects were healthy controls or 
MCI at initial assessment  
 APOE genotype available 
 
Minimum one 
follow-up at 12 
months or later 
 Female APOE- ε4 carriers more likely to develop 
MCI/AD (HR=1.81 women; HR=1.27 men; P=0.011)  
 Compared to APOE- ε3/ ε3, APOE- ε3/ ε4 females more 
likely to convert from MCI to AD (HR=2.17 women; 
HR=1.51 men, P=0.022) see figure 1.1  
 In MCI, APOE- ε4 -sex interaction, significant for tau 
load (total tau: P=0.009; TAU:Aβ ratio P=0.020) 
 
Sampedro  
(Sampedro, 
Vilaplana et al. 
2015) 
Cross-
sectional 
study 
N=274 
 AD Neuroimaging Initiative 
(ADNI) database  
 aged 55 to 90 years 
 healthy elderly control 
individuals 
 available CSF and/or MRI and/or 
a FDG-PET analyses 
 
NA 
 
 Female APOE- ε4 carriers showed brain hypo-
metabolism in the temporal cortex P=0.001 
 Female APOE- ε4 carriers showed cortical thinning in 
AD vulnerable areas, P<0.001 
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Breitner 
(Breitner, Wyse 
et al. 1999) 
Cross-
sectional  
N= 5,092 
 Aged ≥65 years 
 Population of Cache County, 
Utah 
NA  Female sex a risk factor for AD only in those with 
APOE- ε4 (OR=1.58, P=0.02) 
Neu  
(Neu, Pa et al. 
2017) 
Meta-
Analysis  
N= ≈58 000  
 27 independent research studies 
 White Participants only mainly 
non-Hispanic  
 Ages 55-85 years excluded all 
patients with a clinical history of, 
or comorbidity 
with any other known 
neurological disease 
Maximum follow up 
10 years 
 No different between sex for APOE- ε4 -AD risk in 
whole group (OR=3.09 men and OR=3.31 women, 
P=0.53)  
 Female E3/E4 had a higher risk of AD between the ages 
of 65 and 75 years (OR=3.14 men and OR=4.37, 
P=0.002) 
 Female E3/E4 had higher a risk of MCI between the ages 
of 55 and 70 years (OR=1.07 men and OR=1.43, 
P=0.05) 
 See figure 1.1  
Fleisher  
(Fleisher, 
Grundman et al. 
2005) 
Cross-
sectional 
study 
N= 193 
 Aged 55 to 90 years 
 Took part in structural brain 
MRI 
 MCI at initial assessment 
 Good general health 
NA  Women with 1 or 2 APOE- ε4 alleles were found to have 
significantly reduced hippocampal volume  
  Men only showed a significant reduction in 
hippocampal volume when carrying 2 APOE- ε4 alleles. 
 Performance on delayed word recall task mirrored this 
trend 
 
Alvarez  
(Alvarez, 
Aleixandre et al. 
2014) 
Cross-
sectional 
study  
N=362 
 Recruited Healthy, MCI and AD 
patients  
 Excluded all patients with any 
other health conditions  
 not taking various neurological 
medications  
 
NA  Female APOE- ε4 carriers showed lower BDNF levels 
(p<0.01) and MMSE scores (p<0.01) than non-APOE- ε4 
carriers 
 Males did not  
Table 1.2 Continued 
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Li  
(Li, Shofer et al. 
2017) 
Cross-
sectional 
study  
N=331 
 Aged 21 to 100 
 medically stable 
 no evidence or history of 
cognitive or functional decline 
NA  CSF total tau and p-tau181 had no gender differences 
 CSF Aβ42 had age×gender×APOE genotype interaction, 
p=0.047   
 Male APOE- ε4, average CSF Aβ42 decreased gradually 
with age up to midlife and then levelled off. 
 Female APOE- ε4, average CSF Aβ42 remained 
relatively high through to age 50 and then had a rapid 
decline after  
Abbreviations: MCI, Mild cognitive impairment; Aβ, Amyloid beta; CSF Cerebrospinal fluid; MRI, Magnetic resonance imaging; FDG-
PET; Fludeoxyglucose positron emission topography; MRI, Magnetic resonance imaging; BDNF, Brain-derived neurotrophic factor; MMSE, 
Mini Mental state examination        
Table 1.2 Continued 
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Female sex exacerbates the neurocognitive impact of an APOE- ε4 genotype  
 
Limited human cognitive and biomarker data supports the sexual dimorphism evident in 
epidemiological (incident disease) studies, indicating earlier onset and more extensive 
pathology in female APOE4 carriers. Differences in cerebrospinal fluid (CSF) TAU and 
Aβ42 load (Altmann, Tian et al. 2014, Li, Shofer et al. 2017) along with aberrant 
Aβ/secretase profiles in autopsy samples (Nyarko, Quartey et al. 2018) and brain 
hypometabolism and cortical thinning (Sampedro, Vilaplana et al. 2015) have been 
observed between female and male APOE4. Fleisher et al. observed reduced hippocampal 
volume and memory performance in female relative to male APOE4 carriers, in whom 
significant pathological changes only occurred when in possession of two APOE4 alleles 
(Fleisher, Grundman et al. 2005). Analysis of >5000 brain samples of varying ages found 
that women carrying the APOE- ε4  gene had more extensive neurofibrillary tangles and 
senile plaques, with onset of pathology beginning considerably earlier (Corder, 
Ghebremedhin et al. 2004). Neuroprotective immune cell (Aβ-specific CD4+ T cell) 
decline was found to occur 10-15 years earlier in female carriers compared to that of male 
carriers (Begum, Cunha et al. 2014). Finally, levels of brain-derived neurotrophic factor 
(BDNF), an important modulator of neuron survival and growth in areas associated with 
memory, have been found to be significantly reduced in APOE4 females relative to age 
matched APOE4 males, and to correlate to poorer MMSE scores (Alvarez, Aleixandre et 
al. 2014).  
Rodent studies also highlight such a trend. It is widely accepted that female APOE4 
targeted replacement (TR) mice present a more extreme phenotype (Raber, Wong et al. 
1998, Rodriguez, Burns et al. 2013), with greater cognitive decline evident from their 
poorer performance on a battery of behavioural tests (Grootendorst, Bour et al. 2005, 
Bour, Grootendorst et al. 2008, Rodriguez, Burns et al. 2013, Heneka, Carson et al. 2015), 
and a greater extent of neurodegeneration (Rijpma, Jansen et al. 2013, Koutseff, 
Mittelhaeuser et al. 2014). For example Bour et al., demonstrated that 15-month female 
APOE4-TR mice had significantly greater deficits in spatial learning and memory 
compared with male APOE4 mice (Bour, Grootendorst et al. 2008). This is consistent 
with findings of Rijpma et al. who found middle aged APOE4–TR female mice had 
decreased presynaptic density within the hippocampus, which was not found in APOE4-
TR males (Rijpma, Jansen et al. 2013). Wang et al, reported learning and memory 
impairment, occurring at a much younger age in APOE4/3xTg (sporadic and familial 
genes) females, which coincided with higher Aβ proteins and β-site amyloid precursor 
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protein cleavage enzyme (BACE1) when compared to female non-Tg, female 3xTg and 
male APOE4 /3xTg mice (Wang, Hou et al. 2016).   
The influence of sex on APOE associated DHA dysregulation is currently limited, 
however our labs recent findings (Martinsen, Tejera et al. 2019), in which a female 
dependant drop in DHA in APOE4-TR mice was observed, supports the notion and 
warrants further investigation. This may potentially result from the known influence of 
sex on liver and systemic fatty acid synthesis and metabolism, and the differential impact 
of APOE4 on brain DHA uptake and status (addressed below in section ‘DHA availability 
and transport to the brain’).  
 
Menopause and sex hormone dysregulation as a potential explanation for sex- 
APOE4 associations in AD 
  
The process of menopause may offer an explanation for the greater AD susceptibility 
exhibited by females (Li, Cui et al. 2014). It may also help to explain why females appear 
to be predisposed to the effects of APOE4 carrier status (Yun, Park et al. 2007, Moser and 
Pike 2016, Mosconi, Berti et al. 2017, Zokaei, Giehl et al. 2017). Earlier onset of 
menopause correlates with poorer cognition later in life (Ryan, Scali et al. 2014). The 
abrupt hormone dysregulation caused by the menopausal process, is likely to have 
significant implications on brain processes and cognition with the neuroprotective 
importance of oestrogens and progesterone well documented in the literature (reviewed 
extensively (Vest and Pike 2013, Depypere, Vierin et al. 2016)). A recent study using 
multimodal brain-imaging techniques highlighted the impact of menopause in AD 
development, with indicators of AD, such as hypo-metabolism, increased Aβ deposition 
and reduced grey and white matter brain volumes all evident to a greater extent as a result 
of menopause (menopause > perimenopause > no menopause) even after controlling for 
age and education (Mosconi, Berti et al. 2017). Interestingly, APOE4 carrier status 
exacerbated menopausal Aβ deposition relative to other groups, which indicates an 
APOE4 -menopause interaction (Mosconi, Berti et al. 2017). 
One would speculate that re-establishing the hormone profile altered in menopause would 
ameliorate these deleterious effects. However, inconsistent effects of HRT have been 
reported in both the general population and APOE4 carriers. These discrepancies are 
likely attributable to the heterogeneity in the initiation, treatment period, dose and 
combination of hormones used. Although currently inconclusive and sparse, the limited 
research available, addressing the impact of APOE genotype on the efficacy of hormone 
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therapy appears to complicate this paradigm further with reports of both improvements 
(Yun, Park et al. 2007, Jacobs, Kroenke et al. 2013, Kunzler, Youmans et al. 2014), and 
no effect (Yaffe, Haan et al. 2000, Kang and Grodstein 2012, Kunzler, Youmans et al. 
2014), in relation to cognition for carriers of APOE4. Although oestrogens and activation 
of their receptors are known to alter APOE expression (Corbo, Gambina et al. 2006, 
Wang, Irwin et al. 2006), the molecular aetiology of possible APOE genotype-hormone-
cognition interactions is not known.  
Further research is needed to establish the benefits of hormone intervention during 
menopause and whether the effects are APOE genotype dependent, thereby warranting 
stratified approaches. 
 
Docosahexaenoic acid (DHA): A dietary component implicated in AD 
risk 
 
The main dietary n-3 fatty acids are alpha-linolenic acid (α-LNA) mainly from plant 
sources, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), with oily fish 
and fish oil supplements being the main dietary source of EPA and DHA (Innes and 
Calder 2020).  
DHA, is a 22-carboxylic fatty acid consisting of 6 C=C double bonds (22:6n-3). An 
important constituent of the CNS, DHA can be synthesised to a limited extent from α-
LNA or obtained directly from the diet.  
DHA in the brain  
 
DHA is particularly concentrated in the brain (Arterburn, Hall et al. 2006), and accounts 
for 15% of the total fatty acids in the cerebral cortex. This dwarfs the levels found in the 
peripheral tissue such as the heart and liver, where DHA contributes about 2% (Arterburn, 
Hall et al. 2006). DHA is distinctly associated with the grey matter (Bradbury 2011), and 
is highly concentrated within metabolically active neuronal regions (Bradbury 2011, 
Crawford, Broadhurst et al. 2013), including synaptic membranes, synaptic vesicles and 
mitochondria (Neuringer, Anderson et al. 1988). DHA concentration varies across 
phospholipid species, and is abundant within phosphatidylserine (PS) and 
phosphatidylethanolamine (PE), where DHA makes up around one third the total fatty 
acid composition (Neuringer, Anderson et al. 1988, Lauritzen, Hansen et al. 2001).  
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Synthesis of DHA in the brain occurs to a very limited extent (Igarashi, DeMar et al. 
2007), failing to increase even in times of n-3 PUFA deprivation (Igarashi, DeMar et al. 
2007). Brain DHA is supplied from the systemic circulation, with the DHA provided from 
the diet or synthesised mainly in the liver from its shorter chain precursor a-linoleic acid 
(α-LNA) (Domenichiello, Kitson et al. 2015), through the actions of desaturase and 
elongase enzymes (Igarashi, Ma et al. 2006).  
Upon entry into the brain, DHA is activated and esterified to the cell membrane 
phospholipids at the sn2 position, where it is believed to have a range of beneficial 
structural and functional roles. The unique highly polyunsaturated, kinked structure of 
DHA increases membrane fluidity, regulating the properties of the membrane and 
therefore affecting a range of properties including membrane protein function. DHA is 
also associated with promoting antioxidant processes, and altering gene expression 
profiles (Hashimoto, Hossain et al. 2016). This occurs through the release of DHA from 
the membrane under the action of phospholipase A2. Although most is quickly re-
esterified and conserved, release from the membrane allows DHA to partake in multiple 
signalling and regulatory processes, the most documented of which is DHA’s role in 
neuroinflammation. The metabolism of DHA via enzymatic processes (e.g. 
cyclooxygenase, or lipoxygenase) or free radical oxidation, transforms DHA into a 
plethora of bioactive lipid metabolites such as resolvins, protectins and maresins (Kuda 
2017, Martinsen, Tejera et al. 2019), known collectively as specialised pro-resolving 
mediators (SPMs), which are renowned for ability to resolve inflammation. 
 
Does DHA intake and status affect dementia risk?  
 
Prospective epidemiological studies, summarised by a number of meta-analyses, indicate 
that a higher consumption of fish and oily fish, the almost exclusive dietary source of 
DHA is associated with reduced dementia and AD risk (Table 1.2) (Kalmijn, Launer et 
al. 1997, Barberger-Gateau, Letenneur et al. 2002, Morris, Evans et al. 2003, Barberger-
Gateau, Raffaitin et al. 2007, Giri, Zhang et al. 2016). To put this beneficial effect into 
perspective, the meta-analyses conducted by Wu and colleagues reported an 11% risk 
reduction in AD with each 100g increment of fish consumption per week (Wu, Ding et 
al. 2015), with Zhang et al. observing that a 0.1g increment in DHA per day was 
associated with 14% and 37% lower risks of dementia and AD respectively (Zhang, Chen 
et al. 2016). This is particularly relevant since the current UK recommended intake of 
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EPA+DHA is >450mg per day provided as two portions (each 140g) of fish per week one 
of which should be oily  
Higher circulating DHA concentrations have been associated with improved cognition 
and reduced dementia and AD risk. Conquer et al. reported that AD patients have lower 
plasma DHA levels, in the total phospholipid, phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) fractions (Conquer, Tierney et al. 2000). This was 
reiterated in the Framingham study where those in the top quartile of plasma PC-DHA 
had a 47% lower dementia risk relative to the bottom quartile (Schaefer, Bongard et al. 
2006), which is consistent with the Rancho Bernado study (Lopez, Kritz-Silverstein et al. 
2011). Interestingly those in the Framingham study in the lowest RBC DHA quartile also 
had lower total brain volume and performed poorer on a range of cognitive tests including 
visual memory, executive function and abstract thinking tasks (Tan, Harris et al. 2012). 
Further to this Yassine et al reported an association between serum DHA and cerebral 
amyloidosis and brain volumes (particularly those areas affected by AD) (Yassine, Feng 
et al. 2016). Although not fully consistent, post mortem brain analysis also indicate that 
DHA levels are reduced in AD (Söderberg, Edlund et al. 1991, Fraser, Tayler et al. 2010). 
This beneficial association appears to also continue into later life. For example, Yassine 
et al. looked specifically at elderly individuals and found participants within the lowest 
serum DHA quartile to have significantly more cerebral amyloidosis (Yassine, Feng et 
al. 2016), However it appears there is little research examining  the effects of DHA within 
the oldest old (85+ years), an area which warrants investigation. 
A high oily fish and DHA consumption is associated with a higher socio-economic status, 
with such subgroups typically being more educated, engaging in higher physical activity, 
having lower prevalence of smoking and higher consumption of plant based foods, all of 
which have been shown to be neuroprotective. Although data analysis approaches correct 
for the impact of such co-variates, not all analyses are fully comprehensive and there may 
be other associated behavioural attributes which have not been considered. Therefore, a 
proportion of the reported benefits of fish/DHA may in certain instances be attributable 
to the residual confounding effect of these associated factors.  
Although collectively the observational data demonstrate that a high, habitual oily fish 
and DHA intake, and DHA status, are associated with a reduction in AD risk, these 
findings have not been consistently supported by randomised controlled trials (RCTs). 
RCTs have yielded conflicting results; some displaying promise (Vedin, Cederholm et al. 
2008, Yurko-Mauro, McCarthy et al. 2010, Lee, Shahar et al. 2013, Stonehouse, Conlon 
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et al. 2013), whilst others have failed to establish any beneficial effects (Quinn, Raman 
et al. 2010, Quinn, Rema et al. 2010, Phillips, Childs et al. 2015). Stonehouse et al. 
observed improved memory and reaction time in healthy young adults supplemented with 
1.16g DHA for 6 months (Stonehouse, Conlon et al. 2013). In the Alzheimer’s Disease 
Cooperative Study (ADCS) which recruited those with mild to moderate AD, no cognitive 
benefits were evident following the consumption of 2g DHA daily for 18m (Quinn, 
Raman et al. 2010). RCTs to date have been predominately in individuals with existing 
MCI or AD who will have already experienced significant neuronal loss, thereby 
potentially missing the ‘window’ of preventive and therapeutic intervention. It is 
increasingly understood that the initial neuropathology which ultimately manifests in 
clinical AD, typically occurs some 20-30 years before any noticeable and measurable 
effects on cognition (Braak and Del Tredici 2011). Therefore, interventions, such as 
DHA, should target pre-clinical at-risk and prodromal groups, in order to maximise the 
individual and population benefits. 
Apparent inconsistencies in RCT findings are also likely to be due to other heterogeneous 
elements of experimental design, such as DHA dose, habitual DHA status of trial 
participants with likely greater benefit in those with a low baseline status, typical of 
western populations (Stonehouse, Conlon et al. 2013) and length of intervention. Brain 
DHA half-life is estimated to be up to 2.5 years, with mechanisms in place to conserve 
DHA in times of deprivation (Rao, Ertley et al. 2007, Rapoport, Rao et al. 2007, Umhau, 
Zhou et al. 2009). Many RCT are therefore too short to result in appreciable differences 
in brain DHA with any observed benefits reliant on changes in systemic process such as 
improved cardiovascular health  
 
Pre-clinical and in vitro studies suggest DHA benefit  
 
Interestingly, a number of cellular and pre-clinical studies demonstrate that DHA can 
ameliorate deleterious biological processes associated with AD, including some of those 
linked to an APOE genotype, as described above. Supplementing AD mouse models with 
a 0.6% DHA diet significantly reduced Aβ plaque formation (Lim, Calon et al. 2005, 
Teng, Taylor et al. 2015) and affected amyloid precursor protein processing in Tg2576 
mice (Lim, Calon et al. 2005). In addition, DHA was also observed to modulate Aβ 
aggregation by stabilising oligomers in APP/PS1 mice (Teng, Taylor et al. 2015). This is 
consistent with in vitro findings (Hashimoto, Shahdat et al. 2009). Similarly, AD rodent 
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models have revealed that DHA supplementation reduces aberrant phosphorylation of 
TAU resulting in improved cognitive performance in 3xTg-AD mice (Arsenault, Julien 
et al. 2011). With DHA known to modulate cellular inflammation by multiple 
mechanisms (Calder 2017), it is of no surprise that DHA supplementation reduces 
neuroinflammation. Combined EPA and DHA supplementation prevented cytokine 
expression and alterations in astrocyte morphology in aged wild type C57BL/6 mice 
(Labrousse VF 2012). Hopperton and Thomas reported an effect of DHA 
supplementation on microglia activation (Hopperton, Trepanier et al. 2016) and 
inflammatory precursor expression (Thomas, Garg et al. 2013) in the same model. It 
should be noted however that such rodent studies tend to employ supra-physiological 
doses of DHA (human equivalent of greater than 2g) (Arsenault, Julien et al. 2011, 
Chouinard-Watkins, Vandal et al. 2017) for a substantial proportion of the mouse lifespan  
(Lim, Calon et al. 2005, Arsenault, Julien et al. 2011, Teng, Taylor et al. 2015). These 
strategies are utilised in the attempt to maximise the chance of observing cognitive 
benefit. However due to the large doses used, and relatively long intervention periods (as 
a proportion of total lifespan) translation to humans is often unrealistic. Despite their 
importance in the research of complex disease, current rodent models of AD have 
recognised limitations (McGowan, Eriksen et al. 2006), associated with dissimilar 
human-to-mouse lifespan and environmental conditions. As a result pathological protein 
profiles may differ chemically and morphologically, and human AD pathology is not fully 
recapitulated (Richardson and Burns 2002). Such inconsistencies in regard to plaque 
pathology may produce ‘effect sizes’ in mouse models which cannot be reached in 
humans, which need to be appreciated when interpreting rodent data. In addition, a wide 
range of rodent AD models exist, each with unique ageing profiles and pathological 
progressions, strengths and limitations. These need to be taken into account when 
collectively interpreting the results from rodent experimentation (Tai, Youmans et al. 
2011).  
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Table 1.3 Prospective cohort studies reporting on fish and DHA intakes and dementia risk 
Study  Study type Basic participant 
criteria 
Follow up 
length 
n-3 PUFA intake or status  Outcome (OR/RR/HR) 
Barberger-
Gateau 
(Barberger-
Gateau, 
Raffaitin et al. 
2007) 
Prospective 
cohort 
 
N=8085 
 ≥65 years 
 Dementia free 
at baseline  
 Male and 
Female  
4 years 1. Weekly consumption of 
fish 
2. Regular n-3 rich oil 
intake  
1. Reduced AD risk (HR 0.65, 95% CI 0.43 to 
0.994) 
2. Reduced all cause dementia risk (HR 0.60, 
95% CI 0.40 to 0.90) in APOE- ε4 non 
carriers only  
3. Reduced dementia risk (HR 0.46, 95% CI 
0.19 to 1.11) 
 
 
Morris  
(Morris, Evans 
et al. 2003) 
Prospective 
cohort 
 
N=815 
 65–94 years 
 Dementia free 
at baseline  
 Male and 
Female  
 
Average 3.9 
years 
1. Weekly consumption of 
at least one portion of 
fish 
2. Total intake of n-3 
PUFA 
1. Reduced AD risk (RR, 0.4; 95% CI 0.2 to 0.9) 
2. Reduced AD risk with increasing n-3 PUFA 
intake (highest quintile RR, 0.3; 95% CI 0.1 
to 0.9) 
Schaefer 
 (Schaefer, 
Bongard et al. 
2006) 
Prospective 
cohort 
 
N=899 
 55-88 years  
 Dementia free 
at baseline 
 Male and 
Female   
 
 
9.1 years 1. Highest quartile plasma 
PC-DHA levels – 
equating to 3 servings 
of fish per week 
1. Reduced all cause Dementia risk (RR 0.53, 
95% CI 0.29-0.97) and AD risk (RR 0.61, 
95% CI 0.31 to1.18) 
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Huang 
(Huang, Zandi 
et al. 2005) 
Prospective 
cohort  
 
N=2233 
 ≥65 years 
 Dementia free 
at baseline 
 Male and 
Female  
  
0.1 to 8.4 years 1. Fatty fish consumption 
≥ times per week 
1. Nominal but not significant Reduction in 
dementia risk (HR 0.79; CI 0.53 to 1.20) in 
APOE- ε4 non carriers only  
2. Nominal but not significant Reduction in AD 
risk (HR 0.69; 0.91 to 1.22) In APOE- ε4 non 
carriers only 
 
 
 
Devore  
(Devore, 
Grodstein et al. 
2009) 
Prospective 
cohort 
N=5395 
 ≥55 years 
 Dementia free 
at baseline  
 reported dietary 
information at 
baseline 
 Male and 
Female   
Average 9.6 
years 
1. High fish intake  
2. n-3 PUFA intake 
1. Those who had a high fish intake (hazard 
ratio: 0.95; 95% CI: 0.76, 1.19) and those 
consuming fatty fish (HR: 0.98; 95% CI: 0.77 
to 1.24) had a similar dementia risk when 
compared to those who typically ate no fish.  
2. Participants in the lowest tertile of long-chain 
N-3 intake, had similar risk of dementia to 
those in the highest tertile (HR: 0.97; 95% CI: 
0.77 to 1.21) 
Wu  
(Wu, Ding et al. 
2015) 
Meta-analysis of 
prospective 
cohort studies  
N=22402 
 Prospective 
cohort studies  
 
Minimum one 
year follow up 
1. Higher intake of fish 
2. Higher long-chain n-3 
fatty acid intake 
3. Increasing 100g per 
week increment of fish 
1. 36% reduced AD risk compared with lowest 
intake group (95% CI 8 to 56%). This 
increased further if using only studies with 
longer follow up. 
2. No statistically significant association with 
long-chain omega-3 fatty acids intake and AD 
risk reduction (RR = 0.89, 95% CI 0.74–
1.08). 
3. 11% reduced AD risk (RR = 0.89, 95% CI 
0.79 to 0.99). 
Table 1.3 Continued 
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Zhang  
(Zhang, Chen et 
al. 2016) 
Meta-analysis of 
prospective 
cohort studies 
 
N= 181580  
 Prospective 
cohort studies 
2.1-21 ears 1. 1 serving of fish per 
week  
2. 0.1-g per day increment 
of DHA 
1. Lower dementia (RR: 0.95; 95% CI: 0.90 to 
0.99), and AD risk (RR: 0.93; 95% CI: 0.90 to 
0.95) 
2. Lower dementia (RR: 0.86; 95% CI 0.76 to 
0.96) and AD risk (RR: 0.63; 95% CI 0.51 to 
0.76) 
AD, Alzheimer's disease; CI, confidence interval; HR, hazard ratio; OR, odds ratio; PUFA, polyunsaturated fatty acid; PC-DHA, 
phosphatidylcholine-docosahexaenoic acid; RR, relative risk. 
 
Table 1.3 Continued 
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DHA availability and transport to the brain 
 
Transport to the Brain  
Effective circulatory transport and BBB uptake of DHA, is crucial for maintaining brain 
supply. DHA derived from the diet, synthesised in the liver or released from reserves in 
adipose tissue is packaged into various plasma pools for transportation (Lefkowitz, Lim 
et al. 2005), either in lipoproteins (esterified as triglycerides (TAG), diacylglycerol, 
phospholipids (PL) or cholesteryl esters or bound to albumin as non-esterified DHA or 
esterified to lyso-phosphatidylcholine (LPC) (Lagarde, Bernoud et al. 2001). The 
importance of each pool in supplying brain DHA is still widely debated; however, current 
evidence indicates that the albumin bound fractions are the predominant sources, with the 
non-esterified DHA pool being quantitatively the major physiological pool despite LPC-
DHA being preferentially incorporated after a single dose (Chen, Kitson et al. 2015). The 
observation of adequate brain DHA status in LDL and VLDL receptor knockouts, 
indicates that direct lipoprotein uptake of DHA is not a significant source (Chen, Ma et 
al. 2008, Rahman, Taha et al. 2010). A more complete understanding of the ability of 
DHA pools and dietary sources to target the brain is of high therapeutic relevance, 
potentially leading to more effective use of DHA intervention to support healthy brain 
ageing.   
 
DHA transport across the blood brain barrier 
The movement of DHA across the BBB may be passive, transporter-mediated or a 
combination of both processes (Figure 1.2). Rodent studies and model membranes have 
demonstrated that un-esterified DHA can freely cross the BBB via simple diffusion 
(yellow arrow) (Ouellet, Emond et al. 2009), supporting the notion, that diffusion alone 
is adequate. Cluster of differentiation 36 (CD36) was previously believed to be a 
transporter of un-esterified DHA, however CD36 knockout mice do not display DHA 
deficits in the brain (3 – red arrow) (Song, Elbert et al. 2010). Similarly, the importance 
of lipoprotein mediated DHA uptake has been questioned; with LRP receptor knockout 
mice exhibiting normal DHA brain levels and supply (4 – red arrow) (Chen, Ma et al. 
2008, Rahman, Taha et al. 2010). Instead, it is now proposed that under the action of 
lipoprotein lipase at the BBB, lipoprotein DHA is released as free fatty acid enabling 
simple diffusion across the BBB (5) (Sovic, Panzenboeck et al. 2005, Chen and Subbaiah 
2013).  
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In contrast, major facilitator superfamily domain-containing protein 2 (MFSD2A) 
provides evidence that transporter mediated routes are indeed necessary for sufficient 
DHA transport to the brain. Expressed in the BBB endothelium, MFSD2A appears to be 
an integral part of DHA transport across the BBB and specifically transports LPC 
esterified DHA (6 – green arrow) (Nguyen, Ma et al. 2014). Mfsd2a’s importance is 
evident from mice lacking the transporter. These knockout mice exhibit 58.8% reduced 
brain DHA levels, accompanied by hippocampal and cerebellum neurodegeneration, 
which manifests as significant cognitive impairment (Nguyen, Ma et al. 2014, Wong, 
Chan et al. 2016).  
In addition to MFSD2A, various fatty acid binding proteins (FABP) have been implicated 
in DHA uptake and retention. Pan et al. discovered a role for the carrier protein FABP5, 
which is the most expressed FABP at the BBB (Lee, Kappler et al. 2015). Confirming 
that FABP5 binds un-esterified DHA with high affinity, the group optimised an in situ 
trans-cardiac perfusion technique and deduced that transport of 14C-DHA, was reduced 
by 36% in Fabp5 deficient mice (Pan, Scanlon et al. 2015). They recently continued this 
line of research, describing how Fabp5 knockout mice have a 14% reduction in cortical 
DHA levels. Loss of FABP5 and subsequent reduction in DHA transport translates to 
significant cognitive deficits, illustrating the importance of both FABP5 and DHA in 
cognitive health (Pan, Short et al. 2016). Interestingly endothelial cell uptake of DHA 
was significantly impaired (-48%) whilst cell transport was unaffected (Pan, Short et al. 
2016), providing evidence that FABP5 influences uptake, and not endothelial cell 
transport, as originally thought (7 – green arrow and 8 – red arrow). Finally, evidence has 
emerged that supports a role for fatty acid transport protein 1 (FATP1) in DHA supply to 
the brain (Ochiai, Uchida et al. 2016). FATP1 appears to be a basal membrane transporter 
with initial cell studies suggesting it contributes to DHA transport across the BBB (9 – 
green arrow) (Ochiai, Uchida et al. 2016). However, in vivo follow up experimentation, 
is required to confirm these initial findings.  
In summary, although DHA has been observed to cross the BBB via simple diffusion, 
there appears to be protein mediated processers in place to ensure an adequate supply of 
this essential molecule, as evidenced by Mfsd2a and Fabp5 knockout rodent model data. 
Further characterisation of these transporters in aged mice is required to confirm their 
importance in adult, non-developmental related DHA brain transport. Overcoming DHA 
transport deficits may enhance DHA supply to the brain, subsequently improving 
cognitive health. Potential methods to achieve this include: supplying DHA in a highly 
bioavailable pool, altering transporter BBB kinetics to favour DHA uptake, or increasing 
35 
 
overall blood DHA status. These methods could be utilised to compensate for the reduced 
delivery efficiency associated with BBB transport deficits e.g. associated with ageing 
(Graf, Duchateau et al. 2010) or APOE genotype.  
Figure 1.2 DHA - BBB transport mechanisms   
Plasma DHA is associated with lipoproteins or albumin depending on esterification status 
(1). Un-esterified DHA can cross the BBB via simple diffusion (2). The uptake of DHA 
via CD36 (3) and LRP (4) mediated processes are now considered insignificant. 
Lipoproteins may still contribute as a DHA pool under the action of lipoprotein lipase at 
the BBB (5). Mfsd2a specifically aids the uptake of LPC-DHA into the endothelium (6). 
FABP5 is implicated in the transport of DHA across the BBB; it is thought that this is 
achieved via endothelial uptake (7) and not cellular transport (8). FATP1 may enhance 
transport of DHA across the basal membrane (9). Green arrow: Potential transport process 
Yellow arrow: Simple diffusion Red arrow: Disproved transport process. Adapted from 
Bazinet et al (Bazinet and Laye 2014) 
 
The influence of APOE genotype on DHA metabolism and status  
 
Human epidemiological evidence along with RCT data indicate that APOE4 carriers are 
less responsive to the neuroprotective benefits of higher DHA intakes (Huang, Zandi et 
al. 2005, Quinn, Raman et al. 2010, Yassine, Braskie et al. 2017). Such findings are in 
agreement with results demonstrating that APOE4 TR mice have significantly lower brain 
DHA concentrations (9% reduction in cortex compared to APOE2) (Vandal, Alata et al. 
2014), and more recent insights suggesting this may occur to a greater extent in females 
(Martinsen, Tejera et al. 2019), therefore indicating impaired DHA transport and/or 
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metabolism associated with an APOE4 genotype. Uptake of DHA into the brain has been 
shown to be significantly reduced in APOE4 TR mice and to progressively decline with 
age (Vandal, Alata et al. 2014), which may be suggestive of BBB transport impairment. 
This potential transport impairment in APOE4 rodents is consistent with findings from 
the Alzheimer's Disease Cooperative Study (ADCS) trial in humans where lower DHA 
levels in the cerebrospinal fluid in APOE4 carriers following DHA supplementation was 
observed (Yassine, Rawat et al. 2016, Tomaszewski, He et al. 2020). The molecular 
aetiology of the proposed reduced BBB transport of DHA in APOE4, and in particular 
any effect on the protein mediated transport mechanisms described above, is currently 
unknown.  
 A recently conducted PET study in humans, exploring the incorporation of 11C-DHA 
surprisingly reported that young APOE4  carriers have increased DHA brain delivery and 
incorporation rates (Yassine, Croteau et al. 2017). Although these findings need to be 
confirmed in a larger study, this apparent increase, contradicts the suggested APOE4 
transport deficits. This may represent a compensatory mechanism to overcome DHA loss 
via altered brain metabolism. The progression to further transport/metabolism deficits 
observed in aged APOE4 carriers may overwhelm this compensatory process leading to 
eventual reduced brain DHA concentrations and predisposing carriers to AD. Further 
investigation is needed to fully establish the effect of APOE4 on DHA transport and brain 
delivery and metabolism and how they are affected by age.  
An altered systemic DHA metabolism, associated with lower overall DHA availability in 
APOE4 carriers may also underlie a lower brain DHA status. Chouinard-Watkins et al, 
observed (using radiolabelled 13C DHA) a reduced DHA plasma incorporation (31% less), 
and significantly increased DHA β-oxidation (80%) in elderly APOE4  carriers 
(Chouinard-Watkins, Rioux-Perreault et al. 2013) relative to APOE4  non-carriers. The 
greater hepatic uptake and β-oxidation of DHA potentially explains the lower plasma 
response observed in APOE4 carriers with high-BMI (Chouinard-Watkins, Conway et al. 
2015). Altered DHA metabolism is apparent in the liver of APOE4 TR  mice, which 
express APOE under murine Apoe promoter producing a physiologically relevant APOE 
model (Tai, Youmans et al. 2011). In these mice, PUFA homeostasis is significantly 
dysregulated, potentially as a result of altered fatty acid transporter expression, 
specifically FABP1 (Chouinard-Watkins, Pincon et al. 2016). Interestingly 
supplementation with a relatively large dose (3g/day) of DHA restored these deficits 
observed in the liver (Chouinard-Watkins, Pincon et al. 2016). In light of this 
observations, supplementation with larger doses of DHA (up to 3 g/day) in APOE4 
37 
 
carriers may present a plausible route to overcome the transport and metabolism deficits 
associated with APOE4 (Chouinard-Watkins, Vandal et al. 2017). Chouinard-Watkins 
and colleagues showed such supplementation prevented memory decline in APOE4 
rodent model with APOE4 TR mice performing similarly to both APOE3 TR mice fed a 
normal diet and the diet highly enriched with DHA (Chouinard-Watkins, Vandal et al. 
2017, Yassine, Braskie et al. 2017). Given the apparent deficits in DHA transport and 
metabolism in those with an APOE4, alternative intervention strategies should also be 
considered. 
To our knowledge, the impact of sex and menopausal status on DHA status and BBB 
transport and its interaction with APOE genotype is currently completely unknown. It is 
proposed as a high priority research area to provide insight into the mechanistic basis for 
the greater effect of the APOE4 allele in females.  
 
Literature review conclusions and research gaps 
 
The implications of the APOE4 genotype in cognition and AD risk are far-reaching and 
complex, detrimentally influencing a range of AD mechanisms from Aβ deposition to 
DHA metabolism. This makes the process of developing a mitigating intervention 
challenging. The extent of APOE4’s influence appears to be modulated to some extent by 
a triad of factors namely sex, age (with impact on menopausal status in women) and DHA 
status. Targeted nutrition strategies may overcome the negative influence of these factors, 
attenuating genetic vulnerability and ‘tipping the balance’ in favour of AD prevention, 
particularly if such an intervention is implemented early in the disease process. From 
current evidence, advocating the consumption of oily fish and DHA appears a robust 
approach to reduce AD risk and in APOE4 carrier’s higher doses may be warranted to 
achieve the benefit associated with non-carriers, due to impairment in transport and 
metabolism. This may also be true for the elderly who display an age dependant transport 
deficit, and females where the effects of the APOE4 genotype are exacerbated.  
Characterisation of the impact of sex and menopausal status on, brain DHA uptake and 
metabolism and responsiveness to DHA intervention, independent of, and according to 
APOE genotype status are identified as research priority area. Dose-response studies in 
sex by APOE genotype groups are needed to identify effective DHA intake doses and 
develop stratified nutrition intervention approaches.  
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Research gaps  
 
With no current disease modifying treatments currently available, Alzheimer’s disease 
poses an ever-increasing health burden globally (Nichols, Szoeke et al. 2019). To date, 
potential AD therapeutics have failed to show significant clinical effectiveness or safety 
required for therapeutic use. In addition, the multifactorial nature of AD may render 
specific drug targets redundant for a proportion of the AD/at risk population. Therefore, 
alternative strategies are warranted. 
DHA and EPA are pleiotropic in their neuroprotective actions and are known to modify 
multiple AD related mechanistic pathways. Furthermore, regular consumption of long 
chain n-3 PUFA (Barberger-Gateau, Raffaitin et al. 2007, Zhang, Chen et al. 2016), and 
greater n-3 PUFAs status are associated with reduced AD risk and improved cognition. 
As a result, n-3 PUFA supplementation has been proposed as a potential intervention 
strategy to overcome APOE4 mediated AD risk. Reports however suggest, that cognitive 
responsiveness to DHA intake is lower in APOE4 individuals (Metherel, Armstrong et al. 
2009, Kofler, Miles et al. 2012, Childs, Kew et al. 2014, Walker, Browning et al. 2014, 
Minihane 2016, Davis, Hecht et al. 2017, Slim, Vauzour et al. 2017), and therefore 
establishing an optimal dosage for APOE4 carriers is warranted. In addition, the 
pathological impact of APOE4 carrier status appears to be modified by sex, with female 
carriers found to have increased MCI or AD risk between the ages of 55 and 70 years 
compared to their male counterparts (Farrer, Cupples et al. 1997, Neu, Pa et al. 2017). 
This may suggest a possible role of menopausal transition, however research exploring 
the impact of menopause on APOE4 genotype is limited. 
If validated, then those with an APOE4 genotype, particularly peri/post-menopausal 
females, are a large ‘at-risk’ population group who could be targeted for preventive 
intervention, such as LC n-3 PUFA supplementation. Even strategies capable of delaying 
disease onset by as little as two years would have profound implications on current 
disease burden (Brookmeyer, Gray et al. 1998).  
 
Hypothesis and study overview  
 
Research Question and Overview  
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The overall aim of this PhD project is to investigate the relationship between APOE 
genotype, menopause and n-3 PUFA status on cognitive outcomes. We aim to establish 
if a menopause *APOE4 interaction exists for circulating and brain n-3 PUFA status and 
brain DHA transport proteins. Furthermore, we explore whether n-3 PUFA 
supplementation can ameliorate APOE4 and menopausal related deficits in cognition, 
along with their underlying molecular mechanisms. To achieve this we fulfil the 
following objectives: 1) Explore the relationship between APOE genotype, hormone 
replacement therapy use, and fish oil intake on n-3 PUFA status and cognition utilising 
data obtained from the CANN study (NCT02525198. (Irvine, Scholey et al. 2018)), 2) 
Establish an APOE-TR model of menopause, 3) Study the combined impact of 
menopause and APOE4 on cognition and identify contributing mechanisms. 4) Determine 
the effectiveness of two clinically relevant doses of n-3 PUFA fish oil supplement in 
ameliorating deficits in cognition and neurophysiology associated with APOE genotype 
and menopause.  
 
Hypothesis  
 
We hypothesise that:  
1. APOE genotype leads to dysregulated n-3 PUFA status and subsequent cognitive 
decline.  
2. Menopause will exacerbate the pathological mechanisms associated with APOE4  
3. n-3 PUFA supplementation will ameliorate these deficits in a dose dependant 
manner  
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 : Influence of APOE carrier-status, oily fish intake 
and HRT on PUFA status and cognition (A CANN study 
analysis) 
  
Introduction 
 
The global incidence of dementia stands at 50 million, and is set to triple by 2050 (Patterson 
2018), with concerns that there are no effective disease modifying treatments. Studies in ‘at 
risk’ humans (e.g. SMI and MCI) are an effective method to identify risk factors, and disease 
markers present at the population level, which can inform us of associated mechanisms. This 
may in turn provide insight from which novel intervention strategies can be developed.  
The APOE4 genotype is a well-established genetic determinant of Alzheimer’s disease 
(AD). Possession of just one APOE4 allele increases AD risk by 2- to 4-fold, and reduces 
disease onset by ~12 years (Corder, Saunders et al. 1993, Roses 1996, Farrer, Cupples et al. 
1997). Despite this, a clear aetiological basis for APOE4 mediated AD risk remains unclear. 
This is largely a result of the complex, pleiotropic nature of APOE, with its interaction with 
non-genetic determinants such as diet and sex, making additional contributions. The ability 
of non-genetic determinants to modulate APOE4 mediated AD risk, supports the prospect of 
disease modifying intervention.   
Incorporation of greater n-3 PUFAs such as DHA into the diet, achieved with greater intake 
of oily fish or fish oil supplementation, is associated with improved cognitive performance 
in older adults (Del Brutto, Mera et al. 2016), and a general reduction in mild cognitive 
impairment (MCI) and AD risk (Barberger-Gateau, Raffaitin et al. 2007, Zhang, Chen et al. 
2016, Zhao, Xiong et al. 2018, Zhang, Han et al. 2019). It has been suggested that carriers 
of the APOE4 allele are more sensitive to n-3 PUFA deficiencies (Nock, Chouinard-Watkins 
et al. 2017), and potentially respond less effectively to supplementation (Chouinard-
Watkins, Rioux-Perreault et al. 2013). This may result from altered metabolism and/or 
transport of n-3 PUFAs in APOE4 carriers (Chouinard-Watkins, Rioux-Perreault et al. 2013, 
Chouinard-Watkins and Plourde 2014, Vandal, Alata et al. 2014, Chen and Bazinet 2015, 
Yassine, Rawat et al. 2016). In fact, specific APOE4 associated disturbances in DHA:AA 
ratios within blood phospholipids have been used to effectively identify individuals with 
MCI/AD (Abdullah, Evans et al. 2017). Interestingly, such deficits appear to be overcome 
by utilising larger doses of DHA when supplementing APOE4 carriers (Chouinard-Watkins 
et al., 2016; Chouinard-Watkins et al., 2017; Tomaszewski, He et al. 2020)). 
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In addition to this, and adding further complexity, a degree of uncertainty remains as to 
which plasma DHA pools are the main sources of DHA, for transfer across the blood brain 
barriers and therefore having the greatest influence on brain DHA maintenance (Lacombe, 
Chouinard-Watkins et al. 2018). Within blood plasma, DHA can be found in various forms, 
esterified to phospholipids (PL), lysophospholipids (LPC), cholesteryl esters (CE), or 
triacylglycerols (TAG) within lipoproteins. Furthermore, DHA may also be complexed with 
albumin as a non-esterified (NE) free FA or esterified to LPC. Red blood cell (RBC) 
erythrocytes and platelets also carry DHA esterified to PLs within their plasma membranes 
(Lacombe, Chouinard-Watkins et al. 2018). Of these pools, the plasma NE-FA, and LPC 
fractions appear to be particularly efficient at targeting the brain (Chouinard-Watkins, 
Lacombe et al. 2018), however PL plasma fractions likely contribute to some extent 
(Chouinard-Watkins, Lacombe et al. 2019). With that said, the erythrocyte contribution 
should not be entirely ignored, as evidence supporting or ruling out its role is limited, despite 
extensive evidence linking improved cognitive outcomes and lower AD risk to those with 
higher n-3 PUFA erythrocyte status (Hooper, De Souto Barreto et al. 2018). This remains an 
active research area, requiring further investigation to unravel the complexity of the process. 
Sex is ever-increasingly acknowledged for its influence on the impact of APOE4 on AD risk 
(Belloy, Napolioni et al. 2019). Compared to males, female APOE4 carriers have increased 
MCI and AD risk between 55-70 years and 65-75 years respectively (Neu, Pa et al. 2017), 
which may be suggestive of a menopausal link. Interestingly, estrogen/sex hormone 
dysregulation has already been implicated in the pathophysiology of AD (Pines 2016) with 
such risk highlighted by the greater cognitive decline associated with premature menopause 
(Ryan, Scali et al. 2014). One would therefore hypothesise that hormone replacement 
therapy (HRT), which aims to restore female sex hormone profiles, may effectively 
overcome this predisposition. However, overall results of HRT in AD prevention have been 
mixed (O'Brien, Jackson et al. 2014, Imtiaz, Tuppurainen et al. 2017). This may in part be a 
result of the so called ‘window of opportunity’ implying that efficacy is dependent on when 
HRT is administered (Davey 2013, Bean, Kumar et al. 2015). Similarly, variations in HRT 
combinations and doses are also likely to contribute to the variation in effectiveness. In 
addition, specific genetic differences may alter a person’s response to HRT. The relationship 
of HRT and the APOE genotype remains vastly understudied but given the established 
impact of sex and the possibility of a menopausal interaction, it is plausible that altering the 
sex hormone profile may differentially effect those carrying an APOE4 allele. Currently, 
only a handful of studies have explored the APOE genotype in HRT, in the context of 
dementia risk or cognition, the results of which have been mixed (Yaffe, Haan et al. 2000, 
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Burkhardt, Foster et al. 2004, Yue, Hu et al. 2007, Ryan, Carrière et al. 2009). A reflection 
of the surprising lack of research, exploring the influence of sex on APOE genotype 
(Michaelson 2014).     
This study utilises data obtained from the CANN (Cognitive Ageing, Nutrition and 
Neurogenesis; NCT02525198) study in which I was actively involved in the clinical visits 
and in particular the biological sample processing and storage for the Norwich cohort, along 
with the data analysis plan and conduct included here. The primary objective of CANN was 
to ‘evaluate whether daily supplementation with a combined flavonoid/DHA rich-fatty acid 
supplement over a 12-month period improved cognitive performance in older adults (≥ 55 
years) with Mild Cognitive Impairment (MCI) or Subjective Memory Impairment (SMI)’. 
The analysis conducted as part of my thesis utilises predominantly pre-treatment, baseline 
data and focuses on female participants within the cohort. Here, we analyse the impact of a 
number of factors including APOE4 carrier status and HRT on erythrocyte PUFA status and 
follow this up with further analysis of these factors on cognition.  
Materials and methods 
 
Figure 2.1 Overview of CANN timeline.  
This project focuses on pre-intervention generated data obtained at screening (V1) and 
Baseline (V2) data (highlighted in gold) which were ~3 weeks apart 
Screening 
(V1)
•Measurements of height and weight were taken for the 
calculation of body mass index (BMI)
•APOE genotyping
•red blood cell (RBC) FA analysis
•neuropsychological test battery to confrim MCI/SMI status
0 month 
(V2)
•Food Frequency Questionnaire
•Neuropsychological test battery
•Fasted Plasma FA analsysis 
•Urine, stool sample
•MRI
3 month
(V3)
•Neuropsychological test battery
•Fasted Plasma FA analsysis 
•Urine, stool sample
•MRI
12 month 
(V4)
•Food Frequency Questionnaire
•Neuropsychological test battery
•Fasted Plasma FA analsysis 
•Urine, stool sample
•MRI
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CANN study design  
The CANN study is a multi-centre, 12-month double-blinded, placebo-controlled parallel 
intervention trial in which participants were randomised onto one of two intervention arms 
(1.5 g docosahexaenoic acid + eicosapentaenoic acid and 500 mg total flavanols from cocoa 
daily or control macronutrient matched placebo), and was completed in 2019. The trial was 
conducted over two study centres; University of East Anglia (Norwich, UK) and the 
Swinburne University of Technology (Melbourne, Australia). 259 individuals with mild 
cognitive impairment or subjective memory impairment, but with no indication of dementia 
(as assessed by the Montreal Cognitive Assessment (MoCA) score ≥18) were actively 
recruited into the study, in which the cognitive benefits of a combined flavonoid/fatty acid 
supplementation were investigated along with the underlying mechanisms of action (Irvine, 
Scholey et al. 2018). As outlined in Fig.1 the trial consisted of a screening visit followed by 
3 clinical visits (0, 3 and 12 months) in which biological samples were collected and a battery 
of cognitive tests were performed. In addition to general health related criteria; participants 
were also excluded from the study based upon a dietary related criteria, which included a 
high n-3 FA status (determined by red blood cell [RBC] n-3 FA index > 6% [EPA+DHA as 
a % of total FAs), and taking fish oils or other n-3 FA-rich supplements. The full 
inclusion/exclusion criteria is given in Table 2.1.  
 
Table 2.1: CANN study Full inclusion/exclusion criteria  
(adapted from (Irvine, Scholey et al. 2018)) 
Inclusion   
Type Criterion 
General Males and females, aged 55 years and above 
 Diagnosis of MCI or SMI with no indication of clinical dementia or depression 
 Willing and able to provide written informed consent, and verbal informed 
consent  
for the telephone eligibility screen, and to comply with all study procedures 
 Fluent in written and spoken English 
 In good general health, including blood biochemical, hematological and 
urinalysis  
results being within the normal range at V1 
 Normal or corrected-to-normal vision and hearing 
 Stable use of any prescribed medication for at least 4 weeks prior to V2 
MRI  
(50% of cohort) 
Aged from 55 to 85 years 
 
Exclusion  
Type  Criterion  
General and health-
related 
Diagnosis of AD or other form of dementia, or significant neurological disorder 
Parent or sibling who developed dementia before 60 years of age 
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AD, Alzheimer’s disease; BMI, body mass index; DBP, diastolic blood pressure; FA, fatty 
acid; MRI, magnetic resonance imaging; NSAIDs, non-steroidal anti-inflammatory drugs; 
SBP, systolic blood pressure 
 
Fatty Acid analysis  
Plasma and erythrocyte total lipids were extracted using the Folch extraction method (Folch, 
Lees et al. 1957), using chloroform/methanol (2:1 v/v) containing 0.01% butylated 
hydroxytoluene (BHT) as antioxidant. Total lipid fractions were subjected to acid-catalysed 
transmethylation for 16 h at 50 ºC, using 1 ml of toluene and 2 ml of 1% sulphuric acid (v/v) 
in methanol (Christie and Han 2010). The resultant erythrocyte and plasma fatty acid methyl 
esters (FAME) were purified by SPE silica cartridges (Clean-up 203 Cusil 156, UCT) and 
thin layer chromatography (TLC) respectively. Plasma FAMEs were visualised under 1% 
iodine in chloroform spray. After elution, FAME were separated and quantified by gas-liquid 
 Past history/MRI evidence of brain damage, including significant trauma, 
stroke, or other serious neurological disorder, including loss of consciousness 
for > 24 h 
Clinically diagnosed psychiatric disorder likely to affect the cognitive measures 
Existing gastrointestinal disorder likely to impact on the absorption of 
flavonoids and FAs (e.g. celiac, Crohn’s, irritable bowel syndrome) 
Major cardiovascular event (e.g. myocardial infarction or stroke) in the last 12 
months 
Carotid stents or severe stenosis 
1 Any other existing medical condition likely to affect the study measures (as 
judged by the trial’s clinical advisor) 
Uncontrolled hypertension (SBP > 160 mmHg, DBP > 100 mmHg) 
BMI ≥ 40 kg/m2 
2 Current or ex-smoker who stopped < 6 months ago 
Prescribed medications likely to influence the study measures  
(as judged by the clinical advisor) 
3 Participated in any other study involving an investigational product in the 
last 4 weeks 
4 Drugs, alcohol, 
smoking 
History of alcohol or drug dependency within the last 2 years 
Taking antipsychotics, high-dose antidepressants (as judged by the clinical 
advisor), cholinesterase inhibitors, benzodiazepines, anti-convulsants, illicit 
drugs/other drugs that can influence psychometric test results. Statins and 
NSAIDs are not exclusionary but use must be stable for at ≥ 2 months prior to 
V2 
Subjective reporting of sedation from any prescribed medication e.g. night 
sedation (Z drugs)/pain relief medication 
5 Dietary-related Known allergy to fish or any other component of the intervention products 
Taking flavonoid-containing supplements 
6 Taking fish oils or other n-3 FA-rich supplements 
High n-3 FA status (determined by red blood cell [RBC] n-3 FA index > 6% 
[EPA+DHA as a % of total FAs) 
High flavonoid intake (> 15 portions of flavonoid-rich foods per day) 
Hypersensitivity to fish products 
7 MRI (50% of 
cohort) 
Presence of metal implants 
Claustrophobia 
Table 2.1 Continued 
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chromatography. Individual methyl esters were identified by reference to authentic standards 
and to well-characterized fish oil (PUFA-3 from menhaden oil, SUPELCO, Supelco Park, 
Bellefonte, USA). Data was collected and processed using the GC Chemstation software 
(version B04-02). Erythrocyte fatty acid analysis was conducted at the University of Stirling 
for UK samples and HealthScope (Melbourne). Plasma fatty acid analysis for both centres 
were performed at the University of Stirling. n-3 index is the combined value of DHA and 
EPA. Total n-3 PUFA is the total of: 18:3n-3, 20:4n-3, 20:5n-3, 22:5n-3 and 22:6n-3. Whilst 
total n-6 is the total of: 18:2n-6, 18:3n-6, 20:2n-6, 20:3n-6, 20:4n-6, 22:4n-6, 22:5n-6.   
Genotyping  
For APOE genotyping, blood was collected into an Cell Preparation Tube (CPT) (BD 
Biosciences, San Diego, CA, USA) to provide a buffy layer and used for genomic DNA 
extraction using a DNA extraction kit (Qiagen, Hildenberg, Germany), as per manufacturer’s 
instructions. DNA was quantified with a NanoDrop spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA, USA) and diluted using MilliQ water (Millipore, Billerica, MA, 
USA) to achieve a concentration in the range of 1–10 ng. APOE genotype was determined 
by two real-time reverse transcription polymerase chain reaction (RT-PCR) single 
nucleotide polymorphism (SNP) genotyping assays, to determine the 112 T/C (rs429358) 
APOE4 polymorphism and 158 C/T (rs7412) APOE2 polymorphism per the Applied 
Biosystems (Foster City, CA, USA) TaqMan SNP Genotyping Assays protocol (2010) 
(Biosystems 2010). The analyses were carried out on a 7500 Fast Real-Time PCR system 
(Applied Biosystems). 
Cognitive assessment 
A neuropsychological test battery was performed at screening and baseline to determine 
cognitive performance. Data was obtained from the cognitive tests outlined below, as 
reported in the CANN methodology paper (Irvine, Scholey et al. 2018).   
The Montreal Cognitive Assessment (MoCA): A rapid screening instrument for mild 
cognitive dysfunction (Nasreddine, Phillips et al. 2005). The assessment assesses different 
cognitive domains: attention and concentration, executive functions, memory, language, 
visio-constructional skills, conceptual thinking, calculations, and orientation. The total 
possible score is 30 points; a score of 26 or above is considered normal and a score of less 
than 17 indicates dementia.  
Logical Memory I and II: Taken from the WMS-R, Logical Memory (Wechsler 1987) is a 
validated clinical measure frequently used to assess verbal memory in patients with MCI and 
AD. Participants are read a short passage, and after hearing the story are asked to retell it 
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from memory. Recall is measured immediately (Logical Memory I) and after a 30-minute 
delay (Logical Memory II). 
California Verbal Learning Test-II: The CVLT-II (Delis 2000) is a reliable and well-
validated test of verbal learning and memory. Participants are read a list of 16 words, 
belonging to four distinct groups (e.g. animals), and must recall them across a series of 
immediate and delayed trials (including an interference trial). The CVLT-II is sensitive to 
subtle episodic memory impairments in patients with MCI (Rabin, Pare et al. 2009). 
Boston Naming Test: The BNT (Kaplan 1983) is a confrontation naming task consisting of 
60 black line drawings of common objects, which participants are asked to identify 
(identification difficulty differs among the objects). The CANN study uses a 30-item version 
of this task (Saxton, Ratcliff et al. 2000). 
Figure Copy: Taken from the RBANS, the Figure Copy task (Randolph, Tierney et al. 1998) 
assesses visuospatial function. The RBANS is a well-validated neuropsychological test 
battery for identifying and characterizing abnormal cognitive decline in older adults that has 
been shown to be sensitive to MCI due to AD (Karantzoulis, Novitski et al. 2013). 
Participants copy a modified Rey-Figure comprising 10 elements and receive 2 points (1 for 
accuracy and 1 for placement) for correct responses on each of the 10 elements, with a 
highest total possible score of 20. 
Digit Span task (Forward and Backward): The Digit Span task, a subtest from WAIS III 
(Wechsler 1997) that assesses attention and short-term memory, comprises the Digits 
Forward and Digits Backward subtests. For each Digits Forward item, a series of digits (e.g. 
'8, 3, 4') is read out and participants must immediately repeat them back in order. If they do 
this successfully, they are given a longer list of digits (e.g. '9, 2, 4, 0'). For Digits Backward, 
the participant is required to repeat back a series of digits in the reverse order. The total score 
on this task is given by the sum score for Digits Forward plus Digits Backward. 
Trail Making Test – A and B: The TMT (Reitan 1955) provides a measure of executive 
function. Participants are required to connect numbered circles on a sheet of A4 paper. There 
are two versions of the test: Version A, in which targets are all numbers in consecutive order 
(1,2,3…25), and Version B, in which the participant alternates between numbers and letters 
(1, A, 2, B…etc.). The participant must finish the test as quickly as possible, without making 
errors or removing the pen from the paper, and the time taken to complete the test indexes 
performance. 
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Test of Premorbid Functioning: The ToPF (Wechsler 2009) estimates premorbid 
intelligence. Participants read aloud a list of 70 irregularly spelled words, such as gnat, lieu 
and subtle, and the total score is the number of words pronounced correctly. Unlike many 
other domains of intelligence and memory abilities, reading recognition is relatively stable 
in the presence of the cognitive decline associated with normal aging or brain injury. The 
ToPF provides a reliable estimate of intelligence in clinical and research settings. 
Cognitive Drug Research test battery: The CDR Computerized Cognitive Assessment 
System (Simpson, Surmon et al. 1991) will be used to measure the effects of the intervention 
on cognition. The battery is sensitive to cognitive changes, including in trials of MCI, 
dementia and SMI. It has been used in 1,200 clinical trials across 3,000 sites in more than 
60 countries. Tasks are presented via color monitors on laptops; with the exception of the 
written Word Recall tasks, performed with pen and paper, with all responses are recorded 
via a two-button (YES/NO) response box. The entire battery takes approximately 25–30 
minutes to complete.  
For the CANN study, the following tasks are completed, in order: Bond-Lader Visual 
Analogue Scale of Mood and Alertness, Leeds Sleep Evaluation Questionnaire, Word 
Presentation, Immediate Word Recall, Picture Presentation, Simple Reaction Time, Digit 
Vigilance, Choice Reaction Time, Spatial Working Memory, Numeric Working Memory, 
Delayed Word Recall, Word Recognition and PRT (Bond 1974). At V1, the CDR is 
completed twice in succession so that participants are well familiarized prior to the clinical 
visits (V2-4). 
iPosition task: The iPosition task (Watson, Voss et al. 2013) assesses relational memory 
function, which is critically reliant on the hippocampus. Participants must spatially 
reconstruct an array of five abstract shapes. In a typical trial, participants view on a computer 
screen, and must then memorize, the location of each shape. Following the stimulus phase, 
there is a brief delay (4 s), during which the objects disappear and then reappear in a line at 
the top of the screen; the participant is then asked to move them back to their original 
location. This task has demonstrated high sensitivity to hippocampal integrity and can detect 
deficits in relational memory in patients with mild hippocampal damage (Watson, Voss et 
al. 2013). 
Verbal Fluency Test: The D-KEFS Verbal Fluency Test is composed of three conditions: 
letter fluency (participant says as many words beginning with a specific letter as possible); 
category fluency (participant says words belonging to a designated semantic category), and 
category switching (participant alternates between saying words belonging to two different 
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semantic categories). The category-switching task can strongly discriminate between healthy 
controls and MCI and AD patients (Nutter-Upham, Saykin et al. 2008). 
 
Statistical analysis  
For the purpose of my thesis, analysis was focused towards female participants. Participants 
with the APOE2/APOE4 allele combination were excluded from the analysis to maintain 
mutually exclusive carrier groups n =136. Data is shown as the mean value ± standard error 
of mean. Extreme outliers were identified in SPSS via visual inspection of frequency 
distribution plot (Q-Q plots) and box plots, those deemed to be significant (1.5 X Inter 
Quartile Range), were omitted from further analyses. All data was screened prior to analysis 
for normality, via visual inspection and Shapiro-Wilk test. If data did not follow normal 
distribution it was subsequently transformed via log or square root transformation. Age, 
BMI, centre, smoker status, hormone therapy, MCI/SMI, APOE4 carrier status, sex, 
education, IQ and fish intake were considered as covariates in the analysis and were chosen 
based upon their potential influence on fatty acid status and cognitive performance.  
Student’s t-test and Pearson’s chi squared test were performed on baseline characteristics 
data p < 0.05 was considered significant.  
Analysis of covariance (ANCOVA) was performed on female participant screening (V1) 
erythrocyte, and Baseline (V2) plasma values to assess the impact of APOE genotype, age, 
BMI, hormone therapy and fish intake (determined via food frequency diaries and 
questionnaires) on fatty acid composition. FA profiles of erythrocyte, total plasma, and the 
PC fraction of the plasma were analysed. For the PC fractions 36:5 and 39.6, 40:6 were 
focused on as they are known carriers of EPA and DHA respectively (Chalil, Kitson et al. 
2018, Lopes, Melo et al. 2019). Data was available for the LPC fraction, however levels 
were undetectable in the majority of participants, and further analysis was deemed 
unnecessary. Analysis was first performed unadjusted with a single explanatory value 
(model M1), after which covariates age, BMI, centre, smoker status, and HRT use were 
subsequently added into the multivariate analysis (If not the subject of analysis) (model M2). 
Effects and interactions where P < 0.05 were considered significant. 
Analysis of covariance (ANCOVA) was also performed on screening (V1) and baseline 
cognitive assessment data (V2), to assess the impact of APOE4 carrier status, HRT, and oily 
fish intake have on cognition. Analysis was performed fully adjusted (model M2) as factors 
such as age and IQ can highly influence cognitive testing. Covariates considered for use in 
this analysis were age, BMI, centre, smoking status, HRT use, MCI/SMI status, APOE4 
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carrier status, sex, education, IQ and oily fish intake (if not the subject of the analysis). 
Effects and interactions where P < 0.05 were considered significant. 
All statistical analysis was performed using IBM SPSS statistics version 25 software  
 
Results   
 
Study population characteristics  
 
The full study population including both female and male participants has been reported 
previously (Irvine, Scholey et al. 2018). For the purpose of this study, a total of 136 female 
participants, 75 in the Norwich cohort and 61 in the Melbourne cohort were used in the 
analysis. APOE genotype frequencies in this study population, reflected the general 
population as reported by others (Lyall, Ward et al. 2016), with APOE3/E3 the most common 
allele combination accounting for ~60 % of the population, whilst rarer combinations 
APOE2/E2 and APOE4/E4 accounted for just ~2% each. SMI and MCI were split evenly 
within carrier status subgroups and did not significantly differ as result of APOE4 carrier 
status (p > 0.05). The average age of female participants was ~65 years ± 0.5, with the E4 
carrier subgroup nominally but not significantly younger than non-carriers (63.7 ± 0.9 and 
65.3 ± 0.7 years respectively p > 0.05). Participants were generally slightly overweight, with 
an average BMI of ~27kg/m2 ± 0.4 regardless of carrier status (p > 0.05). 
Table 2.2 Baseline characteristics of female from the CANN study population utilised for 
analysis within this study. 
 
All values are mean ± SEM. Brackets represent % of study population. Student’s t-test was 
used to test for differences in age and BMI resulting from APOE4 carrier status. Pearson’s 
Chi squared test was used to test for differences in frequency distributions of SMI and MCI 
 
Overall (n=136) Non - ɛ4 Carrier (n= 97) ɛ4 Carrier (n=39) P 
value  
Genotype  
Breakdown (n) 
  E2/E2 = 3 (2.2%) 
 E2/E3 = 10 (7.4%) 
 E3/E3 = 84 (61.8%)  
 E3/E4 = 36 (26.5%) 
 E4/E4 = 3 (2.2%)  
 
Age (y) 64.9 ± 0.5 65.3 ± 0.7 63.7 ± 0.9 0.172 
BMI (kg/m2) 26.9 ± 0.4 26.9 ± 0.5 26.8 ± 0.9 0.842 
SMI 71 (52.2%) 51 (37.5 %) 20 (14.7 %) 0.891 
MCI 65 (47.8%) 46 (33.8 %) 19 (14.0 %) 
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between E4 carriers and non-carriers. BMI, body mass index, SMI subjective memory 
impairment, MCI, Mild cognitive impairment. 
 
Factors influencing n-3 PUFA status  
 
Altered erythrocyte and plasma n-3 PUFA status has been widely associated with health, 
disease and cognitive function (Conquer, Tierney et al. 2000, Calder and Yaqoob 2009). We 
therefore explored how n-3 PUFA status is influenced by a range of potential determinants 
which are described in each section. Taking both erythrocyte and plasma fractions provide 
us with a more detailed understanding of n-3 PUFA status. RBC provides a greater long-
term assessment, due to the greater stability of RBC n-3 PUFAs (mainly esterified in the PLs 
membrane), ~3month to alter. Whereas the more dynamic plasma n-3 PUFAs, mainly 
lipoprotein associated or free fatty acid, is influenced by recent intake and is sensitive to day 
by day changes (Harris and Thomas 2010).  
 
Greater oily fish intake increases n-3 PUFA status, whilst rising BMI reduces n-3 
PUFA status  
 
As expected, incremental intake in oily fish portions (None, 1-3 per month, one or more 
portions a week) a rich source of long chain n-3 PUFA led to an increase in n-3 PUFA status, 
with erythrocyte, DHA, n-3 index and total n-3 increasing whilst AA and AA:DHA ratio 
reduced (p < 0.05). Although initially significant (model M1), when fully adjusted EPA did 
not reach significance (p = 0.094). Interestingly, significance was restricted to erythrocytes, 
although both plasma and particularly PC fractions showed strong trends in response to fish 
consumption. Conversely, increasing BMI had the opposite effect, significantly reducing 
erythrocyte DHA and n-3 index (p<0.05) whilst EPA was trending towards significance (p 
= 0.072). Once again, these changes were only significant in the erythrocyte fraction, 
although strong trends were observed in the PC fractions. 
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Table 2.3 Baseline Erythrocyte and plasma FA profile according to Fish intake and Body mass index. 
 
All values are mean ± SEM. Fish intake groups: Never (n = 27), 1-3 portions per month (n = 53), 1 portion or more per week (n = 53). BMI 
groups < 25 kg/m2 (n = 55), 25-30 kg/m2 (n = 50), ≥30 kg/m2  (n = 28). Model one (M1) ANOVA main-effects model (unadjusted) including 
only fish intake or BMI as an explanatory variable. Model 2 (M2) ANOVA mixed effects model (adjusted) including covariates age, centre, 
carrier status, smoking status, HRT and either oily fish intake, or BMI. Group differences were determined using unadjusted ANOVA with 
Tukey post hoc.  Bold font indicates significant p value (p < 0.05) different letters indicate different mean. FI, Fish intake; BMI, body mass 
index; RBC, Red blood cell; DHA, Docosahexaenoic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; AA, Arachidonic acid; 
AA:DHA, Arachidonic acid: Docosahexaenoic acid ratio, PC, phosphatidylcholine
 
FI T1 
(Never) 
 
FI T2 
(1-3 /month) 
FI T3 
(1+ per/ 
week) FI M1 FI M2 
BMI  
< 25 kg/m2 
BMI 25-30 
kg/m2 
 
 
BMI  ≥30 
kg/m2 BMI M1 
BMI 
M2M2 
RBC (%)           
DHA 3.42 ± 0.14 a 3.87 ± 0.10 b 3.94 ± 0.10 b 0.002 0.004  4.02 ± 0.10 3.77 ± 0.10 3.53 ± 0.14 0.022 0.045 
EPA 0.85 ± 0.05  1.00 ± 0.03 0.97 ± 0.04 0.006 0.094 1.01 ± 0.03 0.93 ± 0.04 0.94 ± 0.06 0.076 0.072 
AA 13.70 ± 0.3 13.30 ± 0.2 12.90 ± 0.2 0.114 0.034 13.20 ± 0.2 13.50 ± 0.2 13.00 ± 0.3 0.321 0.579 
n-3 index 4.27 ± 0.15 a 4.92 ± 0.10 b 4.95 ± 0.12 b 0.0001 0.002 5.04 ± 0.10 4.77 ± 0.11 4.49 ± 0.16 0.008 0.027 
Total n-3 PUFA 7.10 ± 0.17 a 7.55 ± 0.13 b 7.56 ± 0.15 b 0.008 0.077 7.69 ± 0.13 7.45 ± 0.15 7.19 ± 0.20 0.044 0.090 
Total n-6 PUFA 30.50 ± 0.3 a 29.30 ± 0.2 b 29.50 ± 0.2 b 0.099 0.028 29.50 ± 0.26 29.63 ± 0.22 29.80 ± 0.34 0.486 0.656 
AA:DHA 4.16 ± 0.16 a 3.56 ± 0.10 b 3.35 ± 0.10 b 0.0001 0.0001 3.35 ± 0.10 3.69 ± 0.10 3.84 ± 0.17 0.032 0.087 
Plasma (µg/ml)           
DHA 1.26 ± 0.13 1.62 ± 0.14 1.40 ± 0.09 0.181 0.216 1.53 ± 0.09  1.44 ± 0.09 1.35 ± 0.14 0.236 0.321 
EPA  0.24 ± 0.03 0.29 ± 0.02 0.25 ± 0.02 0.322 0.415 0.26 ± 0.18 0.28 ± 0.02 0.24 ± 0.03 0.398 0.605 
AA  1.71 ± 0.14 1.80 ± 0.09 1.67 ± 0.14 0.508 0.582 1.62 ± 0.09 1.80 ± 0.14 1.76 ± 0.18 0.705 0.842 
Plasma PC 
fractions 
(µg/ml)  
          
PC 36:5 EPA 
containing 
47.88 ± 2.52 57.12 ± 2.73 56.28 ± 2.94 0.231 0.525 58.80 ± 2.73 55.23 ± 2.94 48.93 ± 2.94 0.246 0.364 
PC 38:6 DHA 
containing 
63.00 ± 3.15 72.45 ± 2.10 74.34 ± 2.31 0.068 0.197 75.60 ± 2.52 69.30 ± 2.10 66.15 ± 2.94 0.061 0.177 
PC 40:6 DHA 
containing 
16.80 ± 1.05 18.90 ± 0.63 18.90 ± 0.84 0.338 0.470 19.10 ± 0.84 18.48 ± 0.63 18.48 ± 1.05 0.734 0.797 
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APOE4 carrier status alters plasma and erythrocyte FA profile in females 
 
APOE4 genotype is believed to alter n-3 PUFA transport and metabolism to and within 
the brain. Altered blood brain barrier integrity leading to reduced transport across the 
blood brain barrier has been proposed as a potential mechanism (Yassine, Braskie et al. 
2017, Tomaszewski, He et al. 2020). Baseline FA composition analysis revealed a 
significant genotype difference in PUFA profiles, with APOE4 carriers displaying 
elevated n-3 PUFA levels, evident from the ~5% higher n-3 index (p < 0.05 table 2.4). 
Interestingly, EPA levels were particularly influenced by genotype, with both erythrocyte 
and PC fractions significantly 15 ± 0.04 % and 12 ± 2.73% higher respectively in APOE4 
carriers (p < 0.05). Plasma EPA levels followed a similar trend however did not reach 
significance (p = 0.076). Although not significant, DHA showed a similar nominal 
increase in the erythrocyte fraction of APOE4 carriers. Conversely, total n-6 PUFA levels 
were significantly lower in APOE4 carriers, as was LA, whilst SFA and MUFA remained 
constant regardless of carrier status. 
 
Table 2.4 Baseline Erythrocyte and plasma FA profile according to E4 carrier status.  
  Non - ɛ4 Carrier ɛ4 carrier M1 M2 
RBC (%)  
DHA  3.77 ± 0.08 3.90 ± 0.11 0.246 0.186 
EPA  0.92 ± 0.03 1.06 ± 0.03 0.005 0.0001 
DPA  2.24 ± 0.04  2.28 ± 0.04 0.555 0.708 
LA 13.16 ± 0.3 12.29 ± 0.4 0.045 0.014 
AA 13.31 ± 0.2 13.14 ± 0.2 0.869 0.919 
ALA 0.41 ± 0.03 0.33 ± 0.04 0.218 0.308 
n-3 index 4.74 ± 0.09 4.96 ± 0.12 0.063 0.027 
Total n-3 7.43 ± 0.11 7.63 ± 0.14 0.139 0.090 
Total n-6 29.93 ± 0.18 28.96 ± 0.25 0.002 0.002 
AA:DHA 3.65 ± 0.08 3.47 ± 0.11 0.259 0.212 
Total SFA 39.54 ± 0.13 39.89 ± 0.22 0.096 0.115 
Total MUFA 20.29 ± 0.26 20.10 ± 0.37 0.725 0.378 
Plasma (µg/ml)  
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All values are mean ± SEM. APOE carrier groups: APOE4 non-carrier (n = 97), APOE4 
carrier (n = 39). Model one (M1) ANOVA main-effects model (unadjusted) including 
only APOE4 carrier status as an explanatory variable. Model 2 (M2) ANOVA mixed 
effects model (adjusted) including covariates age, BMI, centre, smoking status, HRT 
status and oily fish intake. Bold font indicates significance (p < 0.05). RBC, Red blood 
cell; DHA, Docosahexaenoic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic 
acid; LA linoleic acid; AA, Arachidonic acid; ALA, Alpha linoleic acid; AA:DHA, 
Arachidonic acid: Docosahexaenoic acid ratio; SFA, saturated fatty acid; MUFA, 
monounsaturated fatty acid, PC, phosphatidylcholine. 
 
HRT*APOE4 status interaction influences baseline n-3 PUFA  
 
With AD/MCI risk in female APOE4 carriers considerably heightened between the ages 
of 55-70 years (Neu, Pa et al. 2017) relative to the wild-type APOE3/E3 genotype, there 
is evidence that APOE4 carriers are particularly sensitive to the impact of menopause on 
cognitive ageing. The ability of HRT to mitigate the effect of age on cognition in females 
remains controversial with response to HRT according to APOE genotype relatively 
unknown (Depypere, Vierin et al. 2016). Given the age of the study population, we can 
assume that the majority of participants will be peri-menopausal if not already post-
menopausal. To explore the impact sex hormones on the participant FA profiles, HRT 
use was incorporated into the analysis. HRT status alone had no apparent impact on FA 
profile. However, an HRT*APOE4 status interaction indicated a potential interactive 
impact on DHA concentrations. Although of borderline significance, both erythrocyte 
DHA (p = 0.06) and PC 38:6 the DHA plasma fraction (p= 0.078) were 17 ± 0.34% and 
15 ± 4.16 lower in APOE4 carriers receiving HRT. The PC 40:6 DHA fraction (p= 0.03) 
was significantly altered due to HRT*APOE4 carrier interaction with 26 ± 1.69% lower 
concentrations in HRT APOE4 individuals relative to non-users. Similarly, erythrocyte 
n-3 index was significantly altered by HRT*APOE4 carrier-status and was reduced by 14 
± 0.25% in APOE4 carriers receiving HRT. Interestingly, this is in contrast to the APOE4 
effect, in which n-3 PUFA levels were elevated, however EPA was not affected by 
DHA  1.35 ± 0.16 1.58 ± 0.12 0.245 0.294 
EPA  0.23 ± 0.014 0.27 ± 0.018 0.068 0.076 
AA 1.71 ± 0.081 1.71 ± 0.12 0.872 0.865 
Plasma PC Fractions (%)  
PC 36:5 EPA containing 53.13 ± 2.1 59.85 ± 2.73 0.009 0.005 
PC 38:6 DHA containing 70.35 ± 1.68 73.29 ± 2.73 0.418 0.354 
PC 40:6 DHA containing 18.27 ± 0.63 19.11 ± 0.84 0.306 0.267 
Table 2.4 continued 
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HRT*APOE4 carrier-status. All HRT*APOE4 carrier-status analysis is exploratory and 
should be evaluated with caution due to low n numbers within the APOE4 carrier HRT 
group. 
Table 2.5 Baseline Erythrocyte and plasma FA profile according to HRT and 
HRT*carrier-status interaction. 
  
 
No - HRT  HRT 
HRT  
M1 
HRT 
M2 
HRT*CS 
M1 
HRT*CS 
M2 
RBC ( µg/ml )        
DHA Non-
carrier 
3.75 ± 
0.08 
3.91 ± 
0.21 
 
0.239 0.479 0.068 0.060 
ɛ4 carrier 3.96 ± 
0.11 
3.28 ± 
0.34  
 
EPA Non-
carrier 
0.91 ± 
0.03 
1.07 ± 
0.10 
0.747 0.943 0.592 0.137 
ɛ4 carrier 1.06 ± 
0.03 
1.03 ± 
0.12 
 
DPA Non-
carrier 
2.25 ± 
0.04 
2.22 ± 
0.13  
 
0.442 0.566 0.452 0.630 
ɛ4 carrier 2.28 ± 
0.05 
2.30 ± 
0.15 
LA Non-
carrier 
13.1 ±  
0.3 
13.3 ±  
0.9 
 
0.073 0.462 0.175 0.460 
ɛ4 carrier 12.1 ±  
0.4 
14.4 ±  
1.3 
 
AA Non-
carrier 
13.3 ±   
0.2 
13.5 ±  
0.5 
 
0.532 0.868 0.563 0.849 
ɛ4 carrier 13.2 ±   
0.2 
12.7 ±  
0.2 
 
ALA Non-
carrier 
0.41 ±  
0.03 
0.47 ± 
0.10 
 
0.061 0.516 0.416 0.730 
ɛ4 carrier 0.31 ± 
0.03 
0.55 ± 
0.23  
n-3 index Non-
carrier 
4.71 ± 
0.09  
4.97 ± 
0.26 
 
0.343 0.542 0.091 0.048 
ɛ4 carrier 5.02 ± 
0.12  
4.31 ± 
0.25 
 
Total n-3 Non-
carrier 
7.40 ± 
0.12  
7.70 ± 
0.32  
0.548 0.494 0.253 0.102 
ɛ4 carrier 7.67 ± 
0.14  
7.17 ± 
0.41 
 
Total n-6 Non-
carrier 
29.9 ±  
0.2   
30.1 ±  
0.6 
 
0.227 0.414 0.505 0.669 
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All values are mean ± SEM. HRT Groups: Non-carrier and no HRT (n = 86), Non-carrier 
and HRT (n = 11), APOE4 carrier and no HRT (n = 36), APOE4 carrier and HRT (n = 3), 
Total no HRT (n = 122), Total HRT (n = 14). Model one (M1) ANOVA main-effects 
model (unadjusted) including only HRT or HRT*carrier-status as an explanatory 
variable. Model 2 (M2) ANOVA mixed effects model (adjusted) including covariates 
age, BMI, centre, smoking status and oily fish intake. Bold font indicates significance (p 
< 0.05) HRT, hormone therapy, CS, carrier-status, RBC, Red blood cell, DHA, 
Docosahexaenoic acid, EPA, eicosapentaenoic acid, DPA, docosapentaenoic acid, LA 
linoleic acid, AA, Arachidonic acid, ALA, Alpha linoleic acid, AA:DHA, Arachidonic 
ɛ4 carrier 28.9 ±  
0.3 
29.9 ±  
1.0 
AA:DHA Non-
carrier 
3.66 ±  
0.09 
3.57 ± 
0.25 
 
0.425 0.482 0.162 0.099 
ɛ4 carrier 3.43 ± 
0.12 
 3.95 ± 
0.44 
Total SFA Non-
carrier 
39.52 ± 
0.13 
39.7 ±  
0.4 
 
0.811 0.932 0.663 0.874 
ɛ4 carrier 39.9 ±  
0.2 
39.7 ±  
1.3 
Total MUFA Non-
carrier 
20.3 ±   
0.3 
20.3 ±  
0.7 
 
0.205 0.657 0.115 0.102 
ɛ4 carrier 19.9 ±  
0.4 
22.2 ±  
1.8  
Plasma (µg/ml)       
DHA Non-
carrier 
1.35 ±  
0.09 
1.8 ± 0.36 
 
0.085 0.125 0.729 0.496 
ɛ4 carrier 1.53 ± 
1.35 
2.02 ± 
0.45 
EPA Non-
carrier 
0.25 ± 
0.018 
0.27 ± 
0.045 
 
0.208 0.109 0.973 0.644 
ɛ4 carrier 0.29 ± 
0.023 
0.23 ± 
0.09  
AA Non-
carrier 
1.71 ±  
0.09 
1.94 ± 
0.36 
 
0.372 0.300 0.717 0.470 
ɛ4 carrier 1.71 ± 
0.14 
1.85 ± 
0.18 
Plasma PC  
Fractions (µg/ml)  
       
PC 36:5 EPA 
containing 
Non-
carrier 
52.92 ± 
2.31 
55.44 ± 
7.14 
 
0.192 0.603 0.143 0.294 
ɛ4 carrier 61.32 ± 
2.73 
43.89 ± 
6.72 
PC 38:6 DHA 
containing 
Non-
carrier 
69.3 ± 
1.68 
79.8 ± 
5.04 
0.962 0.833 0.057 0.078 
ɛ4 carrier 72.45 ± 
2.94 
61.53 ± 
2.94 
PC 40:6 DHA 
containing 
Non-
carrier 
18.27 ± 
0.63 
19.95 ± 
1.47 
0.490 0.337 0.050 0.033 
ɛ4 carrier 19.74 ± 
0.84 
14.49 ± 
1.47 
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acid: Docosahexaenoic acid ratio, SFA, saturated fatty acid, MUFA, monounsaturated 
fatty acid, PC, phosphatidylcholine. 
 
Age does not influence PUFA profile in female study participants  
To determine if the aforementioned association between APOE4 carrier status and PUFAs 
was influenced by age, we analysed baseline PUFA levels across distinct age tertiles (≤ 
59, 60-69 and ≥ 70 years). Although PUFA concentration in circulation appeared to 
increase significantly with age this effect was not significant. An age*genotype 
interaction was not detected in this analysis, suggesting that APOE4’s impact on PUFA 
status is not influenced by ageing 
 
Table 2.6 Baseline Erythrocyte and plasma FA profile according to age and age*carrier-
status interaction. 
  T1 (≤ 
59) 
T2 (60-
69) 
T3 (≥ 70) Age 
M1 
Age 
M2 
CS*age 
M1 
CS*age 
M2 
RBC (%)         
DHA 
 
Non-
carrier 
3.80 ± 
0.14 
3.60 ± 
0.12 
3.99 ± 
0.13 
0.680 0.525 0.909 0.992 
ɛ4 
carrier 
4.02 ± 
0.25 
3.84 ± 
0.13 
4.13 ± 
0.36 
EPA 
 
Non-
carrier 
0.88 ± 
0.06 
0.93 ± 
0.04 
0.95 ± 
0.05 
0.154 0.381 0.581 0.795 
ɛ4 
carrier 
 0.96 ± 
0.08 
1.10 ± 
0.04 
1.11 ± 
0.06 
AA 
 
Non-
carrier 
13.55 ± 
0.35 
13.2 ± 
0.19 
13.31 ± 
0.39 
0.498 0.784 0.206 0.270 
ɛ4 
carrier 
13.54 ± 
0.40 
12.85 ± 
0.18 
14.38 ± 
1.2 
n-3 Index Non-
carrier 
4.68 ± 
0.18 
4.67 ± 
0.14 
4.95 ± 
0.12 
0.590 0.410 0.929 0.993 
ɛ4 
carrier 
4.98 ± 
0.29 
4.93 ± 
0.14 
5.24 ± 
0.39 
Total n-3 Non-
carrier 
7.44 ± 
0.23 
7.34 ± 
0.17 
7.63 ± 
0.15 
0.432 0.356 0.934 0.855 
ɛ4 
carrier 
7.66 ± 
0.29 
7.57 ± 
0.17 
8.09 ± 
0.18 
Total n-6 Non-
carrier 
30.9 ± 
0.3 
30.0 ± 
0.2 
29.0 ±  
0.4 
0.965 0.854 0.029 0.013 
ɛ4 
carrier 
28.7 ± 
0.3 
29.0 ± 
0.3 
30.1 ±  
0.7 
AA:DHA Non-
carrier 
3.65 ± 
0.15 
3.77 ± 
0.13 
3.39 ± 
0.14 
0.888 0.675 0.530 0.636 
ɛ4 
carrier 
3.5 ± 
0.30 
3.45 ± 
0.13 
3.51 ± 
0.15 
Plasma (µg/ml)         
DHA  
 
Non-
carrier 
1.30 ± 
0.14 
1.35 ± 
0.09 
1.58 ± 
0.18 
0.646 0.826 0.247 0.312 
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All values are mean ± SEM. Groups: Non-carrier T1 (n = 21), Non carrier T2 (n = 32), 
Non carrier T3 (n = 24), APOE4 carrier T1 (n = 10), APOE4 carrier T2 (n = 26), APOE4 
carrier T3 (n = 3), Total T1 (n = 31), Total T2 (n = 78), Total T3 (n = 27). Model one 
(M1) ANOVA main-effects model (unadjusted) including only age or age*carrier-status 
as an explanatory variable. Model 2 (M2) ANOVA mixed effects model (adjusted) 
including covariates BMI, centre, smoking status, HRT status and oily fish intake. Bold 
font indicates significance (p < 0.05). CS, carrier-status,  RBC, Red blood cell, DHA, 
Docosahexaenoic acid, EPA, eicosapentaenoic acid, AA, Arachidonic acid, AA:DHA, 
Arachidonic acid: Docosahexaenoic acid ratio, PC, phosphatidylcholine.  
 
Factors influencing cognition  
 
Participants of the CANN study underwent comprehensive cognitive testing. Given that 
both APOE4 carrier status and HRT have been associated with cognitive decline and were 
both linked to altered n-3 PUFA status in the earlier analysis, we continued to explore 
how these factors may influence cognition utilising the CANN cognitive data.  
 
APOE4 carrier status is associated with a reduction in verbal fluency, memory speed 
and executive function 
 
In general, APOE4 carriers appeared to perform worse than their non-carrier counterparts 
on the battery of cognitive tests. Notably, verbal fluency was 10% lower (Non – carrier: 
12.4 ± 0.3, APOE4 carrier: 11.1 ± 0.4,  p < 0.05, Table 2.7), speed of memory with 8% 
ɛ4 
carrier 
1.70 ± 
0.23 
1.62 ± 
0.14 
1.04 ± 
0.23 
EPA  
 
Non-
carrier 
0.23 ± 
0.02 
0.24 ± 
0.02 
0.28 ± 
0.04 
0.561 0.836 0.780 0.699 
ɛ4 
carrier 
0.32 ± 
0.05 
0.28 ± 
0.02 
0.27 ± 
0.09 
AA  Non-
carrier 
1.89 ± 
0.77 
1.67 ± 
0.14 
1.71 ± 
0.14 
0.733 0.727 0.658 0.336 
ɛ4 
carrier 
1.80 ± 
0.23 
1.76 ± 
0.16 
1.35 ± 
0.26 
Plasma PC 
fraction (µg/ml) 
        
PC 36:5 EPA 
containing 
Non-
carrier 
47.46 ± 
2.31 
53.13 ± 
3.15 
58.59 ± 
4.62 
0.160 0.273 0.237 0.260 
ɛ4 
carrier 
70.98 ± 
11.76 
79.38 ± 
8.61 
119.28 ± 
8.40 
PC 38:6 DHA 
containing 
Non-
carrier 
68.46 ± 
2.73 
68.67 ± 
2.52 
75.81 ± 
3.36 
0.692 0.702 0.220 0.336 
ɛ4 
carrier 
80.22 ± 
7.77 
97.65 ± 
8.61 
134.61 ± 
10.05 
PC 40:6 DHA 
containing 
Non-
carrier 
18.06 ± 
1.05 
17.64 ± 
0.84 
20.16 ± 
1.26 
0.130 0.110 0.742 0.756 
ɛ4 
carrier 
 21.00 ± 
2.31 
28.35 ± 
3.15 
41.16 ± 
6.30 
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lower speed (Non – carrier: 4207 ± 103s, APOE4 carrier: 4584 ± 205s, p < 0.05, Table 
2.7) and executive function was 6% lower performance (Non – carrier: 118 ± 2, APOE4 
carrier: 111 ± 3, p < 0.01, Table 2.7).  
 
Table 2.7 Baseline cognitive test performance according to E4 carrier status 
 
 
 
Cognitive test Non - carrier 
 
 
ɛ4 Carrier M2 P Value 
MoCA 26.9 ± 0.2 26.4 ± 0.4 0.096 
Verbal Fluency  12.4 ± 0.3 11.1 ± 0.4  0.033 
Verbal Fluency 
responses  
12.3 ± 0.4 12.3 ± 0.4 0.936 
Original 
Misplacement 
247 ± 8 245 ± 10 0.507 
Accuracy single item 
placement  
2.40 ± 0.07  2.34 ± 0.1 0.251 
Power of Attention 
(ms) 
1350 ± 15 1315  ± 20 0.748 
Continuity of 
Attention 
91.8 ± 0.3 91.8 ± 0.5 0.607 
Response Variability 
(%) 
50.9 ± 1.0 52.3 ± 2.1 0.755 
Cognitive reaction 
time (ms) 
219 ± 7 202  ± 11 0.145 
Quality of working 
Memory (SI) 
1.72 ± 0.04 1.71 ± 0.05 0.264 
Quality of working 
episodic memory 
182 ± 5 179  ± 10  0.260 
Speed of Memory 
(ms) 
4261 ± 91 4583  ± 205 0.028 
Quality of Memory 353 ± 7 349 ± 11.0 0.112 
Executive Function 117 ± 2 110 ± 3  0.009 
Picture Recognition  86.3 ± 1.3 84.8 ± 2.5 0.299 
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All values are mean ± SEM. APOE carrier groups: APOE4 non-carrier (n = 97), APOE4 
carrier (n = 39). (M2) ANOVA mixed effects model (adjusted) including covariates 
MCI/SMI, Education, IQ, age, BMI, centre, smoking status, HRT status and oily fish 
intake. Bold font indicates significance (p < 0.05) 
 
HRT impacts on cognitive performance and is influenced by APOE4 carrier status  
 
Incorporating HRT status into the analysis revealed that both HRT mediated and 
HRT*APOE4 carrier effects. In general, receiving HRT was associated with improved 
cognitive performance. MoCA, cognitive reaction time, speed of memory and executive 
function tasks were significantly improved in those receiving HRT. Interestingly, a 
number of cognitive tests were significantly influenced by HRT*APOE4 carrier status 
interaction including the picture recognition test which was dramatically improved by 15 
± 3.11% in the APOE4*HRT group compared to non-HRT users. Again, as with the FA 
analysis, all HRT*APOE4 carrier-status analysis is exploratory and should be evaluated 
with caution due to low n numbers within the APOE4 carrier in the HRT group. However, 
the highly significant result in this section are encouraging. 
 
Table 2.8 Baseline cognitive test performance according to HRT and HRT*carrier-status 
interaction. 
 
 
Cognitive test  
APOE4 
carrier  
Non - HRT HRT HRT 
M2 
CS*HRT 
M2 
MoCA Non-
carrier 
26.8 ± 0.2 27.7 ± 0.6 0.029 0.314 
ɛ4 
carrier 
26.2 ± 0.4 28.0 ± 1.5  
Verbal Fluency  Non-
carrier 
12.3 ± 0.4 13.2 ± 1.0 0.714 0.799 
ɛ4 
carrier 
11.1 ± 0.4 11.3 ± 1.8 
Verbal Fluency 
responses  
Non-
carrier 
12.3 ± 0.4 12.8 ± 1.0 0.547 0.801 
ɛ4 
carrier 
12.2 ± 0.6 13.3 ± 0.7 
Original 
Misplacement 
Non-
carrier 
246.2 ± 8.7 257.2 ± 22.8 0.624 0.295 
ɛ4 
carrier 
248.7 ± 11.2 212.1 ± 42.2 
Accuracy single item 
placement  
Non-
carrier 
2.4 ± 0.07 2.1 ± 0.2 0.963 0.224 
ɛ4 
carrier 
2.3 ± 0.1 2.6 ± 0.3 
Power of Attention Non-
carrier 
1354.0 ± 15.7 1326.0 ± 51.5 0.766 0.866 
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All values are mean ± SEM. Groups: Non-carrier and no HRT (n = 86), Non-carrier and 
HRT (n = 11), APOE4 carrier and no HRT (n = 36), APOE4 carrier and HRT (n = 3), 
Total no HRT (n = 122), Total HRT (n = 14). Model 2 (M2) ANOVA mixed effects model 
(adjusted) including covariates MCI/SMI, Education, IQ, age, BMI, centre, smoking 
status, and oily fish intake Bold font indicates significant p values (p < 0.05) HRT, 
hormone therapy, CS, carrier-status. 
 
Erythrocyte n-3 index has little impact on cognitive performance  
 
Higher RBC n-3 index has been associated with improved cognitive performance and 
reduced AD risk. Similarly, n-3 index was found to be altered in APOE4 individuals in 
our earlier analysis. However, in this study n-3 index was not associated with cognitive 
performance. We found no evidence of a significant n-3 index or n-3 index*carrier-status 
on cognitive performance across n-3 index tertiles. A similar result was attained when 
focusing solely on erythrocyte DHA (data not shown). 
ɛ4 
carrier 
1314.6 ± 19.4 1323.0 ± 152.2 
Continuity of 
Attention 
Non-
carrier 
91.8 ± 0.3 91.6 ± 0.7 0.448 0.222 
ɛ4 
carrier 
91.6 ± 0.5 93.3 ± 1.2 
Response Variability Non-
carrier 
50.7 ± 1.0 52.4 ± 3.6 0.748 0.875 
ɛ4 
carrier 
52.2 ± 2.3 53.6 ± 8.4 
Cognitive reaction 
time  
Non-
carrier 
220.8 ± 8.1 212.4 ± 17.3  0.000 0.001 
ɛ4 
carrier 
210.7 ± 10.3 97.3 ± 15.7 
Quality of working 
Memory 
Non-
carrier 
1.70 ± 0.04 1.8 ± 0.05 0.614 0.191 
ɛ4 
carrier 
1.72 ± 0.05 1.5 ± 0.31 
Quality of working 
episodic memory 
Non-
carrier 
182.5 ± 5.7 182.3 ± 17.8 0.101 0.063 
ɛ4 
carrier 
174.0 ± 9.8 239.4 ± 17.8 
Speed of Memory Non-
carrier 
4267.6 ± 95.7 4209.3 ± 306.5 0.029 0.036 
ɛ4 
carrier 
4674.3 ± 211.8 3527.0 ± 604.9 
Quality of Memory Non-
carrier 
352.1 ± 8.5 366.2 ±17.0 0.136 0.151 
ɛ4 
carrier 
345.3 ± 11.2 391.9 ± 46.8 
Executive Function Non-
carrier 
116.7 ± 2.2 124.4 ± 8.8 0.014 0.147 
ɛ4 
carrier 
108.4 ± 3.1 135.8 ± 11.8 
Picture Recognition  Non-
carrier 
86.9 ± 1.3 81.8 ± 4.7 0.473 0.031 
ɛ4 
carrier 
83.9 ± 2.6 96.7 ± 1.7 
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Table 2.9 Influence of n-3 Index on cognitive performance 
 
 
Cognitive test  
APOE4 
carrier  
T1 n-3 
Index 
T2 n-3 
Index 
T3 n-3 
Index 
n-3 
index 
M2 
CS*n-3 
Index 
M2 
MoCA Non-carrier 27.1 ±  
0.4 
27.1 ±  
0.5 
26.5 ±  
0.4 
0.413 0.612 
ɛ4 carrier 26.4 ±  
0.6 
26.6 ±  
0.5 
26.1 ±  
0.7 
Verbal Fluency  Non-carrier 12.3 ±  
0.6 
13.4 ±  
0.4 
11.7 ±  
0.6 
0.663 0.689 
ɛ4 carrier 11.6 ±  
0.8 
11.2 ±  
0.7 
10.6 ±  
0.5 
Verbal Fluency 
responses  
Non-carrier 11.8 ±  
0.6 
12.7 ±  
0.7 
12.5 ±  
0.7 
0.230 0.289 
ɛ4 carrier 12.7 ±  
0.7 
11.4 ±  
1.1 
12.8 ±  
0.9 
Original Misplacement Non-carrier 244.0 ± 
14.2 
236.0 ± 
13.7 
260.0 ± 
15.0 
0.782 0.788 
ɛ4 carrier 233.2 ± 
18.0 
244.5 ± 
18.0 
257.8 ± 
20.3 
Accuracy single item 
placement  
Non-carrier 2.4 ±  
0.1 
2.5 ±  
0.1 
2.3 ±  
0.1 
0.816 0.540 
ɛ4 carrier 2.4 ±  
0.2 
2.3 ±  
0.2 
2.3 ±  
0.2 
Power of Attention Non-carrier 1322.1 ± 
27.6 
1334.4 ± 
26.3 
1400.8 ± 
24.6 
0.280 0.270 
ɛ4 carrier 1302.0 ± 
46.7 
1320.2 ± 
39.4 
1320.6 ± 
22.1 
Continuity of Attention Non-carrier 91.3 ±  
0.7 
92.2 ±  
0.5 
91.8 ±  
0.5 
0.397 0.270 
ɛ4 carrier 91.6 ±  
0.6 
90.8 ±  
1.1 
92.9 ±  
0.6 
Response Variability Non-carrier 51.2 ±  
1.6 
51.1 ±  
1.8 
50.2 ±  
1.6 
0.276 0.274 
ɛ4 carrier 50.5 ±  
3.6 
57.3 ±  
4.4 
48.9 ±  
2.7 
Cognitive reaction time  Non-carrier 214.5 ± 
11.8 
214.6 ± 
11.4 
229.8 ± 
16.1 
0.479 0.281 
ɛ4 carrier 205.4 ± 
26.7 
202.9 ± 
18.7 
198.4 ± 
12.7 
Quality of working 
Memory 
Non-carrier 1.6 ±  
0.1 
1.8 ±  
0.1 
1.8 ±  
0.1 
0.065 0.783 
ɛ4 carrier 1.6 ±  
0.1 
1.7 ±  
0.1 
1.8 ±  
0.1 
Quality of working 
episodic memory 
Non-carrier 186.7 ± 
9.3 
192.7 ± 
8.7 
173.2 ± 
10.3 
0.783 0.239 
ɛ4 carrier 170.2 ± 
20.4 
179.0 ± 
19.8 
185.7 ± 
10.0 
Speed of Memory Non-carrier 4328.2 ± 
184.9 
4079.3 ± 
137.1 
4346.8 ± 
156.5 
0.661 0.329 
ɛ4 carrier 4890.2 ± 
695.7 
4551.0 ± 
214.5 
4397.4 ± 
179.1 
Quality of Memory Non-carrier 347.6 ± 
15.1 
367.1 ± 
12.8 
349.7 ± 
13.3 
0.533 0.545 
ɛ4 carrier 329.2 ± 
21.3 
346.4 ± 
21.4 
365.6 ± 
13.9 
Executive Function Non-carrier 115.7 ± 
4.1 
121.3 ± 
3.5 
115.3 ± 
4.1 
0.312 0.615 
ɛ4 carrier 117.5 ± 
7.6 
109.9 ± 
4.5 
106.2 ± 
5.0 
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All values are mean ± SEM. Groups: Non-carrier and T1 (2.8 - 4.49) n-3 index (n = 31), 
Non-carrier and T2 (4.5-5.19) n-3 Index (n = 31 ), Non-Carrier and T3 n-3 (5.20-6.1) 
Index ( n = 32), APOE4 carrier and T1 (2.8 - 4.49)  n-3 Index (n = 13), APOE4 carrier 
and T2 (4.5-5.19)  n-3 Index (n = 13 ), APOE4 carrier and T3 (5.20-6.1) Index (n= 13) 
Total T1 (2.8 - 4.49)  n-3 index (n = 44 ), Total T2 (4.5-5.19)   n-3 Index (n = 45 ), Total 
T3 (5.20-6.1) n-3 Index (n = 45). Model 2 (M2) ANOVA mixed effects model (adjusted) 
including covariates MCI/SMI, Education, IQ, age, BMI, centre and smoking status. Bold 
font indicates significant p values (p < 0.05) HRT, hormone therapy, CS, carrier-status. 
 
Discussion  
 
Intake of oily fish, the predominant source of the long chain n-3 PUFAs, EPA and DHA 
in the human diet has been associated with improved cognition in older adults (Witte, 
Kerti et al. 2014, Del Brutto, Mera et al. 2016), and reduced AD risk (Wu, Ding et al. 
2015). The transport and/or metabolism of n-3 PUFAs such as DHA, may be altered by 
the APOE4 genotype, increasing carrier susceptibility to n-3 PUFA deficiency, and 
cognitive decline (Nock, Chouinard-Watkins et al. 2017). In addition, AD and MCI risk 
associated with APOE4 appears to be exacerbated in females between the ages of 55 – 70 
years (Neu, Pa et al. 2017), suggesting a potential menopausal involvement. Here we 
perform a set of exploratory analyses on data obtained from the CANN study (Irvine, 
Scholey et al. 2018), to investigate the impact of APOE carrier-status, oily fish intake and 
HRT on PUFA status and cognition, accounting for multiple confounding variables. Our 
analysis reveals that APOE carrier-status and its interaction with HRT are associated with 
both altered circulating n-3 PUFA status and cognitive performance. Furthermore, we 
report that APOE4 influenced specific cognitive functions, particularly verbal and 
executive functions, whilst generally HRT was more wide-spread evident from 
improvement in MoCA test performance. Our results also provide evidence to suggest 
that HRT is neuroprotective, and that these effects are more extensive in APOE4 carriers. 
Despite fish intake significantly increasing n-3 PUFA status, cognitive performance was 
not improved in those with a higher erythrocyte n-3 index.  
Blood PUFA status was influenced by oily fish intake, BMI, APOE-carrier status and 
APOE-carrier status*HRT interaction. As expected, incremental consumption of oily fish 
portions was found to increase n-3 PUFA status, whilst reducing n-6 PUFA levels. This 
PUFA change was restricted to erythrocytes, and absent in the plasma/PC fractions, and 
Picture Recognition  Non-carrier 89.0 ±  
2.2 
83.9 ±  
2.6 
86.6 ±  
1.3 
0.868 0.382 
ɛ4 carrier 84.5 ±  
5.1 
82.5 ±  
4.7 
87.5 ±  
3.2 
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coincides with reports advocating erythrocytes as a biomarker of long-term oily fish 
intake due to their slower turn-over rate (half-life 120 days) (Sun, Ma et al. 2007). 
Conversely, BMI had the opposite impact, with erythrocyte DHA and n-3 PUFA status 
following an inverse relationship with BMI. Interestingly, this is in line with Howe and 
colleagues (Howe, Buckley et al. 2014), who reported that this effect was gender specific, 
and may indicate that adiposity in females is regulated by DHA status, or vice versa.  
Generally, APOE4 carrier status led to an overall increase in n-3 PUFA status, most 
apparent in the erythrocyte, with EPA markedly increased in most fractions. This increase 
was also found to some extent by Fisk and colleagues (Fisk, Irvine et al. 2018), however 
the effect in this study was limited to males, and the erythrocyte fraction was not analysed. 
Although somewhat paradoxical given both low n-3 PUFA status and APOE4 genotype 
are associated with greater AD risk, such a phenomenon has been reported as a result of 
increasing age (Walker, Browning et al. 2014, Fisk, Irvine et al. 2018), and may reflect 
reduced tissue uptake. n-3 PUFA transport deficits and reduced brain uptake have been 
reported in APOE4 mouse models (Vandal, Alata et al. 2014, Nock, Chouinard-Watkins 
et al. 2017), and may contribute to the elevated blood levels with less entering the brain. 
The present analysis, which found a substantial link between EPA levels and APOE4 
carrier status in females, warrant further exploration.   
Age was assessed to determine its influence on PUFA status and to distinguish a distinct 
age group in which APOE4 carrier status may have the greatest impact. Although age 
mediated increases in n-3 PUFA status have been previously reported (Walker, Browning 
et al. 2014, Fisk, Irvine et al. 2018), we did not observe a significant difference across our 
age tertiles despite a nominal increase in a number of n-3 PUFAs. This may reflect our 
exclusive use of females, in which the impact of age may be less pronounced, and also a 
relatively limited age range compared to the Fisk et al., analysis who included individuals 
between 20-70 years. Similarly, an age*carrier-status interaction was not observed 
indicating that the impact of APOE4 on n-PUFA status in females was not age specific, 
although this may be explained by the modest number of participants in the oldest tertiles.  
HRT alone had no effect on the FA profile. However, continuation of this analysis 
addressing the HRT*carrier-status interaction revealed effects on the n-3 index and DHA 
profiles across erythrocyte and PC fractions. HRT appeared to mitigate the elevated n-3 
PUFA levels identified in APOE4 carriers. HRT has been previously shown to increase 
circulating levels of DHA and EPA in postmenopausal women (Sumino, Ichikawa et al. 
2003), which appeared to occur to some extent in our APOE3 participants. To our 
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knowledge this is the first analysis to investigate such parameters across genotypes. With 
that said this remains an exploratory analysis and needs to be validated in a study with 
larger numbers of APOE4 HRT individuals. Furthermore, our analysis provided no 
consideration for the type of HRT prescribed nor the years or commencement or length 
of usage which are all likely to influence the impact of HRT on PUFA status. 
Overall, cognitive performance was influenced by APOE4 carrier-status, HRT and 
APOE4 carrier status*HRT, whilst surprisingly, erythrocyte n-3 index and DHA levels 
did not influence cognitive performance. APOE4 carrier status was associated with 
reduced performance on a subset of specific cognitive tests. The tests significantly 
impaired by possession of an APOE4 allele were verbal fluency, speed of memory and 
executive function tasks. These tasks are indicative of poorer language function, 
executive function and semantic memory (Bertola, Mota et al. 2014), and are in line with 
a recent longitudinal study in which similar deficits were apparent in non-AD, healthy 
ageing APOE4 carriers (Li, Qiu et al. 2019). This is promising given previous studies 
have yielded mixed results (Small, Rosnick et al. 2004), highlighting the necessity of 
multi-domain cognitive testing and the importance of controlling for confounding 
variables. Vulnerable brain networks associated with APOE4 genotype have been 
established in mouse models (Badea, Wu et al. 2019), and may account for the specific 
impairment in cognition. As suggested by Li et al (Li, Qiu et al. 2019), knowledge of the 
specific cognitive domains impaired, may be useful in the future for predicting an APOE4 
carriers risk of developing MCI or dementia. 
Interestingly, HRT alone led to a general improvement in cognition evident from the 
significant increase in MoCA test score, which is in line with a recent randomised control 
trial in which HRT intervention was assessed in females with MCI (Yoon, Chin et al. 
2018). Although still controversial these results provide evidence that if the correct 
timing, form and dosage of HRT is established it may offer an effective method of 
intervention to reduce MCI and AD risk. This may be un-surprising given the 
neuroprotective, neurotrophic, neurogenerative, anti-oxidative and anti-inflammatory 
actions that estrogens impart upon the brain (Li, Cui et al. 2014). Speed of memory, and 
executive function tasks, which declined in APOE4 carriers were conversely improved 
by HRT. This may indicate that those with both APOE4 carrier status and menopause 
receive a ‘double hit’ of deleterious factors leaving the associated brain regions 
particularly vulnerable.   
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In addition to the general impact of HRT and in line with previous reports (Rippon, Tang 
et al. 2006, Ryan, Carrière et al. 2009), we also observed a HRT*APOE-carrier 
interaction, which was suggestive of an increased benefit of HRT in carriers of APOE4 
genotype. Of the cognitive tests significantly altered were reaction time and speed of 
memory, which were dramatically improved in APOE4 carriers receiving HRT. These 
tasks are indicators of cognitive processing speed and the dramatic improvement is 
potentially indicative of alleviating the aforementioned ‘double hit’. In addition, the 
picture recognition task saw APOE4 carriers receiving HRT improve performance by 15 
± 3.11%. Deficits in recognition memory have been previously linked to ovarian failure 
and menopause (Hara, Park et al. 2012, Bastos, Pereira et al. 2015), but interestingly here 
it appears to be particularly associated with APOE genotype. Estrogens are known to 
interact with APOE, with experimental models reporting that estrogen may modulate 
APOE expression (Safieh, Korczyn et al. 2019), and may in part explain the APOE 
genotype specific responses to HRT. 
Finally, increased n-3 index was not associated with improved cognitive function in this 
study. This is in contrast to a number of previous reports in which this association has 
been identified (Lukaschek, von Schacky et al. 2016, Hooper, De Souto Barreto et al. 
2018). This is likely due to the exclusion criteria in which participants with high n-3 index 
were excluded from the study. Therefore, a subset of the population with high n-3 index 
(probably consuming greater amounts of oily fish) are missing, potentially explaining the 
lack of association in this study cohort. Furthermore, it is becoming increasingly evident, 
that a higher n-3 index and DHA status in the plasma may indicate defective brain DHA 
uptake (particularly in APOE4 carriers) which would negate the expected positive 
associations between DHA status in the circulation and cognition. 
 
Conclusion  
 
APOE ε4 is associated with alterations in erythrocyte and PC PUFA status and poorer 
performance on cognitive tasks specifically associated with language and executive 
functions. Incorporating HRT data revealed a significant improvement in cognitive 
performance in response to treatment, which appeared to be more extensive in APOE4 
carriers. Interestingly, as well as improving cognitive function, HRT appeared to reverse 
the elevated n-3 PUFA status associated with APOE4 carrier status. Further research with 
a larger cohort of APOE4 individuals with granular HRT data such as the Millions 
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Women’s Study or the UK Biobank is required to validate this exploratory analysis. 
Future studies exploring HRT should control for APOE genotype in light of our findings. 
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 : APOE4 genotype exacerbates the impact of 
menopause on cognition and synaptic plasticity in APOE-TR 
mice 
 
This chapter has been prepared in the form of a research paper  
Title: APOE4 exacerbates the impact of a menopause mimic on cognition and synaptic 
plasticity in the APOE-TR mouse model 
Authors Matthew G Pontifex, Anneloes Martinsen, Rasha Saleh, Glenn Harden, Noemi 
Tejera, Michael Müller, Chris Fox, David Vauzour, Anne-Marie Minihane  
 
Introduction 
 
The development of sporadic late-onset Alzheimer’s disease (AD) is complex and 
multifactorial, with more than 20 susceptibility loci including Apolipoprotein E (APOE) 
(Giri et al., 2016). APOE4 is the strongest prevalent genetic risk factor with an allele 
frequency of 14% in the general population and concentrated in AD (allele frequency ~ 
40% in Caucasians) (Bang, Kwak et al. 2003). The APOE4 gene increases AD risk in a 
gene-dose dependent manner, rising 2–3 fold for heterozygous APOE4 carriers and 12-
fold in homozygotes (Corder, D. E. Schmechel et al. 1993, Farrer, Cupples et al. 1997), 
with age of onset considerably reduced in APOE4 carriers (Bertram, McQueen et al. 2007, 
Davidson, Gibbons et al. 2007). However, a large proportion of APOE4 carriers do not 
develop AD, indicating that this genotype is predictive rather than prognostic (Henderson, 
Easteal et al. 1995), with its affect influenced by environmental and biological variables. 
There is accumulating evidence that the penetrance of APOE4 genotype is influenced by 
sex (Farrer, Cupples et al. 1997, Snyder, Asthana et al. 2016), which may underlie the 
finding that almost two thirds of AD cases are females (Podcasy and Epperson 2016). In 
a large meta-analysis Neu and colleagues reported increased MCI and AD risk in females 
versus males APOE4 carriers between 55-70 years and 65-75 years respectively (Neu, Pa 
et al. 2017). Despite this observation, little is known of the aetiology underlying this 
susceptibility. However, given the age at which females are at increased risk (Neu, Pa et 
al. 2017) and the fact that earlier onset of menopause correlates with poorer cognition in 
later life (Ryan, Scali et al. 2014), it is plausible that menopause acts as a mediating factor.  
Within the central nervous system APOE is the main lipid transporter (Holtzman, Herz et 
al. 2012). In comparison to other organs, the brain is highly enriched with the n-3 
polyunsaturated fatty acid (PUFA) docosahexaenoic acid (DHA) accounting for ~15% of 
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total brain lipids (Bradbury 2011). We have recently reported a strong association 
between age, female sex, and an APOE4 genotype, with decreased cortical DHA and a 
number of specialized pro-resolving mediators in APOE4, which together may contribute 
to the development of cognitive decline and AD pathology (Martinsen, Tejera et al. 2019). 
DHA is specifically concentrated within the synaptosome  (Neuringer, Anderson et al. 
1988) (which in turn is estrogen responsive) thus it is unsurprising that reduced DHA 
status is consistently linked to poorer cognitive outcome and increased AD risk (Weiser, 
Butt et al. 2016). Synaptic loss and dysfunction, which has been characterised in both 
menopause and APOE4 individuals, is directly associated with cognitive decline and 
occurs in the initial stages of AD (Kim, Yoon et al. 2014).  
With an aetiological link accounting for the greater female APOE4 susceptibility 
distinctly lacking (Pontifex, Vauzour et al. 2018), we posit menopause as a contributing 
factor, given the neuroprotective properties of estrogen (Li, Cui et al. 2014), and greater 
cognitive decline associated with early menopause (Ryan, Scali et al. 2014). Here, in a 
transgenic mouse model we assessed the combined impact of APOE genotype and ovarian 
failure on cognitive performance hypothesising that APOE4 animals will be more 
susceptible to estrogen loss. Furthermore, we determine if changes in cognitive 
performance relate to alterations in brain fatty acid profiles and synaptic plasticity. Our 
model system combines the humanised targeted replacement (APOE-TR) mouse model 
with 4-Vinylcyclohexene diepoxide (VCD) treatment. VCD injection is an established 
method used to induce ovarian failure in rodents (Kappeler and Hoyer 2012) and credited 
for its ability to establish an intermediary human like ‘perimenopause’ phase, whilst 
maintaining ovarian tissue integrity.  
 
Material and methods  
 
Study approval 
All experimental procedures and protocols used in this study were reviewed and approved 
by the Animal Welfare and Ethical Review Body (AWERB) and were conducted within 
the provisions of the Home Office Animals (Scientific Procedures) Act 1986. 
 
Animal model and experimental design  
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Forty eight female humanised APOE3 (B6.129P2-Apoetm2(APOE*3)Mae N8) and APOE4 
(B6.129P2-Apoetm2(APOE*4)Mae N8) targeted replacement mice homozygous for the human 
APOE3 or APOE4 gene (Taconic, Germantown, NY, US) were used in these experiments 
(Sullivan, Mezdour et al. 1997, Knouff, Hinsdale et al. 1999, Martinsen, Tejera et al. 
2019). Mice were maintained in a controlled environment (21 ± 2°C; 12-h light–dark 
cycle; light from 07:00 hours) and fed ad libitum on a standard chow diet (RM3-P, Special 
Diet Services, Essex, UK) until the age of 4 months, ensuring normal development. 
Following this run-in period, mice were switched to a semi-purified high fat diet (45 
kCal% fat) (D17080301, Research diets, New Brunswick, NJ, USA) for the remaining 
duration of the experiment (See Table S1 for full dietary composition).  
 
At 8 months of age and to assess the impact of menopause, mice from each genotype 
received intra peritoneal (i.p.) injections of either VCD (160mg/kg body weight) diluted 
in sesame oil, or sesame oil vehicle (sham) for a total of 14 injections over 3 weeks. 8 
months was selected as it is roughly midlife for the animals (when human menopause 
occurs) and before natural ovarian failure is known to occur in C57BL/6 mice (Gosden, 
Laing et al. 1983, Chen, Perez et al. 2014). Following completion of the final behavioural 
test, 12-month aged animals were sedated with isoflurane (1.5%) in a mixture of nitrous 
oxide (70%) and oxygen (30%) and transcardially perfused with an ice-cold PBS 
containing protease (SIGMAFASTTM Protease inhibitor, Sigma, Devon, UK) and 
phosphatase (1 mM sodium pyrophosphate and 50 mM sodium fluoride, Sigma, Devon, 
UK) inhibitors. Sera were isolated via centrifugation at 2000 x g for 10 min. Brains were 
rapidly removed, halved, snap frozen and stored at -80°C until biochemical analysis. 
Ovaries were rapidly removed and processed for histology.  
 
Behavioural assessment 
All behavioural tests were performed when mice were 12 months of age and immediately 
prior to sacrifice. A visual placing test was performed on each animal on the first day of 
testing, to ensure animals were not visually impaired (Pinto and Enroth-Cugell 2000).  
Spatial learning and memory was evaluated with the Barnes Maze as previously described 
(Patil, Sunyer et al. 2009). Briefly, the maze consisted of a brightly illuminated (800 lux 
lighting) circular platform (92cm diameter), with 20 evenly distributed holes located 
around the circumference and visual cues (4 simple shapes) placed at the periphery. The 
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experiment was conducted over a 5-days period, with each mouse tested/trained on ability 
to locate the escape box 4 times per day during days 1-4. On day 5, a probe test was 
conducted, the maze was rotated 90°, the escape box was removed and mice were placed 
in the centre of the maze in which they were free to navigate for one minute. Percentage 
time in correct quadrant was determined using the Smart 3.0 tracking software (Panlab, 
Kent, UK).  
 
The novel object recognition (NOR), a measure of recognition memory, was performed 
as described previously (Davis, Eacott et al. 2013, Leger, Quiedeville et al. 2013), with 
slight modifications. Briefly, on day 1 mice were habituated in grey 50x50x50cm 
apparatus illuminated with low lux (100 lux) lighting, mice were placed into the empty 
maze and allowed to move freely for 10 minutes. On day 2, mice were conditioned to a 
single object for a 10-minute period. On day 3, mice were placed into the same 
experimental area in the presence of 2 identical objects for 15 minutes, after which they 
were returned to their respective cages and an inter-trial interval of one hour was 
observed. One familiar object was replaced with a novel object. Mice were placed back 
within the testing area for a final 10 minutes. Videos were analysed for a 5-minute period, 
after which if an accumulative total of 15 seconds with both objects failed to be reached, 
analysis continued for the full 10 min or until 15s was achieved. Those not achieving 15s 
were excluded from the analysis (Denninger, Smith et al. 2018). A discrimination index 
was calculated as follows: DI = (TN−TF)/(TN+TF), where TN is the time spent exploring 
the novel object and TF is the time spent exploring the familiar object. 
 
Y-maze spontaneous alternation test, a measure of spatial working memory was 
performed on the final day of behavioural testing as previously described (Thomas, 
Morris et al. 2017). Briefly, the Y-maze apparatus comprised of white Plexiglas in the 
following dimensions (38.5 × 8 × 13 cm, spaced 120° apart) and was illuminated with low 
lux (100 lux) lighting. Mice were placed in the maze and allowed to explore freely for 7 
minutes whilst tracking software recorded zone transitioning and locomotor activity 
(Smart 3.0 tracking software, Panlab, Kent, UK).  
 
Histological and biochemical analyses 
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Ovaries were trimmed of fat and fixed in 10% formalin for 24h before being paraffin 
embedded, and processed for haematoxylin and eosin (H&E) staining as described 
previously (Chen, Kang et al. 2015). Follicle stimulating hormone (FSH) concentrations 
were determined by ELISA (Abnova KA2330) in sera samples as per manufacturer’s 
instructions. 
 
Fatty acid profile in the brain 
Total lipids were extracted from sub-cortical brain tissues (n=5/6 per group) using the 
Folch extraction method (Folch, Lees et al. 1957). Fatty acid methyl esters (FAME) were 
obtained using acid-catalysed transesterification (Christie and Han 2010). FAME were 
evaporated under oxygen free nitrogen, and re-suspended in 500 µl of iso-hexane, SPE 
silica cartridges (Clean-up 203 Cusil 156, UCT) were used for purification purposes. The 
purified FAMEs were separated by gas chromatography using a Trace 1300 series Gas 
Chromatograph (thermo scientific, Stafford House, Boundary Way, Hemel Hempstead. 
HP2 7GE, U.K.) equipped with a PTV injector modified for on-column injection, and a 
flame ionisation detector. A fused silica capillary column (TraceGOLD™ TG-5MS 
Guard GC Column with SafeGuard column, 30 m × 0.32 mm × 0.25 µm; Thermo Fisher 
Scientific, Hemel, Hempstead, UK) was employed, and hydrogen was used as carrier gas. 
The temperature gradient was from 50 to 150°C at 40°C/min and then to 200°C at 
2°C/min followed by 214°C at 1°C/min and finally to 220°C at 40°C/min, where it was 
held for 5 min. Individual methyl esters were identified by comparison to known 
standards (Marine oil FAME mix RESTEK #35066). Data were collected and processed 
using the Chromeleon software package (version 7.2).  
 
Immunoblotting 
Cortices were homogenised in lysis buffer (CelLyticTM MT, Sigma, UK) containing 
protease (cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail, Roche, UK) and 
phosphatase (PhosSTOPTM, Roche, UK) inhibitors. Protein concentration was determined 
using the Pierce™ BCA Protein Assay Kit (ThermoFisher, UK). Protein electrophoresis 
was conducted under denaturing conditions as previously described (Vauzour, Corsini et 
al. 2018). The following antibodies were used: anti p-Akt Ser473, (1:1000; Cell 
Signalling, UK), anti-total-Akt, (1:1000; Cell Signalling, UK), anti BDNF (1:500; Santa 
Cruz Biotechnology, USA), anti APOE (1:1000; Cell Signalling, UK), anti GAPDH 
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(1:2500, Cell Signalling, UK), anti-beta-actin (1:2500, Cell Signalling, UK ) and anti-
Rabbit IgG (H + L) DyLightTM 680 Conjugate (1:10,000, Cell Signalling, UK). Bands 
were revealed by fluorescence using an Odyssey 9120 Infrared imaging system (LI-COR 
Biosciences, Ltd, UK). Relative band intensities were quantified using the ImageJ 
software (Schneider, Rasband et al. 2012). 
 
RNA isolation and qRT-PCR 
RNA isolation, cDNA synthesis and qRT-PCR were carried out as previously described 
(Vauzour, Rodriguez-Ramiro et al. 2018). Briefly, total RNA was isolated from the brain 
samples using the Qiazol reagent (Qiagen, UK). One μg of total RNA was treated with 
DNase I (Invitrogen, UK) and used for cDNA synthesis using Invitrogen™ Oligo (dT) 
primers and M-MMLV reverse transcriptase. Quantitative real-time PCR (qRT-PCR) 
reactions were performed using SYBR green detection technology on the Roche light 
cycler 480 (Roche Life Science, UK). Results are expressed as relative quantity scaled to 
the average across all samples per target gene and normalised to the reference genes 
TATA-box binding protein (Tbp) and glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh), which were identified as optimal housekeeping selection/combination using the 
Normfinder software (Day, Chambers et al. 2018). The primer sequences are given in 
Supplementary Table S2.  
 
Statistical Analysis 
All data is presented as mean ± SEM. Data analysis was performed in GraphPad Prism 
version 8 (GraphPad Software, CA, USA). After checking for normality/equal variances 
and performing log transformation if necessary, comparisons among groups were 
performed on normally distributed data using two-way ANOVA, followed by post-hoc 
Sidak test. P-values of less than 0.05 were considered statistically significant.  
 
 
Results  
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Repeated injections of VCD result in ovarian failure independently of APOE 
genotype 
 
Repeated injections of VCD in APOE3-TR and APOE4-TR mice resulted in a 
considerable loss of ovarian follicles (Fig. 1A) and a 5-fold increase in serum follicle 
stimulating hormone (FSH) levels (VCD: 2.84 ± 0.32 ng/mL; Sham: 0.52 ± 0.14 ng/mL; 
p < 0.0001 Fig. 1B), irrespective of APOE genotype. Neither VCD treatment nor 
genotype had any impact on body weight (p > 0.05 Fig. 1C). Concomitant with VCD 
injections and subsequent ovarian/hormonal changes, a 2-fold increase in brain 
expression of estrogen receptor (ER) Esr2 (VCD: 1.85 ± 0.19 fold; Sham 0.87 ± 0.14 
fold; p < 0.0001 Fig. 1D), and a nominal 1.3-fold increase in Esr1 (VCD: 1.18 ± 0.14 
fold; Sham: 0.92 ± 0.12 fold; p > 0.05 Fig 1E) were observed.  
Figure 3.1VCD treatment leads to ovarian failure dependently of APOE genotype in 
APOE3-TR and APOE4-TR mice. 
A) Representative images of APOE3-TR and APOE4-TR female mice ovaries stained 
with hematoxylin and eosin show important loss of ovarian follicles following repeated 
i.p. injections of VCD; B) VCD injected groups display elevated serum follicle 
stimulating hormone (FSH) levels (n=5/6); C) Body weight was unaffected by VCD 
treatment or genotype (n= ≥8); D-E) Brain expression of estrogen receptors Esr1 and 
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particularly Esr2 mRNA levels, are up-regulated in response to VCD injections. Data are 
presented as mean ± S.E.M  *p< 0.05. **P < 0.01, ***P < 0.001. 
 
Whilst APOE4 impairs working spatial memory, VCD causes additional deficits to 
recognition memory 
Y-maze, Barnes maze and novel object recognition were employed to establish the impact 
of genotype and VCD treatment on cognitive performance (Fig. 3.2). VCD had no effect 
on the spatial learning and memory tasks, as assessed by the Y-maze and the Barnes maze 
(Figure 3.2A and 3.2B). However, a genotype dependant effect was observed, with 
APOE4 animals displaying ~15% lower cognitive performance than their APOE3 
counterparts as assessed by the Y-maze (p < 0.001 Fig. 3.2A). This was consistent with 
the Barnes maze, where APOE4 animals spent ~45% less time in the correct quadrant, (p 
< 0.001 Fig. 3.2B). Representative trajectory maps are shown in Fig. 3.2C. 
Unlike spatial learning and memory, recognition memory as assessed by the NOR test 
was influenced by menopausal status, and in a genotype dependent manner, with VCD 
injected APOE4 animals losing the ability to distinguish between novel and familiar 
objects, (p < 0.05 Fig. 3.2D). 
Figure 3.2 APOE4 and VCD treatment influence cognition. 
A) Y-maze spontaneous alternation task (n≥8) and B) Barnes probe test (n≥8) identify 
deficits in spatial memory as a result of APOE4 genotype, VCD treatment had no impact; 
C) Representative trajectory’s from APOE3 Sham (top) and APOE4 sham (bottom) 
during the probe test, filled circle denotes former location of escape box; D) Performance 
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on Novel Object Recognition task (n≥8) was severely compromised in the APOE4 VCD 
group. Data are presented as mean ± S.E.M  *p< 0.05. **P < 0.01. 
 
VCD injections reduce brain DHA levels independently of APOE genotype.  
 
A significant 13% genotype independent lower brain DHA concentration was observed 
in VCD injected animals independent of their APOE genotype (VCD: 11.47 ± 0.35 %; 
Sham: 13.13 ± 0.16%; p < 0.001 Fig. 3.3A). Higher total mono-unsaturated fatty acids 
(MUFAs) was observed in APOE3 carriers following VCD injections (p < 0.05; Table 
3.1). These changes were mirrored by a decrease in total saturated fatty acids (SFAs) in 
APOE3 (p < 0.05). DHA:AA ratio was 8% lower following VCD treatment (p < 0.05), in 
APOE4 animals but remained constant in APOE3 regardless of treatment.  
To identify whether the observed lower DHA was related to deficits in DHA transport, 
gene expression profiles of key DHA transporters in the brain were assessed. Fatp4 
expression was 1.5-fold lower in APOE4 VCD injected animals (p > 0.05 Fig. 3.3B). 
Similar trends were observed for Fatp1 and Acsl6 although it did not reach significance 
(Fig. 3.3c-d). No effect was observed for Mfsd2a and Fabp5. 
Figure 3.3 HF VCD treatment reduces brain DHA levels.  
A) GC-FID analysis revealed lower brain DHA levels in VCD treated groups (n=5/6); B-
F) Expression of key transporter proteins involved in DHA transport and uptake. Data are 
presented as the mean ± S.E.M  *p< 0.05. **P < 0.01.
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Table 3.1: Brain fatty acid composition of experimental animals 
 
APOE3 APOE4 Genotype 
P value 
Intervention 
P value 
Interaction 
P value 
Fatty acid  HF Sham HF VCD HF Sham HF VCD 
   
Total n-3 PUFA 13.30 ± 0.20 a 11.60 ± 0.70 b 13.20 ± 0.30 11.80 ± 0.50 0.964 0.004 0.805 
20:5 n-3 (EPA)  0.02 ± 0.01 0.06 ± 0.03 0.02 ± 0.01 0.03 ± 0.14 0.466 0.147 0.414 
22:6 n-3 (DHA) 13.20 ± 0.20 a 11.20 ± 0.50 b 13.10 ± 0.30 a 11.70 ± 0.50 b 0.650 0.001 0.519 
Total n-6 14.20 ± 0.20 12.60 ± 0.40 14.80 ± 0.90 13.20 ± 0.60 0.274 0.011 0.979 
20:4 n-6 (AA) 9.37 ± 0.21 8.10 ± 0.39 8.95 ± 0.25 8.67 ± 0.50 0.860 0.058 0.221 
DHA:AA 1.40 ± 0.03 1.39 ± 0.05 1.48 ± 0.01 a 1.36 ± 0.03 b 0.619 0.049 0.134 
Total SFAs 38.70 ± 0.40 a 35.50 ± 0.90 b 36.60 ± 0.60 36.90 ± 1.20 0.689 0.100 0.054 
16:0 17.60 ± 0.50 a 14.70 ± 0.70 b § 16.20 ± 0.50 17.30 ± 0.90 § 0.406 0.207 0.010 
18:0 20.10 ± 0.30 18.90 ± 0.50 19.30 ± 0.20 18.30 ± 0.60 0.138 0.025 0.802 
20:0 0.31 ± 0.02 a 0.41 ± 0.03 b 0.28 ± 0.02 0.33 ± 0.03 0.053 0.014 0.343 
22:0 0.22 ± 0.04 0.38 ± 0.05 § 0.26 ± 0.01 0.19 ± 0.06 § 0.099 0.110 0.030 
Total MUFAs 25.40 ± 0.40 a 30.50 ± 0.80 b § 27.30 ± 0.90 27.90 ± 1.40 § 0.448 0.021 0.013 
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18:1 n-9 18.20 ± 0.50 a 21.20 ± 0.80 b 19.30 ± 0.60 19.30 ± 1.20 0.684 0.091 0.084 
20:1 n-9 2.03 ± 0.18 a 3.04 ± 0.20 b 2.28 ± 0.20 2.21 ± 0.21 0.166 0.028 0.013 
24:1 n-9 1.37 ± 0.09 a 1.96 ± 0.18 b § 1.56 ± 0.11 1.14 ± 0.24 § 0.080 0.641 0.008 
 
(n=5/6 per group). PUFA; Polyunsaturated fatty acid, 20:5 n-3 EPA; Eicosapentaenoic acid, 22:6 n-3 DHA; Docosahexaenoic acid, 20:4 n-
6 AA; Arachidonic acid, DHA:AA; Docosahexaenoic acid to Arachidonic acid ratio, SFAs; Saturated fatty acids, 16:0; Palmitic acid, 18:0; 
Stearic acid, 20:0; Eicosanoic acid, 22:0; Docosanoic acid, MUFAs; Monounsaturated fatty acids, 18:1 n-9; Oleic acid, 20:1 n-9; 11-
Eicosenoic acid, 24:1 n-9; Nervonic acid. Data is % of total fatty acids and mean value ± S.E.M. 2-way ANOVA. Letters a,b denote significant 
difference between intervention whilst § denotes significant genotype effect as analysed via post hoc. The full table can be found in 
supplementary data (Table S3)
Table 3.1 continued 
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VCD injections trigger a lower synaptic plasticity response in APOE4-TR mice 
 
Lower APOE protein levels were observed in APOE4 compared to APOE3 animals (p < 
0.0001; Fig. 3.4E), which was not influenced by VCD treatment. Expression of the 
hAPOE transgene was constant across all groups indicating a post-transcriptional impact 
of genotype (p > 0.05 Fig. 3.4E).  
 
VCD treatment led to a significant reduction in brain BDNF protein levels (p < 0.05 Fig. 
3.4B), with post-hoc analysis indicating a significant, 2-fold reduction limited to APOE4 
VCD treated animals when compared to sham (APOE4 VCD: 0.74 ± 0.01 arbitrary unit; 
APOE4 Sham: 0.146 ± 0.01 arbitrary unit; p < 0.05). This was reflected at the gene level 
in which a 30% reduction in Bdnf expression was observed (p < 0.05; Fig. 3.4F), (APOE4 
VCD: 0.77 ± 0.04 fold; APOE4 Sham: 1.11 ± 0.157 fold; p < 0.05). As PI3K, and in 
particular AKT/PKB are involved in BDNF regulation we next sought to capture their 
response to intervention. As with BDNF, AKT Ser473 protein was significantly altered 
in a genotype*VCD dependent manner (p< 0.05 Fig 3.4C). Akt1 gene expression was 
similarly ~ 20% lower in the VCD APOE4 group (p <0.05 Fig. 3.4G); however, this did 
not reach significance in post hoc analysis. VCD treatment also resulted in altered NMDA 
receptor related signalling (Fig. 3.4H-J). The transcription factors Creb1 (p < 0.05; Fig. 
3.4H) and Atf4 (p < 0.0001; Fig. 3.4I) were downregulated in response to VCD treatment. 
Similarly, further along the pathway, NMDA R2b expression itself, Grin2b (p < 0.05 Fig. 
3.4J) and the highly associated Ephb2 (p < 0.05) were also downregulated. Post hoc 
analysis determined that this effect was widespread affecting both genotypes when 
compared to sham counterparts, with the exception for Ephb2 in which the reduced 
expression was only evident in the APOE4 VCD treated group. In addition to the VCD 
effect, genotype influenced expression of Cbd1 (p < 0.05) independently of VCD 
treatment.  
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Figure 3.4 Selective impact of genotype and VCD on synaptic plasticity related genes and proteins;  
A) APOE protein was lower in the cortex of APOE4-TR animals; B) BDNF protein was lower in APOE4 VCD treated animals; C) AKT 
protein was similarly lower in APOE4 VCD treated animals; D) representative western blots for both APOE3 and APOE4, Sham and VCD 
treated animals (n=6); F-L) Hippocampal expression profiles relating to synaptic plasticity (n=5/6); F-G) Showing VCD mediated reductions 
in BDNF – AKT signalling (also observed at protein level); H-K) altered NMDA receptor signalling and L) genotype related reduction in 
Cbd1 expression. Data are presented as the mean ± S.E.M  *p< 0.05. **P < 0.01 ***P <0.001
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Discussion 
 
Several studies report that female carriers of the APOE4 genotype are at a higher risk of 
AD (Neu, Pa et al. 2017); however little is known as to how this predisposition manifests 
(Pontifex, Vauzour et al. 2018). Here we sought to determine whether the cumulative 
APOE4*menopause effect, contributes towards this greater risk. With VCD treatment 
emerging as a robust model to assess the implications of menopause in neurological 
disease (Marongiu 2019), we investigated for the first time the impact of VCD mediated 
ovarian failure in the APOE-TR mouse model, focusing on cognition, brain FA profiles 
and synaptic plasticity related signalling. Deficits in spatial learning and memory were 
related to the APOE4 genotype, with an additive effect of menopause and APOE4 carrier 
status on recognition memory. Furthermore, the VCD insult lowered brain DHA and 
synaptic plasticity signalling related genes and proteins.  
 
Unlike previously published data by us and others reporting a strong impact of APOE4 
genotype on body weight gain in male mice (Dose, Huebbe et al. 2016, Slim, Vauzour et 
al. 2017), no effect of APOE genotype nor VCD injections was observed in our female 
mice. This observation is in agreement with previous reports indicating limited impact of 
menopause (Haas JR 2007) and APOE4 (Jones, Watson et al. 2019) on body weight gain 
in female mice.  
 
Y-maze and Barnes maze revealed APOE4 dependant deficits in spatial learning and 
memory, which has previously been reported using the water-maze task (Bour, 
Grootendorst et al. 2008). This impairment was found to be APOE4 female specific and 
was intriguingly absent in the APOE4 male mice (Bour, Grootendorst et al. 2008). We 
did not detect any exacerbation of spatial deficits as a result of menopause. Conversely, 
recognition memory decreased in response to the menopause mimic in APOE4 animals 
only. Impairment of recognition memory has been previously reported in chronic 
ovariectomised C57BL6 mice (Bastos, Pereira et al. 2015), and aged rhesus monkeys 
(Hara, Park et al. 2012), suggesting that the medial temporal lobe and surrounding cortical 
areas are particularly sensitive to ovarian failure. Here we report that this effect is 
exacerbated by APOE4. Together, these behavioural tests describe both genotype and 
genotype*VCD mediated cognitive deficits and highlight how this ‘double hit’ of factors 
results in a broader cognitive impairment.  
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Reduced DHA intake and status is associated with neuropathology, cognitive decline and 
higher AD risk (Tan, Harris et al. 2012, Weiser, Butt et al. 2016, Zhang, Chen et al. 2016). 
APOE4 is implicated in reduced uptake of DHA into the brain (Chouinard-Watkins and 
Plourde 2014, Vandal, Alata et al. 2014), whilst menopause and estrogen depletion have 
been shown to affect DHA homeostasis (Marin and Diaz 2018). To our knowledge the 
impact of both menopause and APOE4 genotype on brain DHA levels has not previously 
been explored. Here we show that brain DHA levels were equally diminished in both 
genotypes following VCD treatment. Interestingly, lower brain APOE levels were 
observed in both APOE4 groups, independent of VCD insult, suggesting that DHA 
concentrations are uncoupled to APOE protein levels. This is in contrast to a previous 
report suggestive of APOE involvement in brain DHA levels (Vandal, Alata et al. 2014), 
however as eluded to, this effect may be more prominent in male mice. Although this is 
the first time brain fatty acid levels have been analysed in a VCD model, and specifically 
APOE-TR animals, previous OVX models have demonstrated similar reductions in DHA 
(Alessandri, Extier et al. 2011), indicating a clear role of reproductive hormones in the 
maintenance of brain DHA. Interestingly, despite DHA being reduced in all VCD 
animals, DHA:AA ratio was only reduced in the APOE4 VCD group. Given that this ratio 
is likely to be an important determinant of neuro-inflammatory status, as AA and DHA 
are fatty acid precursors of potent pro-inflammatory eicosanoids (Zárate, El Jaber-
Vazdekis et al. 2017) and specialised pro-resolving mediators respectively (Duvall and 
Levy 2016, Martinsen, Tejera et al. 2019), this may offer in part an explanation as why 
the APOE3 animals were more resilient to the reduced brain DHA and remain 
unimpaired. Furthermore, in APOE3 the VCD mediated fluctuations of higher total 
MUFA and lower total SFA (absent in APOE4) may have influenced cognition to some 
extent. Higher MUFA intake has previously been shown to improve brain function whilst 
lower MUFA brain levels are associated with AD, ageing and depression (Fernandes, 
Mutch et al. 2017). A number of pathways have been proposed to explain the benefits of 
MUFAs including the maintenance of membrane flexibility (López, Ilincheta de 
Boschero et al. 1995) and the actions of MUFA’s as anti-inflammatory and antioxidant 
derivatives (Naqvi, Harty et al. 2011), which have been shown to modulate 
neuroinflammation in Apoe KO mice (Alemany, Navarro et al. 2010). 
 
Probing key DHA transporter proteins, did not indicate any conclusive differences in 
expression profiles that could account for the reduced DHA observed. Of the transporters 
measured only Fatp4, showed a significant genotype related change with expression 
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generally lower in APOE4 animals. The fatty acid transporters i.e. Fatp1 and Fatp4 have 
been shown to bind DHA and facilitate its transport across the endothelial cell membrane 
(Lo Van, Sakayori et al. 2016). This lower expression may in part explain the genotype 
reductions in DHA observed by other groups if this effect is exacerbated by age. In 
addition, although not significant, Acsl6 was recently described from knockout studies as 
being a key mediator of neuroprotective DHA within the brain (Fernandez, Kim et al. 
2018) and was nominally lower in both APOE3 and APOE4 animals in response to VCD 
treatment. Previous work has indicated that blood brain barrier transporter protein cell 
localisation and membrane shedding are influenced by APOE and neuropathology. This 
could influence the capacity to uptake DHA into the brain (Abisambra, Fiorelli et al. 2010, 
Bachmeier, Shackleton et al. 2014), and should be a focus of future research. On the other 
hand, as previously mentioned the change may be independent of transport, and instead 
related to metabolic disturbances which lead to greater β-oxidation of DHA (Chouinard-
Watkins, Rioux-Perreault et al. 2013). This is conceivable given the role estrogens play 
in bioenergetic systems within the brain, such as mitochondrial function (Rettberg, Yao 
et al. 2014). 
 
Given the APOE proteins known role in neurite outgrowth (Nathan, Jiang et al. 2002) and 
neuronal repair processes (Mahley and Huang 2012), APOE4 specific reductions in 
spatial memory might be expected in light of the diminished protein levels observed in 
this experimentation. Further investigation may be warranted to establish if these lower 
ApoE4 levels are constant across sexes given that spatial memory deficits are APOE4 
female specific (Bour, Grootendorst et al. 2008). Estrogen is involved in the regulation 
of synaptic plasticity in key areas of the brain including the hippocampus (Arevalo, 
Azcoitia et al. 2015). Esr1 (ERα) and particularly Esr2 (ERβ) knockout mice, have 
identified deficits in synaptic plasticity in specific brain regions indicating the detrimental 
impact of ER dysregulation (Chhibber, Woody et al. 2017). The ovarian failure observed 
in the VCD treated APOE-TR mice led to an upregulation of hippocampal estrogenic 
receptors, although this effect is inconsistent with conflicting reports in OVX studies 
(Sárvári, Kalló et al. 2014, Bastos, Pereira et al. 2015, Lalert, Kruevaisayawan et al. 
2018). The ERs are intrinsically linked to synaptic plasticity, acting as transcription 
factors or modulating key signal transduction pathways (Arevalo, Azcoitia et al. 2015). 
We observed that menopause dramatically altered synaptic proteins and signalling in the 
brain. BDNF signalling was particularly affected in APOE4 VCD treated animals, with 
the effect absent in all other groups, mirroring NOR performance. This led to a reduction 
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in p-AKT at Ser473 most likely via the PI3K mediated signalling pathway (Autry and 
Monteggia 2012), known to be influenced by estrogen and ERs (Arevalo, Azcoitia et al. 
2015). Reduced activation of AKT is known to inhibit neuronal cell survival and may in 
part explain the more extensive cognitive decline observed in the APOE4 VCD group. 
VCD treatment also led to further synaptic dysfunction with all treatment groups 
displaying reduced hippocampal expression of Grin2b (NMDA R2b) in combination with 
reduction in CREB family transcription factors (Creb1 and Atf4) all of which are integral 
to synaptic plasticity. Additionally, we noted that altered Ephb2 expression, essential for 
NMDA receptor localisation and proper functioning (Nolt, Lin et al. 2011), was only 
apparent in APOE4 VCD treatment group, which may suggest that as well as having 
reduced NMDA receptors seen in all VCD treated animals, the functionality is 
compromised as a result of APOE4*VCD treatment. Similarly, increased Ephb2 
expression has been found to compensate for AD related NMDA receptor impairment 
(Archundia Herrera, Subhan et al. 2017), once again offering a possible explanation as to 
how APOE3 animals may have remained unimpaired. Finally, with implications in 
hippocampal synaptic plasticity, adult neurogenesis and subsequent memory 
consolidation we assessed endocannabinoid, specifically CBD1 regulation (Scarante, 
Vila-Verde et al. 2017). An APOE4 dependant reduction in Cbd1 expression was 
observed, CBD1 receptor antagonism and subsequent endocannabinoid dysregulation has 
been associated with deficits in learning and memory (Horton, Goonawardena et al. 
2019).  Recently CBD1 activation has been reported to be neuroprotective conferring 
specific improvement in spatial memory (Patricio-Martínez, Sánchez-Zavaleta et al. 
2019), therefore diminished CBD1 may contribute the spatial memory deficits we 
observed in APOE4. However, research connecting APOE and endocannabinoid 
signalling, particularly within the brain is limited, but warrants further investigation given 
these results.  
 
Conclusion 
 
Despite its well-established impact on late-onset AD risk, the aetiological basis of the 
APOE4 genotype associated cognitive deficits and neuropathology remains elusive. Sex, 
and menopausal status remain overlooked factors that likely influence the progression of 
neurological diseases such as AD. Here we provide evidence of menopause-related risk 
and suggest a greater sensitivity in APOE4 carriers, with APOE4 animals displaying 
greater cognitive impairment and deficits in synaptic plasticity.
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Introduction 
 
APOE4 is the strongest common genetic risk factor for the development of Alzheimer’s 
disease (AD) (Michaelson 2014); however a fundamental understanding of its role in AD 
has been clouded by the pleiotropic nature of the APOE gene (Safieh, Korczyn et al. 
2019). Evidence suggests that the AD risk associated with an APOE4 genotype is greater 
in females (Farrer, Cupples et al. 1997, Snyder, Asthana et al. 2016), particularly between 
the ages of 55-70 years (Neu, Pa et al. 2017), which may in part account for the greater 
overall incidence of AD in women (Podcasy and Epperson 2016). The specific age at 
which this heightened risk occurs, coupled with the importance of oestrogens in 
cognition, and the association between menopause and cognitive decline are indicative of 
a potential menopausal involvement (Ryan, Scali et al. 2014, Arevalo, Azcoitia et al. 
2015). From the limited evidence currently available (Pontifex et al., submitted (Porrello, 
Monti et al. 2006, Bojar, Stasiak et al. 2016, Karim, Koc et al. 2019)), neurological 
deficits associated with menopause may be exacerbated by an APOE4 genotype.  
 
Docosahexaenoic acid (DHA) is the primary n-3 PUFA in the brain, accounting for ~15 
% of total lipids (Bradbury 2011). Epidemiological studies show that higher 
docosahexaenoic acid (DHA) intake and status, primarily achieved through intake of oily 
fish, improves cognitive performance and reduces AD risk (Zhang, Chen et al. 2016, 
Zhang, Zhuang et al. 2018). Although evidence from randomised control trials with DHA 
supplementation has been inconsistent (Jiao, Li et al. 2014, Weiser, Butt et al. 2016, Bo, 
Zhang et al. 2017), potentially due to study set up (e.g. length of intervention, disease 
progression), the benefits of DHA supplementation have been widely reported in shorter-
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lived, rodent models of AD (Teng, Taylor et al. 2015, Fang, Shi et al. 2019, Takeyama, 
Islam et al. 2019). Such models have revealed several brain structural and functional roles 
for DHA (Belkouch, Hachem et al. 2016), including; neuronal signalling, 
survival/neurogenesis, anti-amyloidogenic and anti-inflammatory effects (Calon, Lim et 
al. 2005, Lim, Calon et al. 2005, Belkouch, Hachem et al. 2016). In addition, human 
studies utilising 11C and 13C labelled carbon have identified APOE4 associated deficits in 
DHA metabolism and transport (Chouinard-Watkins, Rioux-Perreault et al. 2013, 
Yassine, Croteau et al. 2017), which may account for APOE4 associated lower brain DHA 
status as we previously reported (Martinsen, Tejera et al. 2019). As a result, APOE4 
carriers may be more vulnerable to dietary n-3 PUFA deficiencies (Nock, Chouinard-
Watkins et al. 2017), which may in turn impact cognition, thus providing a rationale for 
higher intakes (Yassine, Braskie et al. 2017). There is evidence that menopause also 
disrupts n-3 PUFA status (Witt, Christensen et al. 2010, Jin, Kim et al. 2016, Colangelo, 
Ouyang et al. 2017). Therefore, post-menopausal APOE4 carriers may be at particular 
risk of DHA deficiency and likely to be responsive to intervention.  
 
We previously reported that both APOE4 and menopause impact cognition, synaptic 
plasticity and brain DHA (Chapter 3). Here we posit that supplementation with DHA-rich 
fish oil, may restore DHA status, and in turn ameliorate the cognitive deficits observed in 
the APOE4 genotype carriers. The effects of DHA supplementation is established by 
administering two physiologically relevant concentrations of DHA-enriched fish oil to a 
VCD, menopause induced APOE-TR mouse model. Behavioural tests of cognition are 
performed and are related to brain fatty acid and synaptic plasticity profiles. 
 
Material and methods  
 
Study approval 
All experimental procedures and protocols used in this study were reviewed and approved 
by the Animal Welfare and Ethical Review Body (AWERB) and were conducted within 
the provisions of the Home Office Animals (Scientific Procedures) Act 1986. 
 
Animal model and experimental design  
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Ninety six female humanised APOE3 (B6.129P2-Apoetm2(APOE*3)Mae N8) and APOE4 
(B6.129P2-Apoetm2(APOE*4)Mae N8) targeted replacement mice homozygous for the human 
APOE3 or APOE4 gene (Taconic, Germantown, NY, US) were used in these experiments 
(Sullivan, Mezdour et al. 1997, Knouff, Hinsdale et al. 1999, Martinsen, Tejera et al. 
2019). Mice were maintained in a controlled environment (21 ± 2°C; 12-h light–dark 
cycle; light from 07:00 hours) and fed ad libitum on a standard chow diet (RM3-P, Special 
Diet Services, Essex, UK) until the age of 4 months, ensuring normal development. 
Following this run-in period, mice were switched to one of the three diets all of which 
were on a background of a semi-purified high fat diet (45 Kcal% fat) (Research diets, 
New Brunswick, NJ, USA) for the remaining duration of the experiment. The three diets 
were as follows, 1) high fat diet (HF); 2) high fat diet with the addition of a lower fish oil 
dose (LFO); 3) and high fat diet with the addition of a higher fish oil dose (HFO) (See 
supplementary Table 1 for full dietary composition). For fish oil enriched diets, a bespoke 
blend of (EPAX 1050 TGN + EPAX 6000 TGN) 4:1 DHA: EPA fish oil) was added to 
the background diet. A 4:1 ratio (w/w) was selected based upon previous studies 
(Chouinard-Watkins, Vandal et al. 2017), highlighting the importance of high DHA in 
APOE4 carriers, however we retained some EPA given that in humans all oily fish sources 
provide both EPA and DHA in variable ratios depending on species. The enriched diets 
provided DHA+EPA at 0.7 or 2.7 g/kg of diet. Given that mean food intake was 3.2 ± 
0.02 g/day this equates to DHA+EPA human doses of 0.51 ± 0.02 g and 1.97 ± 0.02 g per 
day respectively, based on allometric scaling and body surface (BSA)-based calculations 
(Reagan-Shaw, Nihal et al. 2008, Sharma and McNeill 2009). To prevent lipid oxidation, 
diets were stored at −20°C until use and fresh feed was provided every 3 days.     
In order to assess the impact of menopause, at 8 months of age, mice from each genotype 
received i.p. injections of either VCD (160mg/kg body weight) diluted in sesame oil, or 
sesame oil vehicle (sham) for a total of 14 injections over 3 weeks. 8 months was selected 
as it is roughly midlife for the animals (when human menopause occurs) and before 
natural ovarian failure is known to occur in C57BL/6 mice (Gosden, Laing et al. 1983). 
Following completion of the final behavioural test, 12-month aged animals were sedated 
with isoflurane (1.5%) in a mixture of nitrous oxide (70%), and oxygen (30%) and 
transcardially perfused with an ice-cold PBS containing protease (SIGMAFASTTM 
Protease inhibitor, Sigma, Devon, UK) and phosphatase (1 mM sodium pyrophosphate 
and 50 mM sodium fluoride, Sigma, Devon, UK) inhibitors. Sera were isolated via 
centrifugation at 2000 x g for 10 min. Brains were rapidly removed, halved, snap frozen 
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and stored at -80°C until biochemical analysis. Ovaries were rapidly removed and 
processed for histology (see below).  
 
Behavioural assessment 
All behavioural tests were performed when mice were 12-month of age and immediately 
prior to sacrifice. A visual placing test was performed on each animal on the first day of 
testing to ensure animals were not visually impaired (Pinto and Enroth-Cugell 2000).  
Spatial learning and memory was evaluated with the Barnes Maze as previously described 
(Patil, Sunyer et al. 2009). Briefly, the maze consisted of a brightly illuminated (800 lux 
lighting) circular platform (92cm diameter) with 20 evenly distributed holes located 
around the circumference and visual cues (4 simple shapes) placed at the periphery. The 
experiment was conducted over a 5-day period with each mouse tested/trained on ability 
to locate the escape box 4 times per day during days 1-4. On day 5, a probe test was 
conducted, the maze was rotated 90° and mice were placed in the centre of the maze in 
which they were free to navigate for one minute. Percentage time in correct quadrant was 
determined using the Smart 3.0 tracking software (Panlab, UK).  
 
The novel object recognition (NOR), a measure of recognition memory was performed 
as described previously (Davis, Eacott et al. 2013, Leger, Quiedeville et al. 2013), with 
slight modifications. Briefly, on day 1 mice were habituated in grey 50x50x50cm 
apparatus illuminated with low lux (100 lux) lighting, mice were placed into the empty 
maze and allowed to move freely for 10 minutes. On day 2, mice were conditioned to a 
single object for a 10-minute period. On day 3, mice were placed into the same 
experimental area in the presence of 2 identical objects for 15 minutes, after which they 
were returned to their respective cages and an inter-trial interval of one hour was 
observed. One familiar object was replaced with a novel object. Mice were placed back 
within the testing area for a final 10 minutes. Videos were analysed for a 5-minute period, 
after which if an accumulative total of 15 seconds with both objects failed to be reached, 
analysis continued for the full 10 min or until 15s was achieved. Those not achieving 15s 
were excluded from the analysis (Denninger, Smith et al. 2018). A discrimination index 
was calculated as follows: DI = (TN−TF)/(TN+TF), where TN is the time spent exploring 
the novel object and TF is the time spent exploring the familiar object. 
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Y maze spontaneous alternation test, a measure of spatial working memory was 
performed on the final day of behavioural testing as previously described (Thomas, 
Morris et al. 2017). Briefly, the Y-maze apparatus comprised of white Plexiglas in the 
following dimensions (38.5 × 8 × 13 cm, spaced 120° apart) and was illuminated with low 
lux (100 lux) lighting. Mice were placed in the maze and allowed to explore freely for 7 
minutes whilst tracking software recorded zone transitioning and locomotor activity.  
 
Histological and biochemical analyses 
Ovaries were trimmed of fat and fixed in 10% formalin for 24h before being paraffin 
embedded, and processed for haematoxylin and eosin (H&E) staining as described 
previously (Chen, Kang et al. 2015). Follicle stimulating hormone (FSH) concentrations 
were determined by ELISA (Abnova KA2330, address) in sera samples as per 
manufacturer’s instructions. Total lipid was extracted from sub-cortical brain tissues 
(n=5/6 per group) and erythrocyte fraction using the Folch extraction method (Folch, Lees 
et al. 1957) as previously reported (Martinsen, Tejera et al. 2019).  
 
Immunoblotting 
Cortices were homogenised in lysis buffer (CelLyticTM MT, Sigma, UK) containing 
protease (cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail, Roche, UK) and 
phosphatase (PhosSTOPTM, Roche, UK) inhibitors. Protein concentration was determined 
using the Pierce™ BCA Protein Assay Kit (ThermoFisher, UK). Protein electrophoresis 
was conducted under denaturing conditions as previously described (Vauzour, Corsini et 
al. 2018). The following antibodies were used: anti p-AKT Ser473, (1:1000; Cell 
Signalling, UK), anti-total-AKT, (1:1000; Cell Signalling, UK), anti BDNF (1:500; Santa 
Cruz Biotechnology, USA), anti p-ERK Thr202/Tyr204 (1:1000; Cell Signalling, UK), 
anti-total-ERK (1:1000, Cell Signalling, UK), anti GAPDH (1:2500, Cell Signalling, 
UK), anti and Anti-Rabbit IgG (H + L) DyLightTM 680 Conjugate (1:10,000, Cell 
Signalling, UK). Bands were revealed by fluorescence using an Odyssey 9120 Infrared 
imaging system (LI-COR Biosciences, Ltd, UK). Relative band intensities were 
quantified using the ImageJ software (Schneider, Rasband et al. 2012). 
 
RNA isolation and qRT-PCR 
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RNA isolation, cDNA synthesis and qRT-PCR were carried out as previously described 
(Vauzour, Rodriguez-Ramiro et al. 2018). Briefly, total RNA was isolated from the brain 
samples using the Qiazol reagent (Qiagen, UK). One μg of total RNA was treated with 
DNase I (Invitrogen, UK) and used for cDNA synthesis using Invitrogen™ Oligo (dT) 
primers and M-MMLV reverse transcriptase. Quantitative real-time PCR (qRT-PCR) 
reactions were performed using SYBR green detection technology on the Roche light 
cycler 480 (Roche Life Science, UK). Results are expressed as relative quantity scaled to 
the average across all samples per target gene and normalised to the reference genes 
TATA-box binding protein (Tbp) and glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh), which were identified as optimal housekeeping selection/combination using the 
Normfinder software (Day, Chambers et al. 2018). The primer sequences are given in 
Supplementary Table 2.  
 
Statistical Analysis 
All data are presented as mean ± SEM. Data analysis was performed in GraphPad Prism 
version 8 (GraphPad Software, CA, USA). After checking for normality/equal variances 
and performing log or box-cox transformations if necessary, comparisons among groups 
were performed using two-way ANOVA, followed by either post-hoc Tukey, or Sidak 
test for comparison across dietary groups, and genotype respectively. P-values of less 
than 0.05 were considered statistically significant.  
 
Results 
  
DHA/EPA supplementation does not protect against VCD-induced ovarian failure 
 
Ovarian follicle loss did not occur in sham injected animals (Fig. 4.1A). Follicle loss 
across the VCD treated groups led to a 5-fold increase in serum FSH levels (ng/ml) (p < 
0.0001 Fig. 4.1B), and was not influenced by genotype nor dietary interventions (p > 
0.05). Neither genotype, VCD treatment nor dietary intervention affected body weight, 
although the addition of HFO nominally reduced body weight gain by 19 ± 2.3% in both 
APOE genotypes when compared to the non-supplemented groups (p > 0.05 Fig. 4.1C). 
Animals consumed on average 3.20 ± 0.02 g/day of their diet, delivering 8.64 ± 0.02 mg 
or 2.24 ± 0.02 mg DHA + EPA in the HFO and LFO groups respectively (equivalent to 
1.97 g or 0.51 g in humans). 
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Figure 4.1: Impact of VCD treatment and DHA/EPA intake on ovarian failure and 
systemic FSH levels.  
A) Representative images show follicles (arrows) in sham injected animals, which were 
lost following VCD treatment regardless of genotype and dietary interventions; B) Serum 
FSH levels were elevated in all VCD treated animal groups (n=5/6); C) Body weight was 
not significantly altered by VCD treatment, genotype or dietary intervention (n= ≥7). Data 
represent the mean ± S.E.M. Different superscripts indicate statistical differences 
between diet groups. FSH: follicle stimulating hormone; HF: high fat; VCD: 4-
vinylcyclohexene diepoxide; LFO: low fish oil dose; HFO: high fish oil dose. 
 
DHA rich fish oil supplementation restores APOE4 induced impairment in 
recognition memory, but does not improve APOE-mediated spatial deficits 
 
As previously reported, VCD treatment completely abolished recognition memory in 
APOE4 animals (Chapter 3), with animals exhibiting no preference between the familiar 
or the novel object (p < 0.05; Fig 4.2A). Deficits in recognition memory were corrected 
by adding DHA enriched fish oil, although only HFO supplementation resulted in a 
significant increase when compared to sham injected animals (p < 0.05; Fig. 4.2A).  
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DHA-rich fish oil supplementation, at either dosage had no significant impact on the 
spatial learning and memory tasks. Barnes maze performance dropped by 2-fold in 
untreated APOE4 animals compared to APOE3 counterparts (p < 0.05 Fig. 4.2B). A trend 
towards increased performance in the APOE4 *VCD treated HFO supplementation group 
was observed but did not reach significance (p = 0.07; Fig. 4.2B). In the Y-maze, a 1.2-
fold decrease in alternation index was observed in APOE4 animals versus APOE3 
(p<0.05), which was not corrected by DHA enriched fish oil intake at either dosage (p > 
0.05; Fig. 4.2C).  
Figure 4.2: High fish oil (HFO) supplementation restores recognition memory.  
A) Performance on NOR task (n=≥7) was restored to sham levels in APOE4 VCD HFO 
group. Spatial memory tasks B) Barnes probe test (n=≥7), and C) Y maze spontaneous 
alternation task (n=≥7) were not significantly improved by fish oil supplementation (p > 
0,05), Data represent the mean ± S.E.M.  *p< 0.05. **P < 0.01. HF: high fat; VCD: 4-
vinylcyclohexene diepoxide; LFO: low fish oil dose; HFO: high fish oil dose. 
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DHA-rich fish oil supplementation replenishes low brain DHA levels mediated by 
VCD treatment. 
Erythrocyte DHA status was not significantly different across genotype, and only HFO 
supplementation resulted in a (% total fatty acids) significant ~2 and 3-fold increase in 
DHA levels in APOE3 and APOE4 animals respectively (p < 0.05; Fig. 4.3A and Table 
4.1). The ~13% genotype independent lower (% total fatty acids) brain DHA observed in 
VCD injected animals was significantly restored by LFO and HFO supplementation (p < 
0.05; Fig. 4.3B and Table 4.1). Brain DHA:AA ratio, an anti-inflammation indicator, was 
significantly increased by fish oil supplementation, in a dose dependant manner, with 
both genotypes increasing by 15 ± 0.1% and 30 ± 0.2% following LFO and HFO 
supplementation compared to VCD treatment alone (p < 0.01; Fig. 4.3C and Table 4.1). 
Although not significant, EPA levels increased by ~3 fold in the APOE4 VCD HFO group 
when compared to HF VCD alone (Table 4.1).  
Figure 4.3: Fish oil supplementation restores brain DHA levels. GC-FID analysis 
revealed that,  
A) there was no significant difference in DHA erythrocyte status across genotype, which 
was only significantly increased by HFO supplementation (n=5/6), B) VCD treatment 
resulted in lower brain DHA status which was restored by both LFO and HFO fish oil 
supplementation (n=5/6), C) DHA:AA status in the brain was increased in a dose 
dependant manner by fish oil supplementation. Different superscripts indicate statistical 
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differences between diet groups. HF: high fat; VCD: 4-vinylcyclohexene diepoxide; 
LFO: low fish oil dose; HFO: high fish oil dose. 
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Table 4.1 Brain and Erythrocyte fatty acid composition of experimental animals (n=5/6 per group) 
 
APOE3 APOE4 Genotype 
P value  
Intervention 
P value  
Interaction 
P value  
Fatty acid  HF 
Sham 
HF VCD 
HF VCD 
LFO 
HF VCD 
HFO 
HF Sham HF VCD 
HF VCD 
LFO 
HF VCD 
HFO 
   
Erythrocyte 
(%) 
           
22:6 n-3 
(DHA) 
1.95 ± 
0.33 ab 
1.85 ± 
0.44 a 
2.08 ± 
0.21ab 
3.98 ± 
0.80 b 
1.19 ± 
0.19 a 
1.65 ± 
0.55 a 
2.31 ± 
0.30 ab 
3.68 ± 
0.38 b 
0.333 0.0001 0.511 
Brain  
(%) 
           
Total n-3 
PUFA 
13.30 ±  
0.20 ab 
11.60 ± 
0.70 a 
13.10 ± 
0.70 ab 
13.60 ± 
0.40 b 
13.20 ±      
0.30 ab 
11.80 ± 
0.50 a 
14.00 ± 
0.40 b 
13.50 ± 
0.50 ab 
0.550 0.001 0.696 
20:5 n-3 
(EPA)  
0.02 ± 
0.01 
0.06 ± 
0.03 
0.02 ± 
0.01 
0.06 ± 
0.03 
0.02 ± 
0.0.01 
0.03 ± 
0.14 
0.01 ± 
0.01 
0.09 ± 
0.03 
0.640 0.067 0.529 
22:6 n-3 
(DHA) 
13.20 ± 
0.20 a 
11.20 ± 
0.50 b 
13.10 ± 
0.70 a 
13.50 ± 
0.40 a 
13.10 ± 
0.30 ab 
11.70± 
0.50 a 
13.70 ± 
0.40 b 
13.40 ± 
0.50 b 
0.479 0.0002 0.765 
Total n-6 
PUFA 
14.20 ± 
0.20 a 
12.60 ± 
0.40 ab 
12.00 ± 
0.50 b 
11.10 ± 
0.30 b 
14.80 ± 
0.90 a 
13.20 ± 
0.60 ab 
12.70 ± 
0.20 b 
11.50 ± 
0.40 b 
0.093 0.0001 0.992 
20:4 n-6 (AA) 9.37 ± 
0.21 a 
8.10 ± 
0.39 ab 
8.28 ± 
0.39 ab 
7.55 ± 
0.28 b 
8.95 ± 
0.25 
8.66 
±0.50 
8.70 ± 
0.22 
7.88 ± 
0.26 
0.354 0.002 0.508 
DHA:AA 1.40 ± 
0.03 a 
1.39 ± 
0.05 a 
1.58 ± 
0.04 b 
1.79 ± 
0.02 c 
1.48 ± 
0.01 ad 
1.36 ± 
0.03 a 
1.58 ± 
0.03 bd 
1.76 ± 
0.03 c 
0.998 0.0001 0.400 
Total SFAs 38.70 ± 
0.40 
35.50 ± 
0.90 
36.70 ± 
1.40 
37.00± 
1.40 
36.60 ± 
0.60 
36.90 ± 
1.20 
37.70 ± 
0.90 
36.60± 
0.80 
0.961 0.409 0.216 
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PUFA; Polyunsaturated fatty acid, 20:5 n-3 EPA; Eicosapentaenoic acid, 22:6 n-3 DHA; Docosahexaenoic acid, 20:4 n-6 AA; Arachidonic 
acid, DHA:AA; Docosahexaenoic acid to Arachidonic acid ratio, SFA; Saturated fatty acid, 16:0; Palmitic acid, 18:0; Stearic acid, 20:0; 
Eicosanoic acid, 22:0; Docosanoic acid, MUFA; Monounsaturated fatty acid, 18:1 n-9; Oleic acid, 20:1 n-9; 11-Eicosenoic acid, 24:1 n-9; 
Nervonic acid. Data is % of total fatty acids and mean value ± SEM. 2-way ANOVA.  Different superscripts denote significant difference 
between means within genotypes whilst § indicates genotype differences (Tukey or Sidak post hoc). The full table can be found in 
supplementary data (Table S4 and S5). 
Total MUFAs 25.40 ± 
0.40 a 
30.50 ± 
0.80 b 
26.50 ± 
1.20 ac 
30.00 ± 
0.80 bc 
27.30 ±  
0.90 ab 
27.90 ± 
1.40 ab 
26.50 ± 
0.80 a 
30.20 ± 
0.90 b 
0.615 0.001 0.054 
Table 4.1 continued 
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Fish oil supplementation enhances synaptic plasticity related genes and proteins  
 
The 31 ± 0.16% reduction in brain Bdnf gene expression (p < 0.05; Fig. 4.4Aі) observed 
in APOE4 VCD injected animals was restored through both HFO and LFO 
supplementation (p < 0.01; Fig 4.4Aі). At the protein level APOE4 VCD treated animals 
also presented with decreased BDNF, which was only restored by the HFO intervention, 
which increased levels ~4-fold compared to non-supplemented VCD treated animals 
(p<0.01; Fig. 4.4Aіі). A similar trend was observed for the AKT signalling pathway, a 
known regulator of BDNF. At the gene level the 16 ± 0.23% reduction in Akt1 gene 
expression observed in the VCD treatment group was nominally but not significantly 
increased with both LFO and HFO (p > 0.05 Fig. 4.4Bі). As with BDNF, at the protein 
level phospho-AKT Ser473 was only significantly increased in the APOE4 HFO 
supplementation group (p < 0.01; Fig 4.4Bіі). ERK, another upstream regulator of BDNF 
also responded similarly. At the gene level Mapk1 which encodes ERK2, was upregulated 
in only the APOE4 HFO group (p < 0.05; Fig 4.4Cі). No significant differences in ERK 
Thr202/Tyr204 levels were detected across genotype, VCD or dietary intervention (p > 
0.05; Fig 4.4Cіі), despite a nominal increase in phospho-ERK 2 in the APOE4 VCD HFO 
group. Both mRNA expression and protein levels of these targets remained constant 
within the APOE3 intervention groups.  
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Figure 4.4: Impact of fish oil supplementation on synaptic plasticity related genes and 
proteins in VCD treated animals;  
A-Cі) BDNF, AKT and ERK signalling (also observed at the protein level). Aі) Lower 
bdnf expression in APOE4 VCD treated animals was restored by fish oil supplementation, 
Bі) Similarly in APOE4 mice there was a trend towards increased AKT expression 
following both LFO and HFO, Cі) Whilst Mapk1 expression increased significantly in 
only APOE4 HFO supplemented animals. Aіі) Brain BDNF protein levels were 
significantly increased in the APOE4 HFO group, Bіі) phospho-AKT Ser473 protein was 
similarly increased in the APOE4 brain by HFO supplementation, Cіі) Although not 
significant, a nominal increase in p-ERK protein was observed in the APOE4 HFO group, 
D) Representative western blots for both APOE3 and APOE4, Sham and VCD treated 
animals (n=4/6), E-K). 
 
Expression of Igf-1 which can increase neurogenesis through PI3K/AKT mediated 
pathways was similarly increased in only the APOE4 HFO group (p < 0.05; Fig 4.5A). 
Although not significantly altered in APOE3 animals (Fig. 4.5B), Creb1 expression in 
APOE4 animals was highly upregulated by 2.7 (p < 0.05) and 2.6 (p =0.068) fold by LFO 
and HFO respectively. Arc a downstream effector of Creb1 showed a similar expression 
profile with fish oil supplementation increasing gene expression amongst APOE4 VCD 
treated animals, however this did not achieve significance (p > 0.05; Fig 4.5C). 
Interestingly, Atf4, a key regulator of learning and memory (Corona, Pasini et al. 2018),  
known to be upregulated via BDNF (Liu, Amar et al. 2018), had significantly reduced 
expression in VCD treated APOE3 and APOE4 animals (p < 0.05; Fig 4.5D) and did not 
improve in APOE3 animals with fish oil supplementation (p > 0.05; Fig 4.5D). 
Conversely, HFO supplementation significantly restored Atf4 expression to that of sham 
in APOE4 mice (p < 0.05; 4.5D). This has been suggested to occur in a tropomyosin 
receptor kinase (TRKB) dependant manner (Liu, Amar et al. 2018). Interestingly, 
expression of Ntrk2 which encodes TRKB was significantly increased in only the APOE4 
VCD treated HFO group when compared to sham counterparts (p <0.05; Fig 4.5E). 
Although only significant in APOE3 LFO treated animals there was a trend in which fish 
oil supplementation mitigated the educed Grin2b expression as a result of VCD treatment 
(p < 0.05; Fig. 4.5F). Lower Cbd1 expression was apparent in all intervention groups 
apart from the LFO group and was not affected by VCD treatment (p < 0.05; Fig 4.5G).  
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Figure 4.5 Hippocampal expression profiles relating to synaptic plasticity (n=5/6);  
A) Igf-1 expression increased in only the APOE4 HFO group, B) Creb1 expression was 
highly upregulated in response to fish oil supplementation in APOE4 animals only, C) In 
APOE4 animals Arc a downstream target of Creb1 followed a similar expression profile, 
with VCD reduced Arc increasing in response to fish oil supplementation, D) Atf4 
expression reduced as a result of VCD treatment in both APOE3 and APOE4 animals, 
however only HFO supplementation in APOE4 animals restored this deficit, E) Ntrk2 was 
similarly only upregulated through HFO supplementation in APOE4 animals. F) Grin2b 
was reduced in response to VCD treatment across both genotypes and improved with fish 
oil supplementation, although significance was limited to the APOE3 LFO group, G) a 
genotype related reduction in Cbd1 expression was apparent across all groups excluding 
LFO. Data represent the mean ± S.E.M.  *p< 0.05. **P < 0.01 ***P <0.001. Different 
superscripts indicate statistical differences between diet groups. HF: high fat; VCD: 4-
vinylcyclohexene diepoxide; LFO: low fish oil dose; HFO: high fish oil dose. 
 
Discussion 
 
APOE4 is pleiotropic, impacting multiple brain physiological processes and pathological 
cascades associated with AD (Zhong and Weisgraber 2009). The ability of DHA to 
modify many of these disease pathways, with its anti-inflammatory and neuroprotective 
properties, makes it an attractive option for use as a dietary strategy to improve cognition 
and potentially reduce AD risk (Frautschy and Cole 2010). This study follows on from 
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our previous report, in which both APOE genotype and VCD mediated deficits in 
cognition and synaptic plasticity associated pathways were established (Chapter 3). Here 
we show that HFO supplementation results in a reversal of APOE4*VCD deficits in 
recognition memory. Conversely, supplementation had only a modest impact on genotype 
related spatial memory impairment. Gene expression and protein analysis supported these 
findings with HFO supplementation, restoring synaptic plasticity related pathways, 
leading to increased BDNF protein abundance and AKT phosphorylation, which were 
both diminished by APOE4*VCD. Deficits in brain DHA resulting from VCD treatment 
and observed in both genotypes, were restored by both LFO and HFO, with the greatest 
DHA:AA ratio achieved by HFO.  
 
As previously reported, body weight did not differ according to APOE genotype and was 
unaffected by VCD treatment in our female mice (Haas JR 2007, Jones, Watson et al. 
2019). Although not reaching significance, body weight in both genotypes, was reduced 
(~20%) in response to HFO supplementation. This has been described in other rodent 
studies (Buckley and Howe 2010), and interestingly in humans, in which female APOE4 
carriers with the highest n-3 index, were found to have the lowest BMI and body fat, a 
phenomenon absent in males (Howe, Buckley et al. 2014). This may indicate a sex 
specific role for EPA and DHA in the regulation of metabolism/adiposity in females 
(Howe, Buckley et al. 2014) and more generally shows how n-3 PUFAs may have sex 
specific effects. 
We previously identified reduced performance in Barnes and Y maze in APOE4 animals, 
indicating a genotype spatial memory impairment, that is independent of VCD treatment, 
and which may be sex specific (Bour, Grootendorst et al. 2008). The absence of a VCD 
influence suggests a predisposition in middle aged APOE4 females, which is uncoupled 
from menopause (Bour, Grootendorst et al. 2008), although sex hormones may still be 
involved. Spatial memory performance was not significantly altered by FO 
supplementation in APOE4-TR mice. Indeed, we found that Barnes probe test 
performance did not significantly improve, despite nominally increasing in response to 
HFO doses. Furthermore, during the learning phase of the Barnes we again observed a 
nominal but non-significant improvement in the HFO group (Figure S2). In contrast to 
spatial memory, HFO supplementation significantly improved recognition memory in 
APOE4 VCD treated animals, indicating that FO supplementation was more effective in 
ameliorating the impact of APOE4*VCD than the APOE4 deficits. There are limited 
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reports evaluating the cognitive impact of n-3 PUFA supplementation in menopausal 
models, and to the best of our knowledge this is the first report in an APOE-TR 
menopause model. In agreement with a previous report, higher doses of DHA appear an 
effective strategy to curb the deleterious impact of APOE4 on cognition. However 
supplementation may be unnecessary in the unimpaired APOE3 animals where fish oils 
had no impact (Chouinard-Watkins, Vandal et al. 2017). This nonetheless may change in 
older APOE3 animals, as they become more susceptible to cognitive decline associated 
with ageing. Utilising specific ‘brain targeting’ DHA, (i.e. in phospholipid form), which 
is metabolised to LPC-DHA and reportedly more efficacious at crossing the blood brain 
barrier (Patrick 2018), may present a way to negate the current need for high doses. 
Interestingly, Sugasini and colleagues reported an improvement in APOE4 mediated 
spatial memory deficits when utilising LPC-DHA, supporting this notion (Sugasini, 
Thomas et al. 2017).   
Both LFO and HFO restored the VCD mediated reduction in brain DHA observed in both 
genotypes. Allessandri and colleagues (Alessandri, Extier et al. 2011) observed a similar 
reduction in brain DHA resulting from OVX, which was restored through 17β-estradiol 
(E2) treatment. Interestingly, they report that 17β-estradiol treatment increased both 
hepatic and brain LC-PUFA synthesizing enzymes such as Δ9-, Δ6- and Δ5-desaturase, 
restoring or maintaining brain DHA. Supplementation with DHA-rich n-3 PUFA in this 
study may similarly restore (Chouinard-Watkins, Pincon et al. 2016), or compensate for 
the dysregulation of these synthesising enzymes, subsequently improving the brain PUFA 
profile. In addition, the dysregulated fatty acid profile caused by menopause reportedly 
leads to alterations in neuronal membrane lipid raft structure, which can in turn disrupt 
the signalosome (Marin and Diaz 2018). Supplementation with DHA could mitigate such 
detrimental effects. Furthermore, brain DHA:AA ratio improved with supplementation in 
line with other reports (Hashimoto, Hossain et al. 2002, Hashimoto, Tanabe et al. 2005). 
Given the pro-inflammatory, free radical characteristics of AA precursors (Hashimoto, 
Tanabe et al. 2005, Zárate, El Jaber-Vazdekis et al. 2017), and the ability of DHA to 
modulate inflammation via specialised pro-resolving mediators (Duvall and Levy 2016, 
Martinsen, Tejera et al. 2019), DHA:AA is a potential indicator of neuro-inflammatory 
status. The increase in DHA:AA was dose dependant, with HFO achieving the highest 
ratio, which may in part explain the greater cognitive benefits associated with HFO.  
As with cognitive performance and brain DHA status, FO supplementation attenuated the 
impact of VCD treatment on synaptic plasticity related signalling. At the protein level 
this was again most apparent in the APOE4 HFO group, in which the abundance of 
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BDNF, and phosphorylation of AKT were significantly elevated. Neurological benefits 
of n-3 PUFA supplementation on both AKT (Zhang, Liu et al. 2015, Shi, Fu et al. 2019), 
and the neurotrophic factor, BDNF (Dong, Xu et al. 2018, Sun, Simonyi et al. 2018), have 
previously been reported. At the gene level Bdnf was significantly upregulated by fish oil 
supplementation, whilst Akt1 was not, suggesting that supplementation led to post-
translational modification of AKT, rather than direct upregulation. The ability of HFO to 
increase BDNF protein and activate AKT, both established intermediates in neuronal cell 
survival and synaptic plasticity (Belkouch, Hachem et al. 2016), provides a mechanistic 
basis for the improvement in cognition observed. Furthermore, Akt1 is a downstream 
target of Ntrk2 (Wu, Chen et al. 2019),and Igf-1(Feng, Lu et al. 2020), both of which were 
upregulated through HFO supplementation, therefore providing two potential routes in 
which the effects of DHA may be propagated. However further studies inhibiting 
components of these pathway are required for confirmation. Interestingly, DHA has 
previously been reported to promote cell survival by maintaining basal AKT activity 
under adverse conditions (Akbar, Calderon et al. 2005), offering an explanation as to why 
these changes were restricted to the ‘challenged’ APOE4 VCD animals. Fish oil 
supplementation also increased the expression of the transcription factors Creb1 and Atf4 
in APOE4 animals, both of which are implicated in BDNF signalling (Liu, Amar et al. 
2018). BDNF’s activation of Atf4 is believed to both; promote protection from 
oxidative/genotoxic stresses and to improve learning and memory (Corona, Pasini et al. 
2018, Liu, Amar et al. 2018), whilst CREB itself is a known regulator of BDNF gene 
expression. CREB can also be activated through ERK (Boneva and Yamashima 2012, 
Sona, Kumar et al. 2018). HFO supplementation resulted in a significant increase in 
Mapk1, and a nominal, but non-significant increase in ERK phosphorylation, highlighting 
an additional route for the observed effects. Interestingly, the genotype reduction of cbd1 
was not significantly improved by FO supplementation. Given that Cbd1 and 
endocannabinoid dysregulation have been previously reported to influence spatial 
memory (Patricio-Martínez, Sánchez-Zavaleta et al. 2019), the absence of recovery in 
response to supplementation may in part explain the subsequent lack of improvement in 
spatial memory performance. Cbd1 has similarly been reported to influence AKT-BDNF 
signalling (Blázquez, Chiarlone et al. 2015); therefore the loss of Cbd1 may be 
responsible for the reduced Akt1 activation, subsequently impeding synaptic plasticity 
and neuronal cell survival. 
 
102 
 
Conclusion 
Female APOE4 carriers are at greater risk of AD, which may in part be explained by a 
menopause*APOE4 interaction. The results of this study suggest that FO 
supplementation, but particularly at higher doses, may be a viable intervention to mitigate 
the deleterious APOE4*menopause interaction. Further investigation is warranted to 
establish if this is the case in humans. 
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 : General discussion: The Interactive impact of 
APOE genotype and oestrogen status on cognition, lipid status 
and synaptic signalling 
Summary of results and general discussion  
 
Main findings 
 
AD contributes towards ~70% of dementia cases, and is a growing concern both in the 
UK, and internationally. Excluding familial early onset AD, the APOE gene is the 
strongest genetic risk factor for AD and is associated with the more common, genetically 
complex form of the disease referred to as late onset AD (LOAD) (Giri, Zhang et al. 
2016). Despite this, and after a quarter century of APOE research, a comprehensive 
understanding of aetiological basis for APOE in AD is lacking (Belloy, Napolioni et al. 
2019). This is predominantly a result of the pleiotropic nature of APOE, with the 
modulatory influence of environmental factors also contributing. There is accumulating 
evidence to suggest that female APOE4 carriers are at heightened risk of AD 
development. According to Neu et al, female risk for MCI and AD is heightened between 
the ages of 55-70 and 65-75 respectively (Neu, Pa et al. 2017). This has led us and others 
to hypothesise a potential menopausal and subsequent sex hormone involvement 
(Scheyer, Rahman et al. 2018). Surprisingly, despite the reiteration of a female APOE4 
predisposition (Farrer, Cupples et al. 1997, Altmann, Tian et al. 2014, Neu, Pa et al. 
2017), and a known importance of oestrogens in learning, memory and AD risk (Scheyer, 
Rahman et al. 2018, Lu, Sareddy et al. 2019), the impact of sex hormones on APOE 
genotype is relatively unknown and thus forms the basis for this thesis. 
In chapter 2, we investigated the impact of APOE carrier-status, oily fish intake and HRT 
on PUFA status and cognition. To do this we utilised the baseline data of 136 female 
participants who took part in the CANN study, a multi-centre, 12-month double-blinded, 
placebo-controlled parallel intervention trial. 
The first part of the analysis showed that oily fish intake, BMI, APOE-carrier status and 
APOE-carrier status*HRT impact PUFA status. As expected, incremental increases in 
oily fish intake from never, to 1/3 times a month, and 1 or more times a week led to a 
15% and 16% greater n-3 index (EPA and DHA) respectively. Interestingly, although this 
increase was observed across erythrocytes, plasma and PC fractions, significance was 
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limited to the erythrocytes, presumably a consequence of the longer half-life of DHA in 
the erythrocyte fraction and therefore more reflective of longer term (months) rather than 
recent (days) intake. BMI had the opposite effect, with a lower DHA and n-3 index with 
increasing BMI. Again, there was a trend for this across all fractions however, 
significance was restricted to the erythrocyte fraction. APOE4 increased n-3 index in our 
female participants. Most notably EPA was significantly increased in the majority of 
fractions analysed. This rise in n-3 index associated with APOE4 may be explained by 
reduced tissue uptake.  
HRT alone had no effect on the FA profile, however analysis exploring the APOE*HRT 
interaction revealed that HRT reduced the elevated n-3 PUFA levels associated with 
APOE4, providing evidence of an APOE4, n-3 PUFA, sex hormone interaction. In the 
second part of the analysis we explored if these factors influenced cognition. APOE4 
carrier-status, HRT and APOE4 carrier status*HRT, influenced cognitive performance, 
whilst n-3 index and DHA status did not. APOE4 led to reduced cognitive performance 
in a specific subset of tasks namely verbal fluency, speed of memory and executive 
function. Interestingly, HRT generally led to improvements in cognition supporting the 
notion that sex hormone dysregulation is associated with cognitive decline. In addition, 
we found that HRT had specific APOE effects dramatically improving time and speed of 
memory as well as recognition memory, which has been linked to oestrogens previously. 
Overall chapter 2 revealed that 1) oily fish intake, BMI, APOE4-carrier status and 
APOE4-carrier status*HRT influence PUFA status 2) APOE4 carrier-status, HRT and 
APOE4 carrier status*HRT, but not n-3 index influence cognitive performance 3) HRT 
may impact APOE4 carriers to a greater extent. 
In chapter 3 we sought to investigate further, with a focus on underlying mechanisms, the 
effect of sex hormone status and APOE4 on cognition in females using a biologically 
relevant animal model. We established a middle aged female menopausal APOE-TR 
mouse model for the first time. To achieve this we administered repeated i.p. injections 
of VCD, gradually depleting ovarian follicle reserves, and thus more closely mimicking 
human menopause, compared to other established techniques i.e. OVX.  
We first wanted to determine if we were successful in establishing the APOE-TR 
menopause model. Histology clearly showed a distinct lack of ovarian follicles in VCD 
treated animals, which was accompanied by a significant increase in the hormone FSH, 
as one would expect with VCD treatment. In addition, hippocampal expression of the 
oestrogen receptors, particularly Esr1, increased substantially in response to VCD 
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treatment, highlighting that VCD treatment was having a neurological impact. Body 
weight remained constant regardless of genotype or VCD treatment. We performed 
behavioural tests to assess how both APOE genotype and VCD treatment impact the 
cognitive performance of the animals and discovered both genotype and VCD mediated 
deficits in cognition. Genotype resulted in spatial memory deficits, observed in both the 
Barnes and Y-maze tasks, whilst a striking reduction in recognition memory was apparent 
in only APOE4 VCD treated animals, indicating an APOE4*VCD interaction. 
Interestingly, as mentioned earlier, the CANN analysis revealed that HRT influenced 
recognition memory in APOE4 carriers only, supporting this APOE4*sex hormone 
influence on recognition memory. The main finding from the animal lipid analysis was 
that VCD injections led to a drop in brain DHA levels in both APOE3 and APOE4 
animals, providing further evidence of a relationship between sex hormones and brain 
DHA status. A significant drop in the DHA:AA ratio, observed only in the APOE4 VCD 
group, and similarly a rise in MUFA, only in the APOE3 VCD group, may contribute to 
the greater cognitive deficits associated with APOE4. However, this requires further 
investigation.  
Surprisingly, despite these changes in brain FA profiles we found little evidence to 
suggest that DHA transporter proteins were compromised at the gene level in response to 
VCD. This suggests that the mechanisms explaining these deficits either occur post-
translationally or are more associated with altered metabolism (transport independent). 
With both APOE4 and DHA implicated in the modulation of synaptic plasticity and as it 
represents one of the first processes to be impaired in AD we probed key synaptic 
plasticity related genes and proteins. Our findings in this section supported our 
behavioural results to some extent. Of notable mention was the significant drop in brain 
BDNF and phosphorylated AKT proteins which was limited to the APOE4 VCD group. 
We also found that VCD alone led to decreased expression of a number of synaptic 
plasticity related genes, including Atf4 and Grin2b suggesting that this effect was not 
limited to APOE4. This raises the question as to how the APOE3 animals appear to be 
protected from these effects in synaptic plasticity metabolism. To summarise in chapter 
3 we, 1) established VCD is an effective way to induce ovarian failure in the APOE-TR 
mouse model; 2) identified that a “Double hit” (menopause and APOE4 genotype) 
resulted in broader cognitive impairment relative to the impact of APOE4 or VCD alone; 
3) APOE4 and APOE4*VCD impair both spatial and recognition memory respectively;  
4) Brain DHA levels are reduced in response to VCD treatment; and 5) APOE4 
exacerbates VCD disturbances in synaptic plasticity related pathways. 
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After establishing an effective model and identifying mechanisms which may account for 
the associated deficits, we proceeded to investigate if an intervention could ameliorate 
the impact of APOE4 and VCD. With n-3 PUFA dysregulation a recurring theme in 
previous experiments and already associated with APOE4 and sex hormone status we 
hypothesised that fish oil supplementation may be a suitable strategy. 
In chapter 3, utilising the same model as established and described in chapter 2, we added 
two further groups to the experiment, HF VCD LFO and HF VCD HFO. Both doses 
which provided ~2g and 0.5g per day were chosen to be at the upper and lower limits of 
physiologically relevant human dosage. ‘Mega-doses’ have been assessed previously 
however their translational potential is questionable. Ovarian follicle loss was also 
observed in all VCD treated animals, with dietary intervention having no impact on FSH 
levels, indicating that any effects were independent of FSH modulation. Behavioural 
analysis, however, revealed that HFO supplementation significantly recovered deficits in 
recognition memory associated with APOE4*VCD. Although a nominal increase in 
spatial memory performance was observed with HFO supplementation, it did not reach 
significance. Fish oil supplementation regardless of dose restored the diminished brain 
DHA levels observed in both genotypes in response to VCD treatment; however HFO 
improved DHA:AA to a greater extent. Again, synaptic plasticity related protein and gene 
expression was largely in agreement with the behavioural analysis. Of particular interest 
was the significant increase of phosphorylated AKT Ser473 and BDNF protein levels 
(key for neuronal cell survival and neurogenesis) observed in APOE4 animals 
supplemented with HFO. Supplementation also significantly increased Creb1 and Atf4 
expression and nominally increased Arc and Grin2b in APOE4 animals. In APOE4 
animals HFO supplementation increased Mapk1, Igf-1 and Ntrk2 expression revealing 
potential routes in which DHA exerts its effects. Overall in chapter 4 we show, 1) High 
dose n-3 PUFA supplementation ameliorates APOE4*menopause mediated deficits in 
recognition memory; 2) n-3 PUFA supplementation is less effective at improving 
genotype related spatial memory impairment; 3) Brain DHA levels diminished by VCD 
treatment are restored by supplementation; 4) DHA:AA increased to a greater extent in 
animals receiving higher n-3 PUFA dosage; and 5) High n-3 PUFA supplementation 
improved APOE4*VCD disturbances in synaptic plasticity related pathways. 
Overall summary of chapter 2 to 4 
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The sex disparity in APOE4 mediated AD risk has been reiterated numerous times over 
the past two decades (Farrer, Cupples et al. 1997, Altmann, Tian et al. 2014, Neu, Pa et 
al. 2017). Throughout the experiments described in this thesis, we sought to determine if 
there was a sex hormone/menopausal component to this risk that was linked to altered n-
3 PUFA status (transport/metabolism) and therefore potentially mitigated through an n-3 
PUFA intervention. CANN analysis revealed significant differences in n-3 index and 
cognition in those receiving HRT, which was more extensive in carriers of APOE4, 
supporting the notion that sex hormones have a disproportionate impact on APOE4, as 
previously reported (Porrello, Monti et al. 2006, Bojar, Stasiak et al. 2016, Riedel, 
Thompson et al. 2016, Mosconi, Rahman et al. 2018). In contrast to the CANN analysis, 
the in vivo animal study in APOE-TR mice did not detect any direct APOE4 or 
APOE4*VCD specific alterations in DHA levels within the erythrocytes or brain. 
However, such genotype effects may only become apparent as late as 18 months of age 
(Martinsen, Tejera et al. 2019). VCD treatment and subsequent ovarian failure led to 
significant reductions in brain DHA status across both genotypes, as has been reported in 
OVX mice (Alessandri, Extier et al. 2011), emphasising the importance of sex hormones 
in maintaining brain DHA homeostasis. APOE4*VCD on the other hand, altered brain 
DHA:AA ratio, similarly important as a lower brain ratio impacts neuroinflammation, 
oxidative stress and synaptic plasticity (Connor, Tenorio et al. 2012, Komprda 2012).  
Recognition memory, assessed via the picture recognition task in the CANN study was 
specifically improved in APOE4 carriers receiving HRT. This corroborates with our 
APOE-TR mouse model results, in which striking deficits in the NOR task were observed 
in the VCD treated APOE4 animals only. Ovarian failure has previously been associated 
with recognition memory deficits (Bastos, Pereira et al. 2015), indicating a particular 
sensitivity of the medial temporal lobe and surrounding cortical areas to sex hormone 
dysregulation. However, our results indicate how this is somehow exacerbated by 
APOE4, a novel finding which warrants further investigation. Conversely, spatial 
memory performance was unaffected by VCD, with deficits wholly attributable to 
APOE4 genotype alone. An interesting finding in itself, considering that Bour et al (Bour, 
Grootendorst et al. 2008), reported these spatial memory deficits to be APOE4 female 
specific. Therefore, indicating a non-menopausal APOE4 female deficit, uncoupled from 
menopause. Based upon our results we posit that this could be linked to the Cbd1 receptor 
downregulation, also independent VCD treatment and observed in all APOE4-TR mice, 
particularly given the importance of the endocannabinoid system and cannabinoid 
receptors in synaptic plasticity and neuroprotection (Blázquez, Chiarlone et al. 2015, 
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Scarante, Vila-Verde et al. 2017, Horton, Goonawardena et al. 2019, Patricio-Martínez, 
Sánchez-Zavaleta et al. 2019). Menopause also had implications for synaptic plasticity 
related signalling in the brain. In accordance with the cognitive data, APOE4*VCD had 
the greatest deleterious impact on synaptic plasticity related signalling, with BDNF and 
AKT signalling particularly affected. BDNF and AKT are key mediators in neuronal cell 
survival, neurogenesis and synaptic plasticity (Autry and Monteggia 2012), and are 
known to be modulated by estrogens/estrogenic receptors (Chhibber, Woody et al. 2017, 
Chhibber and Zhao 2017).  Interestingly these deficits could possibly be attributable to 
the aforementioned PUFA disturbances. As reported by Marin et al (Marin and Diaz 
2018), alterations of highly specific lipid raft compositions, known to occur through sex 
hormone dysregulation, can disrupt the signalosome,  therefore reducing neuronal 
protection and synaptic plasticity. In addition, we also disprove the theory that these 
menopausal effects relate to reduced APOE protein (Riedel, Thompson et al. 2016), 
which remained constant regardless of VCD insult. On the other hand, levels were 
significantly reduced by APOE4 genotype and may therefore likely represent a 
mechanistic basis for the APOE4 effect. 
In light of the alterations in n-3 index, caused by both APOE genotype and menopause 
we speculated that DHA enriched n-3 PUFA fish oil supplementation may offer a viable 
intervention strategy to mitigate the impact of these factors. Overall, our results suggested 
clear benefits of supplementation on the APOE4*menopause interaction. Recognition 
memory which was modulated by APOE4*sex hormones, in both CANN participants and 
in the APOE-TR model, was significantly improved in the APOE4 HFO group. The 
improvement appeared to be consistent with the synaptic plasticity gene expression and 
protein analysis. The APOE4 HFO group that had significantly improved NOR task 
performance, also had increased BDNF protein abundance, and AKT activation. 
Increases in Igf-1, Mapk1 and Ntrk2 expression, were also observed in this group 
providing 3 routes in which the DHA enriched supplement may be mediated. Again, these 
diverse signalling changes may be consistent with restoring the lipid raft profile, which 
in turn may strengthen the signalosome (Marin and Diaz 2018), and should be explored 
further. However, this may not be the full story as both LFO and HFO led to restoration 
of the diminished brain DHA levels, whilst synaptic plasticity and subsequent cognitive 
benefit were largely limited to HFO. This may be indicative of either further underlying 
processes which were not established in this experimentation, or perhaps reiterates the 
importance of the DHA:AA ratio which was increased significantly more by HFO.  
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Figure 0.1 Graphical summary of findings from chapters 3 and 4 
 
Conversely, the spatial memory deficits that were associated with APOE4 genotype 
alone, did not significantly improve with FO treatment. Although, Barnes maze 
performance did show signs of improvement in response to HFO in both the learning and 
test phases, consistent with that reported by Chouinard Watkins et al (Chouinard-
Watkins, Vandal et al. 2017). Similarly, analysis of the CANN data, did not detect any 
cognitive improvement relating to n-3 index. Together, this may therefore indicate the 
necessity of the higher, and potentially DHA enriched doses to overcome APOE4 
mediated deficits. Specific brain targeting forms of DHA may offer an alternative 
approach to these higher doses, as shown by Sugasini and colleagues (Sugasini, Thomas 
et al. 2017, Sugasini, Yalagala et al. 2019), who reported an improvement in the APOE4 
mediated spatial memory deficits when utilising DHA in LPC form.  
Altogether, our findings suggest that APOE4 exacerbates the detrimental impacts of 
menopause, whilst supplementation with high but physiologically relevant DHA enriched 
n-3 PUFAs may offer some protection. Therefore, such supplementation should be 
considered and studied further in these ‘at risk’ menopausal APOE4 carriers. 
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Discussion of experimental models and methodology 
 
Analysis of CANN study data: strengths and limitations 
 
This PhD research project began by examining female participant data obtained from the 
CANN study, to explore how a number of potential determinants including: APOE, HRT, 
and n-3 PUFA intake influence PUFA status and cognition. As described in chapter 2, the 
CANN study was a multi-centre (Norwich and Melbourne), 12-month double-blinded, 
placebo-controlled parallel intervention trial (Irvine, Scholey et al. 2018). However, for 
the purpose of our analysis, we focused primarily on female participant baseline and 
screening data. Participants were prospectively recruited based upon their MCI or SMI 
status and age, and the study was devised to actively assess many of the determinants 
explored in this analysis, with the exception of HRT. This provided us with significant 
power to evaluate the effects of APOE genotype and n-3 PUFA status. Conversely, the 
number of APOE4 carriers receiving HRT was quite low, as acknowledged in chapter 2 
and therefore this analysis should be viewed as exploratory, with any conclusions treated 
with caution. However, the size of the effect changes and statistical significance was 
indeed promising. In addition, given that HRT use was not a major ‘focus’ in the RCT, 
information regarding the type, combination and onset of HRT use was not available and 
was another weakness of this analysis, given the known influence these factors can have 
on HRT effectiveness. One of the exclusion criteria for the CANN study was participants 
with high omega-3 fatty acid status. This was determined using the RBC omega-3 fatty 
acid index, and participants with a level greater than 6% of total fatty acids were excluded. 
Therefore, interpretation of this data should consider that a subset of the actual population, 
with a high n-3 index, and therefore likely consuming higher amounts of EPA and DHA 
were not represented. This may contribute to the lack of significant impact on cognition 
associated with an increasing n-3 index, particularly as we later indicate the necessity of 
higher n-3 PUFA doses. A particular strength was the comprehensive data gathered 
during the CANN study, allowing us to incorporate many relevant covariates into our 
analytical model, which are sometimes not included in other studies, improving the 
validity and robustness of our results. Similarly, we had access to comprehensive fatty 
acid analysis data, therefore giving us comprehensive overview of PUFA status both short 
and long term. Another strength of this analysis was the extensive cognitive test battery, 
which was performed during the CANN study. This enabled us to explore specific 
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cognitive domains, and establish subtle differences in our non-demented participants, that 
may have otherwise been missed.  
 
In vivo human APOE-TR VCD menopause induced mouse model: strengths and 
limitations 
 
Model: In chapters 3 and 4, a VCD menopause induced APOE-TR mouse model was 
utilised. Such a model has extensive benefits from a research perspective. Firstly, APOE-
TR mice, express the human form of APOE under the control of the murine regulatory 
sequence (Sullivan, Mezdour et al. 1997, Knouff, Hinsdale et al. 1999), resulting in APOE 
protein production in a physiological relevant manner. The use of both APOE3-TR and 
APOE4-TR mice enabled us to make direct behavioural and biochemical comparisons 
and establish isoform-specific effects. This in vivo approach also enables greater control 
of many confounding variables and full access to all tissue (e.g. brain) which would have 
been problematic, or unachievable when studying a human population. Although not a 
complete AD model, the less severe phenotype attributed to APOE4-TR mouse compared 
to related crosses (i.e APOE4-5xFAD aka E4FAD), enabled us to age our animals. This 
provided time for the dietary intervention to be delivered and have an effect, whilst 
simultaneously allowing us to induce menopause utilising the VCD method at a more 
relevant age. In addition, this also meant that the more subtle impacts of APOE, 
menopause and diet could be studied, and were not masked by an overwhelming genotype 
effect. The other major component of the model was the addition of menopause. To 
induce menopause we opted to use the VCD method (Kappeler and Hoyer 2012), which 
is gaining popularity for its ability to specifically target and deplete ovarian follicle 
reserves whilst maintaining ovarian tissue integrity (Marongiu 2019). Furthermore, the 
VCD model with its gradual follicle depletion, more closely resembles human 
menopause, in comparison to other experimental options such as OVX which result in 
abrupt, more widespread change. To our knowledge, this was the first time that VCD had 
been used in an APOE-TR mouse model and therefore we conducted a short pilot study 
prior to the main experimentation to assess efficacy and tolerance. Similarly, such 
methods had been previously reported in equivalent aged animals (Chen, Perez et al. 
2014). One main weakness of the VCD menopause model is the requirement of ~ 14 i.p. 
injections; however, the alternative approach, OVX requires an invasive surgical 
procedure. In the attempt to minimise any issues associated with i.p., we altered the side 
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of injection delivery, monitored body weight/physical appearance of the animals, and 
included 2 recovery days (no injections) at the halfway point. 
Dietary intervention: Typical western style diet is ~ 35 Kcal% from fat, for this study a 
slightly exaggerated version (~45 Kcal%) was provided to all of the mice, so that we 
remained in a physiologically relevant range whilst ensuring exacerbation of the genotype 
effects to accelerate cognitive decline(Moser and Pike 2017). The DHA to EPA ratio of 
the diets containing dietary fish oil (HFO and LFO) was 4:1 and was selected based upon 
the Chouinard Watkins study (Chouinard-Watkins, Vandal et al. 2017), in addition to 
other evidence highlighting the importance of high DHA for APOE4 carriers. We retained 
some EPA however given that in humans all oily fish sources provide both EPA and DHA 
in variable ratios depending on species. Furthermore, EPA has been shown to be 
cardioprotective, which could contribute to the cognitive benefits (Bhatt, Steg et al. 2019). 
The HFO and LFO diet provided the human equivalent of 0.5g and 2g, EPA+DHA per 
day, corresponding to 1-2 portions of oil fish a week portion or 1 portion per day, and 
roughly respectively. These two doses were chosen as they fall within current guidelines 
worldwide, one representing the standard recommended intake in health adults (0.5g 
EPA+DHA per day) with the higher dose often recommended for the purposes of 
triglyceride lowering or as an anti-inflammatory (Skulas-Ray, Wilson et al. 2019). Supra-
physiological doses have been utilised previously in rodent studies but their translational 
potential is questionable, and may also be problematic from a sustainability viewpoint. 
Therefore, we opted to stay within a physiological range. We did not have the financial 
resources to include both a low-fat diet group, and a low-fat VCD group for both the 
APOE3 and APOE4 TR mice, which would have been an appropriate approach to 
uncouple the effect of the HF diet. To a lesser extent, the addition of wild type C57BL/6 
(genetic background for the APOE-TR mice), carrying murine Apoe may have also 
provided further controls.  
Behavioural tests: were performed at 12 months to assess cognition in our animals. The 
tests chosen allowed us to measure distinct forms of memory (recognition and spatial) 
relevant in AD progression. All tests performed were relatively non-invasive, utilising 
the animal’s natural behaviours, therefore minimising potentially confounding factors 
such as stress. Additionally, the researcher was blinded throughout behavioural 
experimentation and analysis to minimise potential bias.  
Outcome Measures: The fatty acid composition of the erythrocytes and the brain was 
analysed from total extracted lipids using gas chromatography. Data was normalised to 
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the internal standard nonadecanoic acid (19:0) and expressed as % of total fatty acids, 
which is common practice. In Chapter 3 and 4, mRNA expression and protein abundance 
of synaptic plasticity related markers were measured using qPCR and western blot 
methods. The two methods provide a cost-effective quantitative and semi-quantitative 
overview of the molecular target, enabling us to gain a transcriptional and post 
translational understanding. In future studies the use of broader analytical techniques such 
as RNA sequencing and metabolomics may be warranted to get a greater overview of the 
mechanisms involved. In addition, immunohistochemistry may offer spatial 
interpretations of these findings.  
 
Overall conclusion 
 
In this PhD project, we investigated the relationships between APOE genotype, sex 
hormones, and n-3 PUFA status. We provide evidence supporting the notion that n-3 
index and DHA status are dysregulated by both APOE4 genotype and menopause. We 
highlight the impact of sex hormones on cognition and reveal that depletion (VCD model) 
and addition (HRT) appear to influence cognition in an APOE4 dependant manner. We 
forward, deficits in synaptic plasticity related signalling as a potential mechanistic basis 
for the cognitive decline observed. Finally, we show that a DHA rich n-3 PUFA fish oil 
supplementation, particularly at higher dosage (2g/day human equivalent) ameliorates the 
deficits associated with APOE4*menopause, improving recognition memory and 
restoring both brain DHA and synaptic plasticity related signalling. Therefore, DHA rich 
supplementation in ‘at risk’ peri/early menopausal APOE4 women should be considered 
as an intervention strategy. Altogether, this PhD project contributes to our understanding 
of the potential mechanisms through which APOE modulates AD risk in females, offering 
novel insights into its interaction with sex hormone status, and n-3 PUFA 
supplementation. It therefore represents an important basis for future nutrigenetics and 
neurological disease research. 
 
Future directions 
 
With novel data and concepts arising from this project we would like to briefly discuss 
future research perspectives. Clearly, there remain many gaps and disparities in our 
knowledge relating to this subject area, many of which derive from the complexity of 
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APOE and the fundamental lack of research exploring its impact in females. We will 
therefore address some of the key questions and gaps, suggesting methods, which we 
believe, could be useful in progressing our understanding. 
How do HRT combinations impact APOE4 mediated AD risk? Can we come to a 
consensus on HRT usage? What are the fundamental mechanisms involved? 
The general use of HRT to prevent disease is highly controversial and debate has endured 
over a number of decades (Cagnacci and Venier 2019). From an AD perspective, our 
results appear to support the pro side of the argument, with cognition improved in both 
carriers and non-carriers alike. Furthermore, the effects of HRT are widespread and may 
modify other disease processes in a deleterious manner (Cagnacci and Venier 2019), 
therefore a holistic, interdisciplinary approach may be needed to truly assess the efficacy 
and safety of HRT. Our research does however highlight how genotypes such as APOE4 
can modulate the overall effectiveness of HRT, and therefore should be carefully 
considered when designing or analysing future HRT research. One of the weaknesses of 
our study was the limited knowledge of the HRT used. Similarly, the age of menopausal 
onset and HRT treatment was not obtained in this study, all of which are known to 
influence efficacy of the treatment. Analyses incorporating this information would 
strengthen our understanding of HRT in AD development. Therefore, to address these 
issues we would envisage a need for either a large cross sectional or prospective study in 
which extensive information regarding HRT and APOE genotype and cognitive measures 
or incident dementia was available. This could then help inform, further clinical trials on 
optimal HRT delivery i.e. doses given, hormone combination, and when to intervene. 
Such clinical data would be required to establish the impact of HRT intervention on 
dementia risk. Given that the transitional ‘peri-menopausal’ phase appears to be a 
significant point in regards to female AD risk/pathology, (Mosconi, Berti et al. 2017, 
Mosconi, Rahman et al. 2018), any clinical trials should consider this as a potential 
intervention point.  
Finally, our results and others clearly implicate sex hormones in cognition; however the 
mechanisms behind this remain somewhat unknown. One suggestions is that peri/post-
menopausal states cause bioenergetics changes (Scheyer, Rahman et al. 2018), and thus 
further PET imaging studies may help inform this process. The link between sex 
hormones and n-3 PUFAs is also an interesting one, particularly in light of Alessandi’s 
(Alessandri, Extier et al. 2011), and Marin’s reports (Marin and Diaz 2018). Further 
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investigation perhaps utilising DHA tracers would help elucidate the fate of DHA in 
response to menopause.  
How does DHA and menopause influence synaptic plasticity?  
We observed striking changes in synaptic plasticity related signalling in APOE4 animals 
in response to both menopause and HFO, however the mechanism behind this remains 
unknown. Taking a reductionist approach and modelling this into neuronal cell models 
may potentially help determine the fundamental mechanism involved. This could 
potentially be achieved by generating a primary neuron cell culture from APOE-TR mice, 
and exposing them to various combinations of estrogens and DHA. Electrophysiological 
methods (e.g. patch clamp) or Multi Electrode Arrays (MEA) could be used to monitor 
neuronal activity, whilst molecular techniques could be employed to monitor gene and 
protein changes. In addition and practically more ambitious, an in-vivo 
electrophysioloical method could be utilised in a similar VCD treated APOE-TR model 
to assess neuronal activity in-vivo. 
Why is recognition memory susceptible?   
In both CANN analysis and our mouse model we found evidence for an APOE4*sex 
hormone influence on recognition memory, Highlighting this as a highly relevant area for 
future research. Recognition memory relies upon neuronal circuitry involving the 
perirhinal cortex, hippocampus, medial prefrontal cortex and retrosplenial cortex 
(Warburton 2018). Dissecting these specific regions, in VCD treated mice and performing 
a high throughput analytical method such as RNA sequencing could highlight key and 
novel changes in gene expression, enabling us to have a greater overview of the processes 
and mechanisms behind this effect. 
 
Could brain-targeting forms of DHA reduce dosage? 
Current evidence appears to recommend higher doses of DHA to benefit APOE4 carriers. 
Indeed our rodent experiments found only the 2g/day human equivalent dosage provided 
any significant cognitive benefit, and others have described the requirement of even larger 
doses (Chouinard-Watkins, Vandal et al. 2017). This is problematic both translationally, 
and also sustainably. Therefore, strategies to increase efficacy and reduce the required 
dose are essential. One potential strategy may be to utilise ‘brain targeting’ forms of 
DHA. As shown in mice by Sugansini and colleagues (Sugasini, Thomas et al. 2017), 
daily gavage with 1mg LPC DHA per day, led to dramatic increase in brain DHA profiles 
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compared to non LPC forms. Given this ~ 3 fold increase in brain DHA observed in LPC 
DHA supplemented animals compared to wild type controls, it would be interesting to 
determine the effect of lower doses, perhaps performing a dose response experiment. 
Similarly, determining the optimal dose required to mitigate APOE4 and menopausal 
impacts would be useful. Finally, the aforementioned ‘brain targeting’ forms of DHA 
have largely been explored in animal models and a large clinical trial would be needed to 
truly assess their translational potential.  
 
Is there an involvement of the gut microbiota? 
The influence of gut microbiota is an emerging factor in neurological disease, including 
AD. We know that APOE4 leads to substantial changes in metabolism. Similarly, recent 
reports from our group have indicated that there are APOE4 specific changes in the gut 
microbiota structure and function (Tran, Corsini et al. 2019). However, given the novel 
nature of these findings there is little known about how menopause or n-3 PUFA may 
influence the process. Therefore, sequencing the gut microbiota profile of VCD treated, 
n-3PUFA supplemented APOE3 and APOE4 animals, may potentially uncover a 
previously unexplored, novel mechanism.
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Appendix   
 
 
Figure S1 Barnes maze learning phase primary error trajectory.  
An upwards shift in primary errors was observed in APOE4 animals in both a) VCD 
treated and b) sham animals. Data represent the mean ± S.E.M  *p< 0.05. **P < 0.01 
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Figure S2 Barnes maze learning phase primary latency trajectory.  
A nominal downwards shift in primary latency was observed in HFO supplemented 
APOE4 animals compared to sham non-supplemented counterparts, however this did 
not reach significance Data represent the mean ± S.E.M  
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Table S1: Full dietary composition of diet used in experimentation 
 
 
Diets 
High Fat 
(HF) 
High Fat - 
Low fish oil 
(HF LFO) 
High fat - 
High fish oil 
(HF HFO) 
% Composition Kcal Kcal Kcal 
Protein 
20 20 20 
Carbohydrate  
35 35 35 
Fat 
45 45 45 
Total 
100 100 100 
Diet component gm/kg gm/kg 
 
gm/kg 
 
gm/kg 
 
Casein 
233 
 
3 
 
85 
 
117 
 
201 
 
58 
 
47 
 
189 
 
0 
 
233 
 
3 
 
85 
 
117 
 
201 
 
58 
 
47 
 
188 
 
1 
 
233 
 
3 
 
85 
 
117 
 
201 
 
58 
 
46 
 
185 
 
5 
 
L-Cystine  
Corn starch 
Maltodextrin 10 
Sucrose 
Cellulose, BW200 
Corn oil 
Palm oil 
EPAX oil 
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Table S2 Primer sequences used for qRT-PCR 
Gene  Description  Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
Chapter 
3 
   
Esr2 Estrogen Receptor Beta GGTCCTGTGAAGGATGTAAGGC TAACACTTGCGAAGTCGGCAGG 
Esr1 Estrogen Receptor Alpha TCTGCCAAGGAGACTCGCTACT GGTGCATTGGTTTGTAGCTGGAC 
Fatp4 Fatty acid transporter protein 4 GACTTCTCCAGCCGTTTCCACA CAAAGGACAGGATGCGGCTATTG 
Acsl6 Acyl-CoA synthetase long-chain family member 6 CAGAGGAACTCAACTACTGGACC CCAATGTCTCCAGTGTGAAGCC 
Fatp1 Fatty acid transporter protein 1 TGCCACAGATCGGCGAGTTCTA AGTGGCTCCATCGTGTCCTCAT 
Mfsd2a Major facilitator superfamily domain-containing protein 2 GGTCTCAGAAGTTGCCAATCGC GAAGGCACAGAGGACGTAGATG 
Fabp5 Fatty acid binding protein 5  GACGACTGTGTTCTCTTGTAACC TGTTATCGTGCTCTCCTTCCCG 
APOE Apolipoprotein E  GGGTCGCTTTTGGGATTACCTG CAACTCCTTCATGGTCTCGTCC 
Bdnf Brain derived neurotrophic factor  GGCTGACACTTTTGAGCACGTC CTCCAAAGGCACTTGACTGCTG 
Akt1 RAC-alpha serine/threonine-protein kinase CCTTTATTGGCTACAAGGAACGG GAAGGTGCGCTCAATGACTG 
Creb1 CAMP responsive element binding protein 1 ACCCAGGGAGGAGCAATACAG TGGGGAGGACGCCATAACA 
Atf4 Activating transcription factor 4 CTCTTGACCACGTTGGATGAC CAACTTCACTGCCTAGCTCTAAA 
Grin2b Glutamate (NMDA) receptor subunit epsilon-2 CTGGTGACCAATGGCAAGCATG GGCACAGAGAAGTCAACCACCT 
Ephb2 Ephrin type-B receptor 2 CAACGGTGTGATCCTGGACTAC CACCTGGAAGACATAGATGGCG 
Cbd1 Cannabinoid receptor type 1 ATCGGAGTCACCAGTGTGCTGT CCTTGCCATCTTCTGAGGTGTG 
Gapdh Glyceraldehyde 3-phosphate dehydrogenase AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 
Chapter 
4 
   
Bdnf Brain derived neurotrophic factor  GGCTGACACTTTTGAGCACGTC CTCCAAAGGCACTTGACTGCTG 
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Akt1 RAC-alpha serine/threonine-protein kinase CCTTTATTGGCTACAAGGAACGG GAAGGTGCGCTCAATGACTG 
Mapk1 Mitogen-activated protein kinase 1  GGTTGTTCCCAAATGCTGACT CAACTTCAATCCTCTTGTGAGGG 
Igf-1 Insulin-like growth factor 1 (IGF-1) GTGGATGCTCTTCAGTTCGTGTG TCCAGTCTCCTCAGATCACAGC 
Creb1 CAMP responsive element binding protein 1 ACCCAGGGAGGAGCAATACAG TGGGGAGGACGCCATAACA 
Arc Activity-regulated cytoskeleton-associated protein GCTGGAAGAAGTCCATCAAGGC ACCTCTCCAGACGGTAGAAGAC 
Atf4 Activating transcription factor 4 CTCTTGACCACGTTGGATGAC CAACTTCACTGCCTAGCTCTAAA 
Ntrk2 Neurotrophic tyrosine kinase receptor type 2 CCACGGATGTTGCTGACCAAAG GCCAAACTTGGAATGTCTCGCC 
Grin2b Glutamate (NMDA) receptor subunit epsilon-2 CTGGTGACCAATGGCAAGCATG GGCACAGAGAAGTCAACCACCT 
Cbd1 Cannabinoid receptor type 1 ATCGGAGTCACCAGTGTGCTGT CCTTGCCATCTTCTGAGGTGTG 
Gapdh Glyceraldehyde 3-phosphate dehydrogenase AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 
Tbp TATA-binding protein CTACCGTGAATCTTGGCTGTAAAC AATCAACGCAGTTGTCCGTGGC 
 
  
Table S3 Full brain fatty acid composition table of HF VCD and HF sham groups 
 
APOE3 APOE4 Genotype 
P value 
Intervention 
P value 
Interaction 
P value 
Fatty acid  HF Sham HF VCD HF Sham HF VCD 
   
Total n-3 PUFA 13.3 ± 0.2 a 11.6 ± 0.7 b 13.2 ± 0.3 11.8 ± 0.5 0.964 0.004 0.805 
20:5 n-3 (EPA)  0.02 ± 0.01 0.06 ± 0.03 0.02 ± 0.0.01 0.03 ± 0.14 0.466 0.147 0.414 
22:5 n-3 0.06 ± 0.02 0.10 ± 0.05 0.05 ± 0.05 0.06 ± 0.02 0.526 0.207 0.526 
22:6 n-3 (DHA) 13.2 ± 0.2 a 11.2 ± 0.5 b 13.1 ± 0.3 a 11.7 ± 0.5 b 0.650 0.001 0.519 
Total n-6 14.2 ± 0.2 12.6 ± 0.4 14.8 ± 0.9 13.2 ± 0.6 0.274 0.011 0.979 
18:2 n-6 0.44 ± 0.05 0.43 ± 0.07 0.44 ± 0.09 0.39 ± 0.06 0.712 0.613 0.993 
20:2 n-6 0.04 ± 0.01 0.08 ± 0.03 0.04 ± 0.02 0.07 ± 0.02 0.719 0.082 0.851 
20:3 n-6 0.26 ± 0.02 0.21 ± 0.02 0.23 ± 0.01 0.23 ± 0.02 0.594 0.154 0.125 
20:4 n-6 (AA) 9.37 ± 0.21 8.10 ± 0.39 8.95 ± 0.25 8.67 ± 0.50 0.860 0.058 0.221 
22:4 n-6 3.31 ± 0.09 3.23 ± 0.14 3.33 ± 0.06 3.07 ± 0.15 0.565 0.148 0.447 
22:5 n-6 0.77 ± 0.13 0.54 ± 0.09 1.07 ± 0.26 0.77 ± 0.10 0.077 0.081 0.777 
DHA:AA 1.40 ± 0.03 1.39 ± 0.05 1.48 ± 0.01 a 1.36 ± 0.03 b 0.619 0.049 0.134 
Total SFAs 38.7 ± 0.4 a 35.5 ± 0.9 b 36.6 ± 0.6 36.9 ± 1.2 0.689 0.100 0.054 
14:0 0.22 ± 0.03 0.24 ± 0.04 0.16 ± 0.04 0.18 ± 0.05 0.151 0.537 0.947 
16:0 17.6 ± 0.5 a 14.7 ± 0.7 b § 16.2 ± 0.5 17.3 ± 0.9 § 0.406 0.207 0.010 
18:0 20.1 ± 0.3 18.9 ± 0.5 19.3 ± 0.2 18.3 ± 0.6 0.138 0.025 0.802 
20:0 0.31 ± 0.02 a 0.41 ± 0.03 b 0.28 ± 0.02 0.33 ± 0.03 0.053 0.014 0.343 
22:0 0.22 ± 0.04 0.38 ± 0.05 § 0.26 ± 0.01 0.19 ± 0.06 § 0.099 0.110 0.030 
24:0 0.31 ± 0.09 0.78 ± 0.18 0.38 ± 0.10 0.53 ± 0.14 0.442 0.032 0.277 
Total MUFAs 25.4 ± 0.4 a 30.5 ± 0.8 b § 27.3 ± 0.9 27.9 ± 1.4 § 0.448 0.021 0.013 
16:1 n-9 0.22 ± 0.05 0.22 ± 0.06 0.20 ± 0.03 0.37 ± 0.06 0.242 0.118 0.120 
16:1 n-7 0.43 ± 0.03 0.42 ± 0.01 0.39 ± 0.02 0.46 ± 0.04 0.845 0.182 0.195 
18:1 n-9 18.2 ± 0.5 a 21.2 ± 0.8 b 19.3 ± 0.6 19.3 ± 1.2 0.684 0.091 0.084 
18:1 n-7 3.62 ± 0.05 3.58 ± 0.16 3.38 ± 0.04 3.46 ± 0.13 0.070 0.897 0.792 
20:1 n-9 2.03 ± 0.18 a 3.04 ± 0.20 b 2.28 ± 0.20 2.21 ± 0.21 0.166 0.028 0.013 
22:1 n-9 0.17 ± 0.02 0.21 ± 0.03 0.21 ± 0.01 0.18 ± 0.02 0.741 0.750 0.128 
24:1 n-9 1.37 ± 0.09 a 1.96 ± 0.18 b § 1.56 ± 0.11 1.14 ± 0.24 § 0.080 0.641 0.008 
Total DMA 8.52 ± 0.27 a 9.82 ± 0.47 b 9.46 ± 0.24 8.61 ± 0.44 0.711 0.549 0.009 
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(n=5/6). PUFA; Polyunsaturated fatty acid, 20:5 n-3 EPA; Eicosapentaenoic acid, 22:5 n-3; Docosapentaenoic acid, 22:6 n-3 DHA; Docosahexaenoic 
acid, 18:2 n-6; Linoleic acid, 20:2 n-6; Eicosadienoic acid, 20:3 n-6; Dihomo-gamma-linolenic acid, 20:4 n-6 AA; Arachidonic acid, 22:4 n-6; Adrenic Acid, 
22:5 n-6 Docosapentaenoic acid, DHA:AA; Docosahexaenoic acid to Arachidonic acid ratio, SFA; Saturated fatty acid, 14:0; Myristic acid, 16:0; Palmitic 
acid, 18:0; Stearic acid, 20:0; Eicosanoic acid, 22:0; Docosanoic acid, 24:0; Tetracosanoic acid, MUFA; Monounsaturated fatty acid, 16:1 n-9; palmitoleic 
acid, 16:1 n-7; palmitoleic acid, 18:1 n-9; Oleic acid, 18:1 n-7; cis-Vaccenic acid, 20:1 n-9; 11-Eicosenoic acid, 22:1 n-9; Erucic acid 24:1 n-9; Nervonic 
acid. Brain fatty acid composition of experimental animals (n=5/6 per group) Data is % of total fatty acids and mean value ± SEM. 2-way ANOVA. Letters 
a, b denote significant intervention difference whilst § denotes significant genotype effect as analysed via post hoc. 
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Table S4 Full brain fatty acid composition of all experimental animal groups (n=5/6 per group) 
 
APOE3 APOE4 Genotype 
P value  
Intervention 
P value  
Interaction 
P value  
Fatty acid  HF Sham HF VCD 
 
HF VCD 
LFO 
HF VCD 
HFO 
HF Sham HF VCD HF VCD 
LFO 
HF VCD 
HFO 
   
Total n-3 
PUFA 
2.05 ± 
0.35 a 
1.89 ± 
0.45 ab 
2.08 ± 
0.21 ab 
3.72 ± 
0.38 b 
1.19 ± 
0.19 a 
1.65 ± 
0.55 b 
2.49 ± 
0.31 ac 
3.94 ± 
0.39 c 
0.416 0.0001 0.286 
20:5 n-3 
(EPA)  
0.02 ± 
0.01 
0.06 ± 
0.03 
0.02 ± 
0.01  
0.06 ± 
0.03 
0.02 ± 
0.01 
0.03 ± 
0.14 
0.01 ± 
0.01 
0.09 ± 
0.03 
0.640 0.067 0.529 
22:5 n-3 0.06 ± 
0.02 
0.10 ± 
0.05 
0.05 ± 
0.02    
0.07 ± 
0.03  
0.05 ± 
0.05 
0.06 ± 
0.02 
0.12 ± 
0.06 
0.04 ± 
0.01 
0.856 0.338 0.502 
22:6 n-3 
(DHA) 
13.20 ± 
0.20 a 
11.20 ± 
0.50 b 
13.10 ± 
0.70 a  
13.50 ± 
0.40 a  
13.10 ± 
0.30 ab 
11.70 ± 
0.50 a  
13.70 ± 
0.40 b  
13.40 ± 
0.50 b 
0.479 0.0002 0.765 
Total n-6 
PUFA 
14.20 ± 
0.20 a 
12.60 ± 
0.40 ab 
12.00 ± 
0.50 b 
11.10 ± 
0.30 b 
14.80 ± 
0.90 a 
13.20 ± 
0.60 ab 
12.70 ± 
0.20 b 
11.50 ± 
0.40 b 
0.093 0.0001 0.992 
18:2 n-6 0.44 ± 
0.05 
0.43 ± 
0.07 
0.39 ± 
0.03   
0.43 ± 
0.04 
0.44 ± 
0.09 
0.39 ± 
0.06 
0.40 ± 
0.04 
0.43 ± 
0.05  
0.724 0.884 0.963 
20:2 n-6 0.04 ± 
0.01 
0.08 ± 
0.03 
0.14 ± 
0.05 
0.10 ± 
0.05 
0.04 ± 
0.02 
0.07 ± 
0.02 
0.09 ± 
0.03 
0.09 ± 
0.02 
0.463 0.067 0.766 
20:3 n-6 0.26 ± 
0.02 a 
0.21 ± 
0.02 a 
0.29 ± 
0.02 a 
0.42 ± 
0.03 b 
0.23 ± 
0.01 a 
0.23 ± 
0.02 a 
0.29 ± 
0.02 ab 
0.40 ± 
0.05 b 
0.562 0.0001 0.777 
156 
 
20:4 n-6 
(AA) 
9.37 ± 
0.21 a 
8.10 ± 
0.39 ab 
8.28 ± 
0.39 ab 
7.55 ± 
0.28 b 
8.95 ± 
0.25 
8.66 ± 
0.50 
8.70 ± 
0.22 
7.88 ± 
0.26 
0.354 0.002 0.508 
22:4 n-6 3.31 ± 
0.09 ac 
3.23 ± 
0.14 a 
2.76 ± 
0.09 b 
2.57 ± 
0.07 b 
3.33 ± 
0.06 a 
3.07 ± 
0.15 ac 
2.89 ± 
0.08 bc 
2.64 ± 
0.15 b 
0.837 0.0001 0.610 
22:5 n-6 0.77 ± 
0.13 a 
0.54 ± 
0.09 a 
0.18 ± 
0.07 b 
0.02 ± 
0.005 b 
1.07 ± 
0.26 a 
0.77 ± 
0.10 a 
0.38 ± 
0.14 b 
0.03 ± 
0.017 c 
0.032 0.0001 0.507 
DHA:AA 1.40 ± 
0.03 a 
1.39 ± 
0.05 a 
1.58 ± 
0.04 b 
1.79 ± 
0.02 c 
1.48 ± 
0.01 ad 
1.36 ± 
0.03 a 
1.58 ± 
0.03 bd 
1.76 ± 
0.03 c 
0.998 0.0001 0.400 
Total SFAs 38.70 ± 
0.40 
35.50 ± 
0.90  
36.70 ± 
1.40 
37.00 ± 
1.40 
36.60 ± 
0.60 
36.90 ± 
1.20 
37.70 ± 
0.90 
36.60 ± 
0.80 
0.961 0.409 0.216 
14:0 0.22 ± 
0.03 a 
0.24 ± 
0.04 a 
0.13 ± 
0.04 ab 
0.09 ± 
0.03 b 
0.16 ± 
0.04 
0.18 ± 
0.05 
0.14 ± 
0.02 
0.10 ± 
0.03 
0.363 0.007 0.544 
16:0 17.60 ± 
0.50 a 
14.70 ± 
0.70 b §  
16.40 ± 
0.60 ab 
16.40 ± 
0.40 ab 
16.20 ± 
0.50 
17.30 ± 
0.90 § 
17.20 ± 
0.60 
16.30 ± 
0.70 
0.305 0.501 0.034 
18:0 20.10± 
0.30 
18.90 ± 
0.50 
19.30 ± 
0.30 
19.60 ± 
0.30 
19.30 ± 
0.20 
18.30 ± 
0.60 
19.60 ± 
0.40 
19.40 ± 
0.30 
0.298 0.104 0.673 
20:0 0.31 ± 
0.02 
0.41 ± 
0.03 
0.29 ± 
0.04 
0.38 ± 
0.02 
0.28 ± 
0.02 
0.33 ± 
0.03 
0.27 ± 
0.03 
0.35 ± 
0.04 
0.068 0.012 0.771 
22:0 0.22 ± 
0.04 
0.38 ± 
0.05  
0.23 ± 
0.06 
0.25 ± 
0.09 
0.26 ± 
0.01 
0.19 ± 
0.06  
0.19 ± 
0.06 
0.25 ± 
0.09 
0.299 0.335 0.302 
24:0 0.31 ± 
0.09 ab 
0.78 ± 
0.18 a 
0.34 ± 
0.10 ab 
0.26 ± 
0.13 b 
0.38 ± 
0.10 
0.53 ± 
0.14 
0.27 ± 
0.08 
0.39 ± 
0.11 
0.669 0.020 0.438 
Total 
MUFAs 
25.40 ± 
0.40 a 
30.50 ± 
0.80 b 
26.50 ± 
1.20 ac 
30.00 ± 
0.80 bc 
27.30 ± 
0.90 ab 
27.90 ± 
1.40 ab  
26.50 ± 
0.80 a 
30.20 ± 
0.90 b 
0.615 0.001 0.054 
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PUFA; Polyunsaturated fatty acid, 20:5 n-3 EPA; Eicosapentaenoic acid, 22:5 n-3; Docosapentaenoic acid, 22:6 n-3 DHA; Docosahexaenoic acid, 18:2 n-6; 
Linoleic acid, 20:2 n-6; Eicosadienoic acid, 20:3 n-6; Dihomo-gamma-linolenic acid, 20:4 n-6 AA; Arachidonic acid, 22:4 n-6; Adrenic Acid, 22:5 n-6 
Docosapentaenoic acid, DHA:AA; Docosahexaenoic acid to Arachidonic acid ratio, SFA; Saturated fatty acid, 14:0; Myristic acid, 16:0; Palmitic acid, 18:0; 
Stearic acid, 20:0; Eicosanoic acid, 22:0; Docosanoic acid, 24:0; Tetracosanoic acid, MUFA; Monounsaturated fatty acid, 16:1 n-9; palmitoleic acid, 16:1 n-7; 
palmitoleic acid, 18:1 n-9; Oleic acid, 18:1 n-7; cis-Vaccenic acid, 20:1 n-9; 11-Eicosenoic acid, 22:1 n-9; Erucic acid 24:1 n-9; Nervonic acid. Brain fatty acid 
composition of experimental animals (n=5/6 per group) Data is % of total fatty acids and mean value ± SEM. 2-way ANOVA. Different superscripts denote 
significant difference between group means, whilst § indicates significant genotype difference (Tukey or Sidak post hoc).  
 
 
16:1 n-9 0.22 ± 
0.05 
0.22 ± 
0.06 
0.27 ± 
0.06 
0.36 ± 
0.05 
0.20 ± 
0.03 
0.37 ± 
0.06 
0.18 ± 
0.06 
0.37 ± 
0.06 
0.748 0.021 0.206 
16:1 n-7 0.43 ± 
0.03 
0.42 ± 
0.01 
0.44 ± 
0.02 
0.48 ± 
0.04 
0.39 ± 
0.02 a 
0.46 ± 
0.04 ab 
0.44 ± 
0.03 ab 
0.50 ± 
0.02 b 
0.972 0.038 0.588 
18:1 n-9 18.20 ± 
0.50 
21.20 ± 
0.80  
18.50 ± 
0.70 
20.60 ± 
0.40 
19.30 ± 
0.60 
19.30 ± 
1.20 
19.00 ± 
0.40 
20.20 ± 
0.40 
0.698 0.026 0.166 
18:1 n-7 3.62 ± 
0.05 
3.58 ± 
0.16 
3.45 ± 
0.15 
3.77 ± 
0.12 
3.38 ± 
0.04 
3.39 ± 
0.13 
3.46 ± 
0.17 
3.59 ± 
0.11 
0.258 0.096 0.769 
20:1 n-9 2.03 ± 
0.18 a 
3.04 ± 
0.19 b  
2.18 ± 
0.17 ac 
2.73 ± 
0.16 abc 
2.28 ± 
0.20 
2.21 ± 
0.21 
2.11 ± 
0.20 
2.82 ± 
0.31 
0.364 0.007 0.071 
22:1 n-9 0.17 ± 
0.02 
0.21 ± 
0.03 
0.18 ± 
0.01 
0.18 ± 
0.04 
0.21 ± 
0.01 
0.18 ± 
0.02 
0.13 ± 
0.04 
0.18 ± 
0.04 
0.718 0.400 0.509 
24:1 n-9 1.37 ± 
0.09 
1.96 ± 
0.18  
1.49 ±  
0.10 
1.90 ± 
0.16 
1.56 ± 
0.11 ab 
1.14 ± 
0.24 a 
1.33 ± 
0.13 a 
2.03 ± 
0.23 b 
0.172 0.008 0.02 
Total DMA 8.52 ± 
0.27 
9.82 ± 
0.47  
8.60 ± 
0.32 
8.23 ± 
0.51 
9.46 ± 
0.24 
8.61 ± 
0.44 
9.07 ± 
0.52 
8.48 ± 
0.72 
0.751 0.320 0.170 
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Table S5 Full Erythrocyte fatty acid composition of all experimental animal groups (n=5/6 per group) 
 
 
APOE3 APOE4 Genotype 
P value  
Intervention 
P value  
Interaction 
P value  
Fatty acid  HF Sham HF VCD HF VCD 
LFO 
HF VCD 
HFO 
HF 
Sham 
HF VCD HF VCD 
LFO 
HF VCD 
HFO 
   
Total n-3 
PUFA 
2.05 ±  
0.35 ab 
1.89 ±  
0.45 a 
2.08 ±  
0.21 ab 
4.60 ±  
0.94 b 
1.19 ±  
0.19 a 
1.65 ±  
0.55 ac 
2.49 ±  
0.31 cb 
3.94 ±  
0.39 b 
0.288 0.0001 0.367 
22:6 n-3 
(DHA) 
1.95 ±  
0.33 ab 
1.85 ±  
0.44 a 
2.08 ± 
0.21ab 
3.98 ±  
0.80 b 
1.19 ±  
0.19 a 
1.65 ±  
0.55 a 
2.31 ±  
0.30 ab 
3.68 ±  
0.38 b 
0.333 0.0001 0.511 
Total n-6 
PUFA 
32.30 ± 
3.80 a 
32.64 ± 
4.15 a 
22.27 ± 
0.86 b 
22.38 ± 
0.68 b 
24.28 ± 
1.25 
26.57 ± 
2.64 
20.91 ± 
1.28 
20.98 ± 
0.46 
0.009 0.0003 0.399 
18:2 n-6 12.35 ± 
1.40 
12.71 ± 
1.36 
12.70 ± 
0.43   
15.14 ± 
0.65 
11.39 ± 
0.55 
11.06 ± 
0.73 
11.25 ± 
0.96 
12.63 ± 
0.85  
0.074 0.0140 0.856 
20:3 n-6 0.63 ±  
0.06  
0.81 ±  
0.11 
0.47 ±  
0.13  
0.83 ±  
0.10  
0.70 ±  
0.01 
0.54 ±  
0.19  
0.58 ±  
0.18  
0.87 ± 
0.05  
0.875 0.149 0.479 
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20:4 n-6 
(AA) 
16.10 ± 
2.61 a 
16.47 ± 
3.28 a 
7.43 ±  
0.49 b 
6.94 ±  
0.61 b 
11.07 ± 
0.83 ab 
13.00 ± 
1.66 a 
7.58 ±  
0.52 b 
6.46 ±  
0.38 b 
0.0730 0.0001 0.379 
22:4 n-6 1.01 ±  
0.16 ab 
1.24 ± 
 0.20 a 
0.46 ±  
0.15 bc 
0.22 ±  
0.14 c 
0.56 ±  
0.15  
0.64 ±  
0.29  
0.65 ±  
0.18  
0.64 ±  
0.18  
0.409 0.042 0.0254 
DHA:AA 0.12 ±  
0.01 a 
0.11 ±  
0.01 a 
0.29 ±  
0.03 b 
0.48 ±  
0.01 c 
0.11 ±  
0.01 a 
0.12 ±  
0.03 a 
0.38 ±  
0.10 b 
0.57 ± 
 0.05 c 
0.530 0.0001 0.624 
Total SFAs 47.81 ± 
3.18 
45.70 ± 
3.95  
51.71 ± 
1.22 
53.07 ± 
1.22 
52.00 ± 
0.77 
49.52 ± 
3.20 
50.64 ± 
2.08 
51.83 ± 
0.68 
0.373 0.199 0.453 
14:0 0.21 ±  
0.02 
0.28 ±  
0.04 
0.23 ±  
0.05  
0.16 ±  
0.04  
0.25 ±  
0.03 
0.12 ±  
0.06 
0.21 ±  
0.05 
0.19 ±  
0.05 
0.404 0.626 0.146 
16:0 30.43 ±  
2.21  
30.53 ±  
3.0   
33.19 ±  
1.35  
32.02 ± 
1.22 
34.37 ± 
0.47 
32.19 ± 
2.14  
31.15 ± 
1.23 
32.55 ± 
0.93 
0.387 0.930 0.325 
18:0 15.81 ± 
1.03 
13.26 ± 
0.86 
16.73 ± 
1.02 
16.54 ± 
1.32 
15.48 ± 
0.56 
15.31 ± 
1.37 
17.45 ± 
1.27 
17.51 ± 
0.63 
0.276 0.046 0.785 
20:0 0.20 ±  
0.02 
0.19 ±  
0.02 
0.31 ±  
0.03 
0.30 ±  
0.01 
0.22 ±  
0.02 
0.19 ±  
0.03 
0.27 ±  
0.03 
0.27 ±  
0.03 
0.614 0.0006 0.642 
22:0 0.48 ±  
0.10 
0.64 ±  
0.10  
0.55 ±  
0.10 
0.79 ±  
0.06 
0.66 ±  
0.04 
0.57 ±  
0.20  
0.67 ±  
0.08 
0.63 ±  
0.08 
0.485 0.286 0.176 
24:0 0.68 ±  
0.05  
0.78 ±  
0.12 §  
0.87 ±  
0.05  
0.96 ±  
0.08  
1.02 ±  
0.10 ab 
1.52 ±  
0.41 a §  
0.89 ±  
0.08 ab 
0.68 ±  
0.15 b 
0.024 0.420 0.023 
Total 
MUFAs 
17.84 ± 
1.00 a §  
 19.78 ± 
1.05 ab 
23.94 ± 
1.37 b 
20.29 ± 
1.48 ab 
22.53 ± 
0.68 §  
22.59 ± 
0.68  
22.69 ± 
1.25  
23.25 ± 
0.68  
0.006 0.052 0.059 
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PUFA; Polyunsaturated fatty acid, 22:6 n-3 DHA; Docosahexaenoic acid, 18:2 n-6; Linoleic acid, 20:3 n-6; Dihomo-gamma-linolenic acid, 20:4 n-6 AA; 
Arachidonic acid, 22:4 n-6; Adrenic Acid, DHA:AA; Docosahexaenoic acid to Arachidonic acid ratio, SFA; Saturated fatty acid, 14:0; Myristic acid, 16:0; Palmitic 
acid, 18:0; Stearic acid, 20:0; Eicosanoic acid, 22:0; Docosanoic acid, 24:0; Tetracosanoic acid, MUFA; Monounsaturated fatty acid, 16:1 n-7; palmitoleic acid, 
18:1 n-9; Oleic acid, 18:1 n-7; cis-Vaccenic acid, 20:1 n-9; 11-Eicosenoic acid, 24:1 n-9; Nervonic acid. Brain fatty acid composition of experimental animals 
(n=5/6 per group) Data is % of total fatty acids and mean value ± SEM. 2-way ANOVA. Different superscripts denote significant difference between group 
means, whilst § indicates significant genotype difference (Tukey or Sidak post hoc) 
16:1 n-7 0.60 ±  
0.06 
0.88 ±  
0.20 
0.88 ±  
0.13 
0.79 ±  
0.12 
0.97 ±  
0.08  
1.00 ±  
0.16  
0.78 ±  
0.09  
0.79 ±  
0.14  
0.293 0.613 0.300 
18:1 n-9 15.08 ± 
0.77 
16.51 ± 
1.02  
20.26 ± 
1.11 
17.49 ± 
1.23 
19.10 ± 
0.85 
19.38 ± 
0.19 
19.03 ± 
1.03 
19.64 ± 
0.69 
0.698 0.026 0.166 
18:1 n-7 1.23 ±  
0.15 
1.48 ±  
0.12 
1.54 ±  
0.15 
1.40 ±  
0.19 
1.62 ±  
0.05 
1.75 ±  
0.04 
1.72 ±  
0.21 
1.33 ±  
0.35 
0.165 0.398 0.678 
20:1 n-9 0.21 ±  
0.01  
0.20 ±  
0.02  
0.36 ±  
0.11 
0.27 ± 
 0.09 
0.24 ±  
0.02 
0.36 ±  
0.16 
0.59 ±  
0.16 
0.71 ±  
0.20 
0.038 0.234 0.465 
24:1 n-9 0.41 ±  
0.05 
0.44 ±  
0.13  
0.55 ±  
0.15 
0.34 ±  
0.12 § 
0.54 ±  
0.06 ab 
0.38 ±  
0.16 a 
0.71 ±  
0.08 ab 
0.93 ±  
0.19 b § 
0.034 0.241 0.103 
